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ABSTRACT
The presence of cirrhosis is associated with significant morbidity and mortality. The
prolonged heavy consumption of alcohol results in the development of cirrhosis in
approximately 20% of people. This variance in risk is attributed to both genetic and
environmental risk factors. To date there have been no systematic genome-wide
association studies to investigate the contribution of common genetic variants to
alcohol-related liver disease risk despite the success of these type of analyses in
cirrhosis of other aetiologies. The work presented in the first half of this thesis
describes the first genome-wide association study of alcohol-related liver disease
identifying three highly replicable risk variants in the candidate loci: PNPLA3, TM6SF2
and MBOAT7. Subsequent to this, an extended GWAS was performed including over
three-hundred additional cases, resulting in the identification of several novel loci. Of
all the identified susceptibility loci, genetic variation in PNPLA3 is by far the most
significant contributor to overall risk. The primary genetic variant in this locus is
rs738409 and has the largest effect on cirrhosis risk of any genetic variants identified.
It encodes a non-synonymous amino acid substitution (Ile148Met) in the PNPLA3
protein and is thought to be functional. This variant was genotyped in a UCL cohort of
phenotypically well-characterized patients with cirrhosis and appropriate controls and
investigated with regards to disease outcome and prognosis using time-to-event
analysis. However, there is considerable debate about the functional significance of
the PNPLA3 variant and to date little, if any, information about its structure. This
information would provide insight into the pathogenesis of alcohol-related liver injury
and identify possible targets for therapy. In the second half of the thesis the work
undertaken to obtain the crystal structure of PNPLA3 is described. Initial computational
structural modelling of the PNPLA3 protein was undertaken to characterize predicted
structural features of the full-length protein to aid understanding of protein and
crystallography process. A range of recombinant protein expression vectors were then
developed for the purification of the protein in multiple expression systems. This led to
the development of a high-yield expression protocol in E. coli obtaining milligram
amounts of protein. Work to functionally characterize this protein is on-going.
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1CHAPTER 1 INTRODUCTION
21.1 - OVERVIEW
Millions of people consume alcohol without ill effects, yet for some its consumption is
associated with significant adverse social, emotional and medical effects. This section
provides an overview of alcohol in the context of its basic chemical properties; the
history of its consumption; the current epidemiology of alcohol use/misuse; the harms
associated with its consumption, especially when misused, with particular focus on the
pathophysiology of alcohol-related liver injury and the interplay between environmental
and genetic factors in its pathogenesis.
1.2 - ALCOHOL
1.2.1 - BEVERAGE ALCOHOL
Ethanol or ethyl alcohol (C2H5OH), otherwise known as alcohol, is the primary agent in
alcoholic beverages such as beer, wine and spirits. Alcohol is a small molecule (molar
mass=46.07 g/mol) that is soluble in water and some non-polar solvents. Pure alcohol,
known as absolute alcohol, is a volatile, flammable, colourless liquid at room
temperature.
Alcoholic beverages are produced through the processes of fermentation and
distillation. Fermentation is the process by which carbohydrates are converted to
alcohol through anaerobic respiration in yeast. The process of fermentation is self-
limiting, as concentrations of alcohol in the fermenting medium above certain
concentrations will kill the yeast. The concentration of beverage alcohol may be
increased by distillation through the selective evaporation of alcohol (boiling point =
78.4oC) from water (boiling point = 100oC).
Beers, ciders and wines are all produced by the fermentation of the sugar found in
malted barley, apple juice or grape juice respectively. Spirits, such as vodka, whisky
and gin, are produced by the distillation of the alcohol produced by the fermentation of
natural sugars extracted from a variety of natural sources. There are many beverages
that are processed significantly beyond the point of fermentation and distillation, such
as mixers or alcopops, fortified wines and white ciders. Due to the large differences in
production methods, the amount of alcohol present in different alcoholic beverages
varies significantly (Table 1-1).
3Table 1-1 The amount of alcohol present in typical alcoholic beverages
Drink Typical volume ofa single measure
Alcohol
concentration
(% ABV)
Units
Wine 250 mL 12 % 3
Beer, Lager,
Cider 567 mL 5.2 % 3
Spirits 25 mL 40 % 1
Abbreviations: ABV – Alcohol By Volume; mL - Millilitre
There are many different systems in use for the quantification of the alcohol content in
beverage alcohol. The alcohol by volume (ABV) is routinely used and it is defined as
the number of mL of pure alcohol present in a 100 mL volume of beverage alcohol at
20oC. A related unit, the alcohol by weight (ABW) may be used to quantify the weight
of alcohol present in a beverage by multiplying the ABV by the relative gravity of
alcohol (0.789). Many nations, have attempted to simplify the quantification of alcohol
content in beverage alcohol into ‘standard units’. In the UK, the widely used ‘unit’
equates to approximately 10 mL or 8 g of absolute alcohol.
1.2.2 - HISTORICAL BACKGROUND
The earliest direct archaeological evidence of purposeful alcoholic fermentation dates
back to beyond 8,000 BC evidenced by chemical residues on ceramic jars used by
Neolithic cultures present in East-Asia287 and the Middle East292. In Europe, there is
clear evidence of wine production by Southern European cultures by 3,000 BC163 and
the production of beer in Northern-Europe by 1,000 BC414. There is also evidence of
alcohol production from the 1st century AD onwards in South America, Africa and the
Indian sub-continent99. By the 17th century, only isolated cultures in North America and
the Pacific islands lacked access to the knowledge, and technology, required to
ferment alcohol until these techniques were introduced.
The discovery of distillation, which is the process of separating the component
substances from a liquid mixture by selective evaporation and condensation, changed
the nature of human alcohol consumption making it far easier to ingest large quantities
of alcohol rapidly. This technique was first used from the 1st to the 4th centuries by
Greek alchemists living in Alexandria, which was then the capital of Roman and later
Byzantine Egypt, where the process was used to purify plant extracts. The distillation
of alcohol is thought to have been developed by Arab chemists who, following the
Muslim conquest of Egypt, applied techniques learned from alchemist scripts present in
Alexandria. Notably, the word alcohol is thought to derive from the Arabic ‘al-kuhl’.
The first unambiguous evidence of distillation appeared from the School of Salerno in
4Italy in the 12th century128. However, early distilled alcohol was primarily reserved for
medicinal uses rather than consumption. It was not until the 17th century onwards that
spirits were widely consumed. A particularly notable period of historical heavy spirit
consumption was the ‘gin craze’ in 18th century Britain where, due to a combination of
increased levies in the price of beer and the popularisation of gin, following the
accession of William of Orange, per capita alcohol consumption significantly increased.
Despite producing alcohol for thousands of years, humans have had little
understanding of the microbiological underpinnings of fermentation. In the 19th century,
Louis Pasteur demonstrated that yeast are living micro-organisms that can convert
sugars into alcohol in the absence of oxygen327. This led to the discovery, by Eduard
Buchner45, that cell-free yeast extracts have the capacity to ferment carbohydrates to
form ethanol. This discovery in turn played a key role in the discovery of enzymes,
which would lay the foundations for the development of biochemistry.
1.2.3 - ALCOHOL CONSUMPTION
Alcohol consumption is ubiquitous; the worldwide average per capita alcohol
consumption for adults (aged 15+ years) is 13.5 g of alcohol per day466. Most countries
control aspects of alcohol production, importation and exportation, distribution,
marketing and aspects of consumption through legislation. Thus, Governments can
control price by imposition of excise duties; distribution by limiting the licensing and
operating hours of outlets and personal consumption by imposing a minimum age-limit
for purchase, and drink-driving laws. It is estimated that nearly a quarter of the alcohol
consumed globally is homemade or illegally produced and therefore outside of
Governmental control466.
The total per capita alcohol consumption in different nations and global regions varies
significantly. For example, the nations of Europe consume over 25% of global alcohol
yet comprise only 15% of the total global population. The factors that mediate the
levels of alcohol consumption within countries and indeed communities are complex.
In some instances there are clear explanations; thus alcohol is proscribed in certain
cultures, for instance Islam, but otherwise a multitude of factors work in concert
including affordability, legislation, socio-demography, the level of economic
development, diverse cultural factors, and beverage preference. Typically, the lowest
levels of alcohol consumption are recorded in North Africa and the Middle East, due to
the predominance in these regions of the Islamic faith, whereas the highest levels of
consumption are predominantly seen in Europe, North America and Russia (Figure
1-1). There are many nations where the profile of alcohol consumption levels is rapidly
changing, largely in relation to income levels; most notably the emerging economies of
India and China, which contain over a third of the global population, have some of the
5most significant increases in levels of alcohol consumption over a five-year period
2006-2010466.
Figure 1-1 Worldwide annual per capita alcohol consumption in 2010
The worldwide annual consumption of alcohol varies significantly with the nations of Europe and
Russia typically consuming the most. Data source: World Health Organization, 2010465
UNITED KINGDOM
Alcohol consumption is prevalent in the UK. An analysis of harmful alcohol use by the
Organisation for Economic Co-operation and Development found that the UK was the
eleventh highest consumer of alcohol out of 40 nations investigated314. Another global
health report by the World Health Organization (WHO) found the average alcohol
consumption for adults in the UK during 2010 was 13.8 litres of pure alcohol per
year466. The predominant alcoholic beverages consumed in the UK were beer (37%),
wine (34%) and spirits (22%).
There are significant demographic differences in alcohol consumption in the UK. As in
other countries, men consume on average more than double the amount of alcohol
compared with women. There are also differences in the patterns and of levels of
consumption by age group. In the UK-wide general lifestyle survey over a single
week84, nearly one third of sixteen to twenty-four year-olds reported heavy drinking
(>12 units/week) in comparison to 3% of those aged over sixty-five. In contrast, older
people were more likely to drink daily where 18% of the over sixty-five year’s old age
group consumed an alcoholic beverage on five or more days of the week. There are
significant regional differences in the patterns of consumption with adults in the North
of England and Scotland more likely binge on alcohol whereas almost a third of adults
in London are teetotal319 (Figure 1-3).
6There have been considerable shifts in the amounts and the types of alcoholic
beverages consumed in the UK over the past century (Figure 1-2). Since the 1950’s
the average alcohol consumption has doubled reaching a peak in 2004 of 11.5 litres of
pure alcohol per year per person. This increase has followed equivalent increases in
the UK gross domestic product. There have also been significant changes in the types
of alcoholic beverage consumed, with decreasing beer consumption and increasing
wine, cider and alcopop consumption (Figure 1-2). In the past fifty years, the year with
the highest yearly consumption levels was 2004 and since then there has been a
moderate decline in total alcohol consumption on average. This decrease in total
alcohol consumption has not resulted from equivalent declines in every member of the
population, as in part this trend reflects an increasing relative number of teetotallers in
the UK population, the number of whom have increased by 40% since 2005319.
Figure 1-2 Annual per capita alcohol consumption in the UK between 1900-2010
The type and amount of alcohol consumed annually per capita has altered significantly over the
past century. Image adapted from: Health Committee report, 2012171
Figure 1-3 The self-reported drinking habits of adults in the UK
The showing the proportion of adults in each region that are: A – binge drinking; B –
teetotal.Data source: Orchard et al., 2015319
7ALCOHOL METABOLISM
Beverage alcohol is absorbed through both the stomach and the upper small
intestine162, entering the body via absorption. Both the stomach and liver are exposed
to high alcohol concentrations during this initial absorption phase: the stomach via
ingestion and the liver via blood received directly from the stomach and small bowel
through the portal vein. Once alcohol has entered peripheral circulation, it rapidly
equilibrates with water in the body and thus most tissues besides the stomach and liver
are exposed to equivalent concentrations of alcohol.
The majority (80-90%) of alcohol metabolism occurs in the liver. The predominant cell
type in the liver, hepatocytes, are responsible for the metabolism of alcohol via a
relatively simple biochemical pathway known as the alcohol metabolizing pathway.
The primary oxidative enzyme responsible for the breakdown of alcohol is alcohol
dehydrogenase (ADH). In humans there are several ADH enzymes divided into four
classes. The class I ADH enzymes (ADH1A, ADH1B and ADH1C) have a high affinity
for ethanol at physiological concentrations, and actively oxidize ethanol into
acetaldehyde in hepatocytes474. ADH enzymes utilise a nicotinamide adenine
dinucleotide (NAD) cofactor, which is reduced by the electrons released from the
oxidation of alcohol (Figure 1-4). Other classes of ADH enzymes may play roles in
alcohol metabolism: notably, the class IV enzyme ADH7, which is predominantly
expressed in the stomach, may play a significant role in gastric tissues when exposed
to high alcohol concentrations and thus contribute to first pass metabolism317.
The acetaldehyde produced through the oxidation of alcohol is highly reactive, having
the capacity to form adducts with important biomolecules including DNA and proteins.
Acetaldehyde is significantly more toxic than alcohol, requiring only sub-micro molar
concentrations to induce an acute toxic response and it is a known mutagen93. For
these reasons, the efficient clearance of acetaldehyde is essential. This process is
effected by three separate acetaldehyde dehydrogenase (ALDH) enzymes: ALDH1A1,
ALDH2 and ALDH1B1, which form homo- and hetero-tetramers with differing substrate
affinities and kinetic profiles for acetaldehyde409.
ALDH2 is primarily responsible for the oxidation of acetaldehyde to acetate. ALDHs
are oxidative enzymes with both cytosolic and mitochondrial isoforms, which utilise a
reduced NAD cofactor to oxidize acetaldehyde to acetate (Figure 1-4). Acetate is non-
toxic, is produced through the metabolism of many other compounds besides alcohol
and may be utilised in the citric acid cycle generating carbon dioxide and water. The
overall metabolism of alcohol is biochemically exergonic where every gram of alcohol
contains 7.2 calories of energy. However, alcoholic beverages provide little nutritional
8benefit besides raw calories although the net energy provided by alcohol metabolism is
contentious250.
The majority of alcohol is metabolized via the ADH enzyme pathway in the liver
although other metabolic pathways exist. The primary non-ADH pathway is the
microsomal ethanol oxidizing system (MEOS)251. The primary enzyme of this system,
cytochrome P450 2E1 (CYP2E1), metabolizes alcohol to produce acetaldehyde
through oxidation. However, unlike ADH this enzymes utilises oxygen and a
nicotinamide adenine dinucleotide phosphate (NADPH) cofactor by transferring
electrons from NADPH to the oxygen molecule forming a superoxide molecule (O2-).
This superoxide molecule can react with alcohol, forming an unstable intermediate,
which quickly breaks down to acetaldehyde that will be further metabolized by ALDH
enzymes. CYP2E1 is a ‘leaky’ enzyme having the ability to create superoxide and
other reactive oxygen species without the presence of substrate, contributing to
oxidative stress in hepatocytes. The MEOS system is inducible, unlike the ADH
enzymes, and thus contributes to the increased efficiency of alcohol metabolism
observed in chronic alcohol misusers 6.
Figure 1-4 A schematic of the primary alcohol metabolizing pathways
There are several pathways through which alcohol is metabolized including the primary pathway
consisting of alcohol and aldehyde dehydrogenase enzymes but also by secondary
mechanisms by the enzyme catalase and the microsomal ethanol oxidizing system.
Image adapted from Day et al, 199286
9The pharmacokinetic elimination profile of alcohol from the body generally follows
dose-independent or zero-order kinetics. Following alcohol consumption, the blood
alcohol content rapidly rises, reaching a maximum after approximately one hour (Figure
1-5). The class I ADH enzymes have a low Km for alcohol (2–10 milligram (mg)/100
mL) and therefore it is readily saturated resulting in a subsequent linear rate of
elimination known as the alcohol elimination rate. This rate varies significantly between
individuals, in a Swedish study of over 1090 (88.3% male) apprehended drink drivers
the average alcohol elimination rate measured over an hour at two time-points was
19.1 mg/100mL of blood per hour206.
Figure 1-5 Pharmacokinetic profile of alcohol clearance
Following the consumption of a single dose of alcohol the blood alcohol content (y-axis) rapidly
rises to reach a peak concentration at the time tmax (x-axis) followed by a linear rate of
clearance. Image modified from Jones et al. 2010205
A number of factors influence the peak blood alcohol content, including the speed at
which beverages are drunk, whether consumed with food, the rate of gastric emptying
and body habitus. There are significant differences in the peak blood alcohol content
by gender where women attain consistently higher blood alcohol concentration than
men following equivalent consumption and controlling for differences in total body
mass96,283. Compositional differences between the typical male and female body
explain these differences as on average, the fraction of body water is lower in women
(mean body water % ± standard deviation = 48.5% ± 8.6%) than men (mean body
water % ± standard deviation = 58.3% ± 6.7%)451. A number of factors also influence
the alcohol elimination rate including functional genetic variation in the genes encoding
ADH and ALDH enzymes75,474, whether certain other drugs are present in peripheral
circulation291, whether chronic alcohol consumption has upregulated the MEOS system
and whether the liver is functionally impaired321. There are also significant, yet small,
differences in the alcohol elimination rate by gender where women have a faster
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alcohol elimination rate than men. This difference may result from higher mass of the
liver in relation to the total water volume in women96.
1.3 - ALCOHOL AND HARM
The consumption of alcohol is associated with wide-ranging problems relating to
physical harm, either through direct injury, or by its contribution towards other health
conditions. In 2012 over three million deaths, 6% of the global total, were attributable
to alcohol466. This is a proportion higher than the total number of deaths attributable to
HIV/AIDS, tuberculosis or violence. The harm attributed to alcohol may be
characterized as either acute or chronic (Table 1-2) relating to whether the effect
results from a single drinking event or from long-term alcohol consumption.
Table 1-2 The acute and chronic physical harm associated with alcohol misuse
Acute Harm
Accidents and injury Pancreatitis
Acute alcohol poisoning Cardiac arrhythmias
Aspiration pneumonia Cerebrovascular accidents
Oesophagitis Neuropraxia
Mallory-Weiss syndrome Myopathy/rhabdomyolysis
Gastritis Hypoglycaemia
Chronic Harm
Accidents and injury Brain damage:
Oesophagitis Dementia
Gastritis Wernicke-Korsakoff syndrome
Malabsorption Cerebellar atrophy
Malnutrition Marchifava-Bignami syndrome
Pancreatitis Central pontine myelinosis
Liver damage: Peripheral neuropathy
Fatty change Myopathy
Hepatitis Osteoporosis
Cirrhosis Skin disorders
Systemic hypertension Malignancies
Cardiomyopathy Sexual dysfunction
Coronary heart disease Infertility
Cerebrovascular accidents Foetal damage
Table adapted from Morgan et al. 2010296
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ACUTE HARM
The risk of acute harm associated with alcohol consumption is strongly related to the
blood alcohol content attained and the effects of this on the individual (Table 1-3).
Depending on the country in which it is used, blood alcohol content is units of mass of
alcohol per volume of blood or mass of alcohol per mass of blood. In the UK, blood
alcohol content is measured as mg of alcohol present in 100 mL of blood.
Table 1-3 The effects of increasing blood alcohol content in a naïve male* drinker
Amount
imbibed
(units)
BAC
(mg/100mL) Effects
2 30 Increased accident risk
3 50 Increased mood; judgement impaired; loss of inhibitions
5 80 Increased risk-taking behaviour; jocularity; drink-drivelimit
10 150 Loss of self-control; exuberance; slurring;quarrelsomeness
12 200 Staggering; diplopia; memory loss
25 400 Oblivion; sleepiness; coma
30 500 Death possible
38 600 Death certain
Abbreviation: BAC – blood alcohol content
*BAC is approximately one-third higher in women drinking the same amount of alcohol as a
man of the same body weight.
Table adapted from Morgan et al., 2010296
A primary cause of acute harm relating to alcohol consumption is either intentional or
unintentional injury. Intentional injuries include those to self or others as a result of
alcohol-related violence and the deliberate self-harm associated with parasuicide.
Unintentional injuries, such as accidents in the home, at work and on the roads, may
affect not only the health of the individual but also that of others. The risk of such
injuries increases exponentially with increasing blood alcohol content422 and are
attributed to the neurobiological effects of alcohol including behavioural disinhibition,
loss of motor-coordination and impaired judgement. Alcohol-related physical harms
account for over a quarter of alcohol-attributable deaths and occur following both
chronic and acute alcohol consumption.
Another harm associated with acute alcohol consumption is alcohol poisoning. At
moderate consumption levels (< 5 units), there is little risk of alcohol poisoning
whereas there is moderate risk of accidental death (Table 1-3). More severe
intoxication results in the significantly increased risk of alcohol poisoning, which may
12
result in death. This occurs when alcohol suppresses vital bodily processes such as
breathing, heart rate and temperature homeostasis. There are many factors that
influence the acute effects of alcohol and hence risk of alcohol poisoning or physical
harm such as gender, whether chronic alcohol consumption has upregulated the
MEOS system, the pattern of alcohol consumption, whether food was consumed with
alcohol, liver function and the body habitus.
CHRONIC HARM
The harm caused by chronic alcohol consumption is a component cause of over two-
hundred health conditions463. The alcohol attributable risk fraction (AAF) may be used
to quantify the relative contribution of alcohol consumption to an outcome of a health
condition. Out of the many conditions in which alcohol consumption is a contributory
factor, cirrhosis has the highest AAF for death360 (Table 1-4). Other conditions with a
high AAF for death include pancreatitis and certain cancers of the mouth and gullet.
The link between alcohol consumption and disease risk is often complex where at
moderate levels may be protective whereas heavy consumption significantly increases
risk361,369.
Table 1-4 Global alcohol-attributable fraction for selected causes of death
Condition
Alcohol
Attributable
Fraction
(%)
Cirrhosis 50
Pancreatitis 25
Oesophageal cancer 22
Interpersonal violence 22
Self-harm & parasuicide 22
Falls 16
Poisoning 18
Traffic injuries 15
Hepatocellular Carcinoma 12
Ischemic heart disease 7
Data from World Health Organisation, 2014466
AT-RISK GROUPS
The chronic and acute harm attributable to alcohol consumption is associated with
significant morbidity and mortality. Many factors mediate alcohol consumption per se,
however, the harm attributable to alcohol is not equal between individuals for a given
level of drinking. There is significant variety in risk between countries: higher income
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countries typically consume greater amounts of alcohol per capita yet lower income
countries the generally have a greater alcohol mortality for a given level of drinking466,
suggesting that socio-economic factors are important. Consistent with this, in most
countries, lower educational levels are associated with greater harm in both men and
women154. Individuals of lower social-economic status may be at greater risk of
alcohol-related harm due to less choice in the drinking environment, less access to
healthcare and a less extensive support network. Individuals in certain age brackets
appear to have increased risk of alcohol-related harm for a given volume of alcohol, in
particular adolescents seem to be at greater risk. In the UK, factors such as younger
age, socio-economic deprivation and urbanicity are all associated with increased
alcohol-related mortality risk117. The factors that mediate these health inequalities are
complex yet the identification of at-risk groups may be key to the minimisation of
alcohol attributable harm via targeted interventions.
GOVERNMENTAL LEGISLATION
Many Governments provide guidance on drinking levels with the aim of minimizing
harm associated with alcohol consumption425. Beyond regulating the price or
availability of alcohol directly, Governments may attempt to minimize harm by
educating and informing alcohol consumers, primarily through increasing awareness of
personal consumption levels and its associated harms. The concept of a standard
drink, which represents a measure of an alcoholic beverage containing a fixed amount
of alcohol, has been a cornerstone of public alcohol advice in several countries despite
concerns that it is overly simplistic. In the UK, a standard drink contains one unit of
alcohol, which roughly equates to a small glass of wine, a pint of beer or a shot of
spirits.
From the 1980’s onwards three bodies have advised the UK Government on
recommended drinking levels associated with different levels of risk (Figure 1-6). For
two decades, these recommendations stated that women should consume less than
fourteen units per week and men less than twenty-one units per week, with two to three
drink free day in between. In addition, daily limits of two to three units are
recommended for women and three to four units are recommended for men. Finally it
recommended that no more than 6 or 8 units of alcohol should be consumed at any
one sitting by men and women respectively95. Recently, the UK department of health
altered these guidelines following a review of current literature by a panel of experts. It
now recommends that consuming no more than fourteen units of alcohol weekly
spread over three days, is associated with low risk of harm in both men and women.
These recommendations do not account for the known different risk profiles and
metabolism profiles between men and women.
14
Figure 1-6 Alcohol consumption and the risk of physical harm
The previous recommended guidelines for low risk, hazardous and harmful drinking in the UK.
*Pregnant women should abstain in the first trimester and then consume no more than 1 to 2
units once or twice weekly. Image adapted from Morgan et al, 2010296
1.3.1 - ALCOHOL USE/MISUSE
Chronic alcohol misuse typically results from the alcohol use disorders, diagnosed as
alcohol misuse and alcohol-dependence. In the UK, these are the most common
alcohol-related diagnoses in the National Health Service303.
HISTORICAL BACKGROUND
Before the late 18th century there was no concept in Western medical literature of
alcohol misuse as an involuntary behaviour and instead ‘drunkenness’ was seen as a
matter of willpower. One of the earliest proponents of a non-voluntary aspect to
alcohol misuse was the American physician Benjamin Rush (1745-1813) who led a
campaign in the USA warning the public of the ill-health resulting from alcohol243. The
first book-length characterization of alcohol as an addiction was made by the British
physician Thomas Trotter (1760-1832) in his 1804 An Essay, Medical, Philosophical,
and Chemical, on Drunkenness and its Effects on the Human Body434. Despite this
early characterization, the impact of Trotters publication on his contemporary
physicians and the medical-profession was limited110. In contrast, the German-Russian
physician Brühl-Cramer (?-1821)222 published a popular book characterizing alcohol
addiction as a disease of the mind. This work promoted the term dipsomania, a Greek
cognate meaning thirst-mania that was used to define alcohol addiction well into the
19th century.
Despite the recognition by some of alcohol dependence as a disease, many more still
remained of the opinion that it was a weakness and a feature of lowmindedness. The
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late 19th and early 20th century saw the birth of the temperance movement as the extent
of the ill effects of alcohol misuse became even more apparent. A notable outcome of
this movement was periods where all alcohol consumption was illegalized, known as
prohibition, most notably in the USA during 1920-1933 but in many other countries as
well. During the late 19th century, scientific theories regarding the causes of alcohol
dependence began to develop such as the proto-evolutionary theory of degeneration.
This theory was used as a medical explanation for alcohol problems in society, which
although fundamentally incorrect, laid the foundations for future studies of inheritance.
However, this concept also resulted in the mass sterilization of alcohol-dependent
individuals in Nazi Germany274.
After the Second World War, the modern disease conceptualization of alcohol
dependence developed, following the clinical characterization of alcohol withdrawal
phenomena such as delirium tremens197 and the acknowledgment of this condition by
large international bodies such as the WHO. This culminated in a seminal paper by
Edwards and Gross111 in which the modern idea of alcohol dependence was proposed
as a clinical entity defined by simple uniform diagnostic criteria. Despite the wide
acceptance of the disease model of alcohol dependence a few individuals in the
medical profession remain critical of this model454.
DIAGNOSIS
The diagnosis of alcohol use disorders is based on two separate but similar systems.
The WHO publishes the International Classification of Diseases (ICD) and the
American Psychiatric Association publishes the Diagnostic and Statistical Manual of
Mental Disorders (DSM)10. These criteria are subject to revisions and there are several
versions of both the DSM and ICD diagnostic criteria. Currently the 4th edition of the
DSM (DSM-IV) of 10th edition of the ICD (ICD-10) are the most widely used in clinical
practice and medical research.
In both the DSM-IV and ICD-10 diagnostic models, the more severe alcohol
dependence criteria is separated from less severe alcohol use criteria. The less severe
alcohol use criteria in the ICD-10 is called ‘harmful use’ whereas in the DSM-IV it is
called ‘alcohol abuse’. In both, this is defined as a pattern of alcohol use that causes
damage to mental and/or physical health. Alcohol dependence is further defined by
cravings for alcohol, tolerance to its neurobiological effects, a preoccupation with
alcohol and continued alcohol consumption despite harmful consequences. The major
difference is that the DSM-IV criteria have a greater emphasis on alcohol use (Table
1-5). The UK’s National Institute for Health and Care Excellence guidelines state:
“Alcohol dependence is characterised by craving, tolerance, a preoccupation with
alcohol and continued drinking in spite of harmful consequences (for example, liver
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disease or depression caused by drinking)”. The recently published 5th edition of the
DSM (DSM-V) has integrated alcohol misuse and alcohol dependence into a single
disorder, known as alcohol use disorder, with mild, moderate and severe sub-
classifications. The 11th edition of the ICD is currently undergoing revision will likely
alter its criteria to become closer to those of the DSM-V438.
The accurate definition alcohol use disorders is also important for genetic and
epidemiological research. The ICD-10 and DSM-IV diagnostic criteria for alcohol
dependence largely overlap and have a high concordance in diagnosis152. Thus, these
diagnostic criteria are interchangeable for research purposes. However, the less
severe diagnosis of alcohol misuse has notable discordances between criteria168.
Therefore, alcohol misuse diagnoses from the DSM-IV and ICD-10 criteria are not
interchangeable for research purposes.
Table 1-5 Comparisons between the ICD and DSM diagnostic criteria for alcohol
dependence
Criterion
Number ICD-10*
Criterion
Number DSM-IV*
1 Strong desire or sense ofcompulsion to use the substance NA NA
2
Impaired capacity to control use as
evidenced by the substance often
being taken in larger amounts or
over a longer period than intended
or by a persistent desire or
unsuccessful efforts to control use
3
Persistent desire or one or more
unsuccessful efforts to cut down or
control drinking
4 Drinking in larger amounts or over alonger period than the person intended
3 Physiological withdrawal 2 Physiological withdrawal
4 Tolerance 1 Tolerance
5
Preoccupation with substance use
as manifested by important
interests being given up or reduced
or a great deal of time spent in
activities necessary to obtain, take,
or recover from the effects of the
substance
5
Important social, occupational, or
recreational activities given up or
reduced because of drinking
6
A great deal of time spent in activities
necessary to obtain, to use or to recover
from the effects of drinking
6
Persistent substance use despite
clear evidence of harmful
consequences
7
Continued drinking despite knowledge of
having a persistent or recurrent physical
or psychological problem that is likely to
be caused or exacerbated by drinking
*In both the DSM-IV and the ICD-10 criteria, a diagnosis of alcohol dependence is made if 3 or
more of the criteria are present together at some time during the previous 12 months
Abbreviations: DSM-IV- Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; ICD-
10 – International Classification of Diseases, 10th Edition
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PATHOPHYSIOLOGY
It has long been realised that reinforcement, tolerance and withdrawal are key
physiological mechanisms that result in substance dependence255. The consumption of
alcohol results in reinforcing effects and in the longer term chronic consumption results
in neuro-adaptive effects that result in tolerance and withdrawal symptoms. Unlike
many other addictive drugs, alcohol does not have a single specific neurotransmitter
binding partner, instead binding to a diversity of receptors in the central nervous
system.
Reinforcement
Reinforcement occurs when a stimulus induces a rewarding state such as euphoria or
relieves an unpleasant state such as anxiety. Alcohol has both euphoric and anxiolytic
effects that follow its consumption and these effects are likely essential for the
development of alcohol dependence. Alcohol causes these effects through interactions
with several neurotransmitter receptors present in the central nervous system. This
diversity in interaction partners include the gamma-amino butyric acid (GABA) system,
the glutamate system and the endogenous opioid system.
Alcohol causes many psychoactive effects through its interactions with GABA systems
in the brain and central nervous system. GABA (C4H9NO2) (Figure 1-7) is the chief
inhibitory neurotransmitter of the central nervous system and binds to, and activates,
two classes of multi-subunit receptors. These are broadly classified as ligand-gated
ion channels, known as ionotropic receptors, and G-protein-coupled receptors known
as metabotropic receptors. These GABA receptors may occur in many isoforms with
differing subunit constituents and thus they are pharmacologically diverse395. The
sedative effects of alcohol are mediated through agonism of GABA receptors resulting
in channel activation293 and the influx of chloride ions into neurons, which leads to the
inhibition of neuronal action potentials. A primary effect of this is sedation, which is
shared with other GABA receptor agonists such as the benzodiazepines. The short-
term sedative effects of alcohol consumption may reinforce alcohol drinking through
relief from anxiety via interactions with GABA receptors in certain regions of the
brain208.
The N-methyl-D-aspartate (NMDA) receptor is also a target of alcohol. This receptor is
an ion channel protein formed of GluN1 and GluN2 hetero-tetramers, which may have
multiple different isoforms. These receptors are activated by the neurotransmitter
glutamate (C5H9NO4), which is the major excitatory neurotransmitter in the brain
(Figure 1-7). NMDA receptors are predominantly located in the central nervous system
and play key roles influencing synaptic plasticity and memory formation. Alcohol is an
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antagonist of the NMDA receptor265: its binding to the NMDA receptor inhibits the
binding of glutamate, in consequence preventing the activation of the receptor resulting
in a decrease in the transmission of nerve impulses. The result of NMDA receptor
antagonism is sedation and memory loss, a feature of acute alcohol consumption that
is shared with other drugs that antagonise the NMDA receptors such as ketamine.
Figure 1-7 The chemical structures of the neurotransmitters glutamate and GABA
A primary reinforcing effect of alcohol consumption is the feeling of well-being or mild
euphoria267 that follows its immediate consumption. This effect in part results from the
release of endogenous opioids in the brain where it has been shown that alcohol
consumption directly promotes their release in brain regions associated with reward
and decision making294. Endogenous opioids activate a physiologically important type
of G-protein-coupled receptor known as opioid receptors, which play a key role in pain
modulation and the regulation of behaviour. Many other addictive substances, such as
morphine, directly activate opioid receptors.
Tolerance and Withdrawal
Tolerance to the psychoactive effects of alcohol and withdrawal symptoms upon
abstinence from alcohol are distinguishing feature of alcohol dependence111. These
phenomena occur due to neuro-adaptive processes that occur in the brain in several
key neurotransmitter systems following chronic exposure to alcohol.
Chronic antagonism of the NMDA receptor by alcohol results in a neuro-adaptive and
compensatory process that upregulates NMDA receptor mediated functions. Chronic
alcohol consumption increases the number of NMDA receptors present in the brain132,
partly counteracting the sedative effects of alcohol resulting in some tolerance to the
psychological effects of alcohol. However, the increased number of receptors may be
responsible for withdrawal effects, as without systemic alcohol in play the increased
receptor numbers result in neuronal over-excitation that can result in seizures,
hallucinations284 and excitotoxicity mediated neuronal cell death193. This process may
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also contribute to the neurodegeneration observed in some alcohol-dependent
individuals.
MANAGEMENT
Psychosocial intervention is key to the management of alcohol misuse and alcohol
dependence and can be delivered by a variety of health care professionals in a variety
of settings302. In addition and perhaps more germane to the concept of a genetic
component to alcohol use is the use of pharmacotherapy to treat the symptoms of
withdrawal and aid the maintenance of abstinence.
The GABAA receptor agonists, benzodiazepines are a routinely prescribed and
efficacious treatment for alcohol withdrawal symptoms including seizures and delirium
tremens9. Long-term benzodiazepine use may result in dependence and therefore
these compounds are generally prescribed on a short-term basis with tapering doses
(three to seven days). Long-acting benzodiazepines such as chlordiazepoxide or
diazepam are most effective at treating alcohol withdrawal symptoms. In patients with
significant liver impairment, long-acting benzodiazepines should be used with caution
due to impaired metabolism and increased risk of toxicity. Another GABAA receptor
agonist that is not a benzodiazepine, called baclofen, may reduce alcohol withdrawal
symptoms256 and have use in patients with liver disease. The opiate receptor
antagonist naltrexone (naltrexone hydrochloride) is prescribed to aid the maintenance
of abstinence and has been shown to have a significant but modest effect on drinking
behaviour in carefully selected patients admitted to intensive treatment programmes64.
There is evidence that treatment outcome relate, at least in part, to the presence of a
functional variant allele in the µ-opioid receptor gene OPRM154. The functional
glutamate antagonist acamprosate (calcium acetylhomotaurinate), which may be co-
prescribed with naltrexone, also aids the maintenance of abstinence275. The
mechanism of action of acamprosate is controversial and it may interact as either a
weak agonist or antagonist of NMDA and GABA. The irreversible ALDH antagonist
disulfiram (Antabuse) is prescribed to aid the maintenance of abstinence63.
Antagonism of ALDH results in the build-up of toxic acetaldehyde molecules following
alcohol consumption, resulting in unpleasant effects including flushing, headache,
nausea, dizziness and an irregular heartbeat and thus acts to maintain abstinence via
negative feedback. Disulfiram often results in over-sensitivity to other common sources
of environmental alcohol.
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1.3.2 - ALCOHOL-RELATED LIVER DISEASE
Alcohol-related liver disease covers a spectrum of changes to the liver that may result
in significant liver dysfunction and potentially death. The stages of alcohol-related liver
disease are not necessarily distinct and may occur simultaneously in a given individual,
including steatosis, steatohepatitis, cirrhosis and hepatocellular carcinoma.
HISTORICAL BACKGROUND
Many ancient cultures attributed importance to the liver as evidenced in ancient
mythical and religious texts. The ancient Babylonians for example, characterized the
basic anatomical structures of sheep livers as a result of their divination practice of
hepatoscopy and thus they are credited with characterization of the liver’s basic
anatomy (Figure 1-8).
Figure 1-8 Babylonian clay liver model(circa 1900 BC)
Clay liver models were used by specialist priests, and were used as a reference source for the
interpretation of individual markings on a sheep liver when predicting the future. Image
obtained from British Museum2
From the 5th century BC until the fall of the Roman Empire in the 5th century AD, many
Greek and Roman scholars studied the liver as epitomised by the prominent Greek
physician, surgeon and philosopher Claudius Gaenus, better known as Galen of
Pergamon (AD129-C200/216). Galen, was a prominent figure in the Roman Empire
and characterized the anatomy of the liver, where he distinguished the hepatic veins
and arteries, and provided theories on how bile and blood travelled through the liver.
Despite clear evidence of liver diseases existing in the ancient world481, knowledge of
liver pathology was limited341; at best, Hippocrates (460 -370 BC) recognised ascites,
jaundice and cysts of the liver408.
The invention of the microscope in the 14th century resulted in a considerable
expansion of the understanding of the detailed pathology and pathophysiology of the
liver. Many of the findings from this period are summarized in the detailed work
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Anatomis hepatis by the English physician Francis Glissons (1599-1677)144. For
example during this period, the disrupted architecture of the liver caused by fibrous
bands of tissues was discovered. The French physician René Laennec (1781 –1826)
coined the term cirrhosis, which was used to describe this pattern of fibrotic tissue
deposition. It is a neologism derived from the Greek kirrhós meaning "yellowish,
tawny" referring to the orange-yellow colour of the diseased liver and the suffix -osis,
meaning condition. Later, during the 19th century, many of the individual cell types in
the liver were distinguished including the hepatocytes, Kupffer cells and hepatic stellate
cells.
It was not until the 19th century that the pathological consequences of excess alcohol
consumption on the liver were first identified. The English physician Matthew Baillie
(1761-1823)18 noted “the process … [of cirrhosis]… is commonly produced by a long
habit of drinking spirituous liqors”. Another English physician, Thomas Addison (1793-
1860) noted the frequent coincidence of heavy alcohol consumption and the deposition
of fat in the liver3. In the early 20th century the American physician Frank Burr Mallory
(1862-1941)271 described the inclusion bodies that bear his name, which are a feature
of alcoholic steatohepatitis. Hepatology as a speciality in its own right developed
during the 20th century but was not recognised as a subspecialty of medicine until the
mid-20th century and at that point, more interest was focused on the role of alcohol
consumption in liver disease.
STAGES
Alcohol-related liver disease is a broad term for a spectrum of abnormalities, which
may occur following the consumption of alcohol at harmful levels for prolonged periods
of time. The spectrum includes steatosis characterized by the accumulation of lipid
droplets in the cytosol of hepatocytes; steatohepatitis characterized by inflammation
and cell death; cirrhosis characterized by disruption of the architecture by fibrous bands
and the presence of regenerative nodules; and hepatocellular carcinoma, which
develops within the cirrhotic liver. The occurrence of these liver lesions is not mutually
exclusive and they may co-exist. Not everyone who drinks heavily develops significant
liver injury and its evolution is significantly modified by subsequent drinking behaviour
(Figure 1-9).
22
Figure 1-9 The stages of alcohol-related liver disease
Each image represents typical microscopic features seen on biopsy. The arrows represent an
estimate of the number of individuals that will progress through each stage of alcohol-relate liver
disease to more advanced forms of the disease. Image adapted from the EASL clinical practice
guidelines, 2012285
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Steatosis
A normal, healthy liver has a lipid content of ~0.5-1.5%. Alcohol consumption results in
the deposition of lipids in the liver and the vast majority of individuals that consume
more than 60 g of alcohol daily will develop steatosis74,109 (Figure 1-9). In severe
steatosis the livers fat content may be as high as 50%. It has been demonstrated that
steatosis is more prevalent in individuals who are obese with alcohol-use disorders,
compared to non-obese individuals with alcohol-use disorders27. Steatosis may rapidly
reverse when alcohol consumption is reduced. However, the presence of steatosis
influences the progression to more severe forms of liver disease404.
Steatohepatitis and Fibrosis
In a subset of individuals, steatosis may be associated with inflammation (Figure 1-9).
This is identified as the histological lesion of alcoholic steatohepatitis, which is
characterized by the ballooning degeneration, necrosis and apoptosis of hepatocytes in
association with neutrophilic infiltration, cholestasis and the formation of Mallory
bodies. Ballooning degeneration occurs when lipids, proteins and water are retained in
hepatocytes. Mallory bodies are proteinaceous deposits, which may be histologically
evident in the damaged hepatocytes. The recurrent generation and resolution of
inflammation leads to the accumulation of fibrous tissue and over time, this may result
in the development of cirrhosis.
Cirrhosis
Cirrhosis is histologically defined by characteristic features including the disruption of
the liver’s normal architecture and its replacement with fibrous bands of collagen and
the presence of regenerative nodules. At a histological level, these features are
graded into three types based on the size and homogeneity of the nodules:
micronodular, macronodular and mixed-nodular cirrhosis.
Hepatocellular carcinoma
The development of hepatocellular carcinoma (HCC) is considered part of the natural
history of alcohol-related liver injury. However, in alcohol-related liver disease it
generally only develops in patients with long-standing alcohol-related cirrhosis and in
this respect differs from other liver disease such as that caused by hepatitis B and non-
alcohol-related fatty liver disease (NAFLD) where tumours may arise in non-cirrhotic
livers. The tumours arise in discrete nodules most likely centred around dysplastic
rests and most tumours are likely to be multifocal227.
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CLINICAL FEATURES
The early stages of alcohol–related liver injury have few clinically evident
manifestations and are therefore asymptomatic. If liver injury is detected at this stage,
it is invariably because patients have presented either because of problems associated
with the alcohol consumption per se or because of the incidental finding of abnormal
liver function tests when they present with another condition. Liver function tests are a
battery of biochemical markers that although they may be abnormal in the presence of
liver injury, are non-specific (Table 1-6). Many factors contribute to variability in liver
enzyme levels, which may confound the accuracy of these tests238 and therefore more
specific testing usually follows up abnormal readings. Some liver function tests may be
normal even in the presence of advanced alcohol-related liver disease.
The clinical manifestations of alcohol-related liver disease become apparent after the
liver has been significantly injured: these stages clinically present as severe alcoholic
hepatitis and cirrhosis.
The clinical symptoms of cirrhosis are largely dependent on the degree to which the
liver is functionally impaired. All of these symptoms relate to the development of (i)
hepatocellular failure, which is associated with a gradual decline in excretory and
synthetic function of hepatocytes, and (ii) the development of portal hypertension as
the blood draining into the liver from the splanchnic circulation is increasingly impeded
because of presence of significant amounts of fibrotic tissue in the liver. Hepatocellular
failure results in the development of jaundice, disturbed blood clotting, low serum
albumin and the failure to detoxify the blood adequately. Portal hypertension results in
an enlarged spleen, low haemoglobin levels, low white blood cell and platelet counts
and the development of collateral blood vessels most notably in the stomach and
oesophagus, which can rupture and bleed. The combination of hepatocellular failure
and portal hypertension results in the development of fluid retention with peripheral
oedema and ascites and the development of the neuropsychiatric syndrome of hepatic
encephalopathy.
Alcoholic hepatitis is a severe, if less common, cause for presentation with alcohol-
related liver disease. This term is applied to the rapid deterioration in liver function, in
either recently abstinent or the ongoing alcohol misuser resulting from inflammatory
processes in the liver. The clinical symptoms of alcoholic hepatitis include
characteristic jaundice as well as other features of hepatic failure such as bruising,
gastrointestinal bleeding, ascites and hepatic encephalopathy. Alcoholic hepatitis
generally has a rapid onset, and therefore the misnomer ‘acute’ is often applied to this
clinical syndrome as a prefix, although the rapid onset invariably represents the clinical
presentation of an already established, albeit undiagnosed, alcohol-related cirrhosis340.
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The histological features of severe alcoholic hepatitis are often the same as those
present in the histological picture known as steatohepatitis. However, only a minority
of alcohol misusers with histological steatohepatitis304 present with clinically syndromic
alcoholic hepatitis and therefore these terms are not synonymous.
Table 1-6 Liver function test biomarkers and factors that may confound their
interpretation
Marker Relating to Alcohol-related Liver Disease Confounders
Gamma-glutamyl
transferase
A key metabolic enzyme found
predominantly in liver tissue. Elevated
levels indicate prolonged heavy drinking but
not necessarily alcohol-related liver disease
Numerous – other causes of
liver damage any cause of
intra or extra-hepatic biliary
obstruction and numerous
enzyme- inducing drugs
Aspartate amino
tranferase
A key metabolic enzyme found in
hepatocytes and many other cell types.
Elevated levels are associated with cell
death but in alcohol misusers are indicative
of excessive alcohol consumption and not
necessarily alcohol-related liver injury as
they may reflect alcohol-related muscle
damage
Cell necrosis in cardiac,
muscle, pancreatic and renal
tissues also cause elevated
levels
Alanine amino
tranferase
A key metabolic enzyme found
predominantly in hepatocytes. Elevated
levels in the blood indicates liver cell
necrosis
A good marker for liver injury –
but not specific to alcohol
Bilirubin (direct and
indirect)
A breakdown product of haemoglobin.
Circulating levels can increase for several
reason including increased loading following
a gastrointestinal bleed; failure of hepatic
clearance in decompensated disease and
haemolysis in the presence of liver failure
and portal hypertension
Not specific for alcohol-related
liver disease. Unconjugated
hyperbilirubinaemia is
observed in approximately
10% of otherwise healthy men
with Gilberts Syndrome*
Albumin
A plasma protein produced and secreted by
the liver. Low levels are observed in
decompensated alcohol-related cirrhosis
reflecting a failure of synthetic function
Hypalbuminaemia may
develop with cirrhosis of any
aetiology and is not specific for
alcohol –related disease;
Hypoalbuminaemia is also a
feature of malnutrition and
other conditions characterized
by fluid retention such as
heart and renal failure
Prothrombin time &
International
Normalised Ratio
Vitamin - K dependent clotting factors are
made in the liver. Synthetic failure may
arise in decompensated alcohol-related
cirrhosis resulting in elevation of the
prothrombin time and prolongation of the
international normalised ratio
Any form of severe acute liver
disease or cirrhosis;
anticoagulant drugs e.g.
warfarin, dietary vitamin k
deficiency and certain genetic
disorders
Alkaline phosphatase
A key enzyme produced by cells lining the
biliary ducts of the liver as well as salivary
gland, intestinal , bone and placental tissue.
Elevated levels can occur in alcohol-related
liver disease when there is a degree of
intra-hepatic cholestasis, but also as a result
of parotid enlargement and alcohol-related
bone disease - isoenzyme fractionation will
help determine the source
Can be elevated in other forms
of liver disease particularly
cholestatic conditions;
elevation is also seen in bone
disease; certain intestinal
disorders and during
pregnancy
*Gilbert’s syndrome results from a defect in the uridine diphosphate glucuronosyltransferase
(UGT1A1) gene, which results in a reduction in the processing of bilirubin for excretion from the
body
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EPIDEMIOLOGY
Steatosis can develop after drinking significant amounts of alcohol over a few days253,
and hence is near universally present in active alcohol misusers. Steatosis alone is
asymptomatic, and for this reason is largely unapparent in many epidemiological
studies of alcohol-related liver disease. A retrospective study423 has shown that 37% of
alcohol misusers with histologically confirmed steatosis develop cirrhosis/fibrosis within
approximately 10 years if drinking (>40 units/week) continues. Hepatic
decompensation resulting from cirrhosis is the most common reason for alcohol-related
liver disease to become symptomatic, and accordingly is the primary morbidity, or
primary cause of mortality, recorded by epidemiological studies. The incidence rate of
cirrhosis in alcohol misusers varies between studies239,241 although its incidence is
probably no more than 20%. The development of cirrhosis substantially increases the
risk of developing hepatocellular carcinoma, and approximately 15% of with patients
with cirrhosis go on to develop it379 at a yearly incidence of 1.4%123. The clinical
syndrome of alcoholic hepatitis is an uncommon cause for alcohol-related liver disease
presentation and there is little information regarding its incidence. At clinical
presentation approximately half will have cirrhosis313. The histological features
steatohepatitis are more common, although in most instances are asymptomatic.
Alcohol-related cirrhosis is a major cause of global mortality accounting for around 1%
of the total deaths, nearly half a million deaths, in the year of 2010361. Deaths
attributable to alcohol-related cirrhosis account for nearly half of the total deaths
resulting from cirrhosis of all aetiologies360. Alcohol is the major cause of cirrhosis in
most parts of the world, with the exception of North Africa and the Middle East. In
Europe, alcohol is the main cause of cirrhosis and total cirrhosis-related deaths (Figure
1-10). There are large national differences within Europe, with the highest cirrhosis
death rates seen in Central and Eastern Europe. In the majority of Western European
countries death rates from cirrhosis are falling, yet in the United Kingdom (Figure 1-11)
cirrhosis death rates are on the increase. Within the UK, there are regional differences
in cirrhosis death rates within the UK where the standardized cirrhosis death rates in
Scotland are almost twice as high as those in both Wales and England242.
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Figure 1-10 The alcohol attributable fraction for cirrhosis deaths in Europe
Data source: World Health Organisation, 2010465
Figure 1-11 Standardized cirrhosis mortality rates
In contrast to other nations in Europe, and in particular France, which is relatively equivalent to
the UK in terms of gross domestic product, levels of development and healthcare, the annual
cirrhosis death rates in the UK have increased in comparison to decreases elsewhere. This
trend may reflect increasing alcohol consumption in the UK. Abbreviations: EU – European
Union; UK – United Kingdom. Data source: World Health Organisation, 2005464
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PROGNOSIS
The prognosis of alcohol-related liver disease is largely dependent on the disease
stage, the level of liver dysfunction and whether abstinence is maintained subsequent
to diagnosis.
Following the development of steatosis, ten year survival rates range from 46% to
72%82. The development of steatosis is an indicator of liver damage and a significant
proportion of individuals with steatosis will go on to develop more severe forms of
alcohol-related liver disease such as cirrhosis. A Danish study following 106 patients
who were diagnosed with alcohol-related steatosis found that 22 (20.7%) developed
cirrhosis80 within 11 years and that mortality was significantly increased in comparison
to a reference population; out of the 79 deaths that occurred in the patients with
steatosis, 20 (25.3%) were liver related. With abstinence, steatosis is reversible and
the risk of developing further stages of alcohol-related liver disease is diminished.
Alcoholic hepatitis presents rapidly and has a poor short-term prognosis, being
associated with significant mortality. As a cause of alcohol-related liver disease, it is
less common than cirrhosis but its true prevalence is unknown. The histological
features of steatohepatitis may be present in 10-35% of hospitalised alcohol-dependent
patients66. In a large cohort (n=1092) of clinically diagnosed alcoholic hepatitis patients
from the UK that were recruited for the steroids or pentoxifylline for alcoholic hepatitis
trial, from the date of presentation, after twenty-eight days 16% of patients had died;
after ninety days 29% of the patients had died; and, after one year 56% of patients had
died427. Common causes of death, or other serious adverse events, in the STOPAH
cohort included gastrointestinal disorders (13% of patients) such as upper
gastrointestinal haemorrhage (4% of patients) or ascites (3% of patients), liver failure
(9% of patients), infections (15% of patients) and renal disorders (4% of patients).
Several prognostic models have been derived specifically to predict short-term survival
in patients with alcoholic hepatitis340. The most widely used of these models is the
modified Maddrey’s discriminant function268. Identified predictors of mortality include
histological features such as the degree of parenchymal neutrophil infiltration,
biochemical features such as serum bilirubin levels and blood clotting activity, and host
factors such as age and the presence of symptoms of significant liver dysfunction. In
patients that survive the short term, abstinence is the key predictor of disease progress
and mortality; this is more likely to happen in women and in individuals in whom the
initial histological findings upon presentation with alcoholic hepatitis were classified as
severe324.
The prognosis in alcohol-related cirrhosis is variable and dependent on the degree of
hepatic decompensation and whether abstinence is maintained post-diagnosis (Figure
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1-12). Consequently, the presentation with cirrhosis, without compromised liver
function, and with the maintenance of abstinence post diagnosis is relatively favourable
with ten year survival rates of 47%142. However, the presentation with cirrhosis with
clinical complications of liver dysfunction such as ascites, hepatic encephalopathy and
bleeding oesophageal varices has a considerably less favourable prognosis (Figure
1-12). In a UK based study containing 100 patients with biopsy-determined alcohol-
related cirrhosis, the seven year survival rates from a post-cirrhosis diagnosis were
72% in abstainers and 44% for those that continued drinking444. A primary treatment
option for chronic liver failure resulting from cirrhosis is orthotopic liver transplantation.
When used as a treatment option for liver failure resulting from alcohol-related
cirrhosis, the prognosis is favourable and is equivalent to survival in patients that have
undergone transplantation due to liver failure resulting from different aetiologies; the 1-
year post-transplantation survival rates following liver failure resulting from alcohol-
related cirrhosis are 66%35. Major causes of death in alcohol-related cirrhosis include
gastrointestinal haemorrhage, renal failure, liver failure and HCC25,379.
Figure 1-12 Survival from clinical presentation with alcohol-related cirrhosis
The cumulative survival in a cohort of patients with alcohol-related cirrhosis is mediated by their
clinical features at presentation (image A) and whether abstinence is maintained subsequent to
a diagnosis of cirrhosis (image B). Image modified from Saunders et al., 1981379
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Prognostic Scoring Systems
Hepatic decompensation may be quantified by several scoring algorithms such as the
Child-Turcotte-Pugh score65,348 (CTP) and the model for end-stage liver disease
score213(MELD); these are commonly used in clinical practice and medical research.
The CTP scoring system determines the level of hepatic decompensation based on a
five point system involving two clinical and three laboratory variables, namely the
presence and severity of ascites and hepatic encephalopathy and the plasma total
bilirubin, and serum albumin concentrations and the prothrombin time or INR. Each
variable is scored from 1 (least) to 3 (maximum) severity. Pugh’s scores of 5 and 6 are
classified as Child’s Grade A or compensated; 7 to 9 as Child’s Grade B or mildly
decompensated and 10 to 15 as Child’s Grade C or severely decompensated. For
purposes of statistical analysis patients with Pugh’s score 5 to 7 are classified as
compensated while patients with Pugh’s scores of 7 to 15 are classified as
decompensated. The primary limitation of the CTP scoring system is the reliance on
clinical assessment resulting in some inconsistency in its scoring.
The MELD scoring system overcomes the clinical assessment limitation of the CTP
scoring system and only requires information from laboratory tests, namely, the serum
bilirubin levels, the international normalised ratio and serum creatinine levels and the
aetiology of liver disease. The score generated by the MELD algorithm typically ranges
from ≤5 to ≥40 where a higher score denotes liver dysfunction.  Typically a MELD 
score ≤15 in cirrhosis indicates compensation whereas a score >15 indicates 
decompensation285.
PATHOPHYSIOLOGY
The pathogenesis of alcohol-related liver disease is multifactorial where complex
interactions between the host and environment mediate liver injury. Alcohol is clearly
the causative agent driving liver injury yet despite this knowledge, the molecular
mechanisms driving disease pathogenesis remain unclear. The identified mechanisms
are largely based on those pathways that have been characterized in animal or cellular
models.
Chronic alcohol consumption results in the deposition of lipids in hepatocytes. Alcohol
may cause this effect through several mechanisms (Figure 1-13). First, the metabolism
of alcohol in the liver is known to significantly alter the ratio of NADH to its oxidized
equivalent231. This alteration in the redox state of the liver likely promotes lipid
accumulation via increasing lipid synthesis and inhibiting lipid oxidation. Second,
alcohol inhibits the key regulator of cellular metabolism, adenosine monophosphate-
activated kinase (AMP-K)186. Inhibition of AMP-K results in the upregulation of
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peroxisome proliferator activated receptors (PPAR) and the downregulation of sterol
regulatory element binding proteins (SREBP), which also results in hepatic lipid
accumulation. There are many other potential mechanisms of hepatic lipid
accumulation in alcohol-related liver disease all relating to impairments in key lipid
processing pathways350 (Figure 1-13).
Further stages of alcohol-related liver disease involve direct injury to the liver via an
upregulation of immune responses through several pathways (Figure 1-14). The
metabolism of alcohol itself may cause inflammation through the generation of
acetaldehyde and reactive oxygen species. Such compounds may react with proteins
forming antigenic adducts upregulating an immune response. Alcohol consumption
also upregulates immune responses both by increasing gut permeability and by altering
the growth and diversity of bacteria present in the gut, allowing small bacterial cell wall
components, known as endotoxins, to enter peripheral circulation via the portal venous
system354. It has been demonstrated that the levels of endotoxins in peripheral
circulation are elevated following heavy alcohol consumption38. Endotoxins are strong
activators of Küppfer cells, a specialised macrophage type found in the liver.
Physiologically, Küppfer cells eliminate bacteria and foreign material in the blood.
However, interactions between endotoxins and the Toll-like receptor 4 (TLR4) found on
the surface of Küppfer cells results in cellular activation and inflammation. In animal
models, the loss of TLR-4 results in insensitivity to endotoxin and also alcohol-induced
liver injury439. A primary effect of Küppfer cell activation is the secretion of cytokines
such as tumour necrosis factor alpha (TNF-α).  Cytokines promote acute inflammation 
and activate apoptosis, resulting in a signalling cascade causing the recruitment of
neutrophils into the liver. Neutrophils increase liver tissue damage by inducing the
necrotic death of hepatocytes.
Inflammation and tissue death frequently resolve, in part, due to liver regeneration.
The liver is characterized by its high capacity for regeneration, although repeated
tissue injury results in a reduced regenerative capacity. In the later stages of alcohol-
related liver disease the loss of hepatocyte proliferative capacity is associated with a
worsening disease92; this process may involve cellular senescence and telomere
shortening453.
Cirrhosis is characterized by the significant functional impairment of the liver due to the
presence of scar tissue or fibrosis and a loss of hepatocyte regenerative capability.
The primary cell-type responsible for the deposition of fibrotic tissue is the hepatic
stellate cell (HSC). Physiologically, HSCs function in the storage of fat soluble
vitamins, such as vitamin A, and extra-cellular matrix homeostasis via the secretion of
matrix metalloproteinases (MMP). These enzymes degrade extra-cellular matrix
32
proteins, and are thus closely regulated by tissue inhibitors of metalloproteinases
(TIMP) under physiological conditions. Liver injury promotes the transition of HSCs
into a myofibroblast-like state, where collagen synthesis is upregulated and, matrix
degradation by MMPs is downregulated resulting in fibrosis. Several other changes
also occur following HSC activation including HSC proliferation and the increased
migration of HSCs to the site of liver injury.
Cirrhosis significantly predisposes to the development of HCC403. HCC, like all cancers
requires, in part, genomic alteration in key oncogenes that result in the uncontrolled cell
cycles. There are several potential mechanisms for hepatocellular carcinogenesis in
the cirrhotic liver113. First, the metabolism of alcohol produces acetaldehyde and other
reactive oxygen species; these are known mutagens and thus may cause somatic
mutations resulting in hepatocyte carcinogenesis. Second, liver damage induces
regeneration via cell replication; the additional cell cycles induced by regeneration
causes telomere shortening, which may increase chromosomal instability, allowing the
genomic alterations necessary for carcinogenesis. Third, hepatocyte proliferation is
impaired in cirrhosis; this may allow for loss of replicative competition in the liver by
healthy hepatocytes, thus promoting tumour formation. Finally, the altered micro and
macro environment of the cirrhotic liver may be directly carcinogenic in itself as it may
contain a combination of unique growth factors and other promoters of tumour
formation.
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Figure 1-13 Mechanisms of alcohol-related steatosis
Chronic alcohol consumption leads to steatosis via generation of acetaldehyde, ROS and ER
stress. The consequences are blockade of PPARα and of AMPK, which is responsible for fatty 
acid oxidation and export via ACC and CPT-1. In addition, chronic alcohol consumption induces
SREBP1c activation, which is responsible for fatty acid synthesis through FAS and fatty acid
desaturation through SCD1. TNF also leads to steatosis by activating SREBP1c. Betaine
reduces homocysteine levels, which thus enhances ER stress. Chronic alcohol consumption
also induces adipose tissue inflammation, which decreases the release of the protective
adiponectin, thus favouring steatosis. All these mechanisms lead to disruption of hepatic lipid
metabolism by increasing lipogenesis and decreasing fatty acid oxidation and export.
Abbreviations: ACC - acetyl CoA carboxylase; AMPK - adenosine monophosphate-activated
protein kinase; CCL2 - CC-chemokine ligand 2; CPT1 - carnitine palmitoylrransferase 1; ER -
endoplasmic reticulum; FAS - fatty  acid synthetase; PPAR-α - peroxisome proliferator-activated 
receptor α; ROS - reactive oxygen species; SCD1 - stearoyl-CoA  desaturase 1; SREBP1c - 
sterol regulatory element-binding protein 1c; TNFR1 - tumour necrosis factor receptor 1. Figure
adapted from Louvet et al., 2015264
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Figure 1-14 Metabolism of alcohol in the hepatocyte and mechanisms of cell injury
Alcohol dehydrogenase and MEOS mainly metabolize alcohol into acetaldehyde, which is
responsible for the generation of ROS. ROS cause oxidative stress, ER stress and steatosis.
ROS are also generated through activation of NADPH oxidase in Küpffer cells. All these
changes in hepatocyte metabolism lead to inflammation and apoptosis. Abbreviations: ADH -
alcohol dehydrogenase; ALDH - aldehyde dehydrogenase; CYP2E1 - cytochrome P450 2E1;
ER - endoplasmic reticulum; GSH - reduced glutathione; HO-1 - haem oxygenase 1; IRF3 -
interferon regulatory factor 3; LPS - lipopolysaccharide; MEOS - microsomal ethanol oxidation
system; NAD - nicotinamide adenine dinucleotide; ROS - reactive oxygen species; TNFR1 -
tumour necrosis factor receptor 1; TLR-4 - Toll-like Receptor 4; UPR - unfolded protein
response. Figure adapted from Louvet et al., 2015264
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1.4 - ALCOHOL AND GENETICS
1.4.1 - ALCOHOL USE/MISUSE
As a phenotype for genetic study, alcohol use/misuse may be investigated under a
variety of phenotypic models. The diagnosis of alcohol dependence is the most widely
studied qualitative phenotype as it has uniform diagnostic criteria and is the most
severe alcohol use phenotype. Alcohol consumption is the most widely studied
quantitative alcohol-use phenotype as this information is routinely collected in large
epidemiological datasets.
ENVIRONMENTAL AND HOST-MEDIATED RISK FACTORS
The consumption of alcohol from early adolescence until early adulthood seems to be a
crucial risk period for the development of later alcohol dependence. Beginning alcohol
consumption in early adolescence (11-14) may be an important risk factor for the
development of alcohol dependence as there is a strong correlation between the age of
alcohol consumption onset and the risk of developing alcohol dependence within 10
years98. During this period of life, the drinking behaviour of others including the familial
group, friends and peers is an important mediator of alcohol consumption levels and
hence risk of developing alcohol dependence. Parental alcohol problems and high trait
anxiety are significant risk factors for alcohol dependence during this period339.
The factors that mediate differences in alcohol-dependence risk by gender, are
complex. It is generally agreed on that constitutional differences and hence differences
in alcohol metabolism between males and females are one of the major factors. There
are also social factors that may influence gender differences in alcohol dependence
risk. Role theory suggests that traditional male gender role encourages alcohol
consumption whereas alcohol consumption is discouraged as part of the traditional
female gender role365. This effect appears to diminish when traditional gender roles are
displaced. It is clear that women who are more educated or have higher socio-
economic status are more likely to consume alcohol at hazardous levels314. It is
thought that this effect is partly due to increased affluence and hence the relative
affordability of alcohol but it may be the case that women with higher economic and
educational status are less likely to underreport drinking behaviour.
There are many other environmentally mediated risk factors such as negative life
events, chronic ill health, spouse stressors and an increased number of friends who
approve of drinking42. Identifying risk factors for alcohol misuse and dependence is
confounded by the complex interplay between the host and environment.
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HERITABILITY AND GENETIC RISK FACTORS
The earliest genetic studies of alcohol use quantified the contribution of environmental
and genetic factors by measuring heritability and familiality of alcohol-use phenotypes.
Heritability is the proportion of the total variation of a phenotype between individuals in
a population that is due to non-environmental genetic variation within a population,
whereas familiality is a measure of how often a phenotype tends to occur within
families. There are three types of study design that have been applied to the
heritability and familiality of alcohol-use phenotypes: twin studies, family studies and
adoption studies.
Twin studies involve comparisons between dizygotic, and monozygotic twins where,
based on the laws of inheritance, it is assumed that additive genetic risk is completely
shared between monozygotic twins while, in contrast, dizygotic twins will only share
half of their additive genetic risk. Using this information, concordance rates of a
phenotype such as alcohol dependence can be calculated by twin-type and statistically
compared. A higher concordance of the phenotype in monozygotic twins than dizygotic
twins suggests that genetic variation is contributing to the phenotype and may be used
to calculate a heritability estimate. Several large twin studies of alcohol dependence
and other alcohol-use phenotypes have been performed, with heritability estimates for
alcohol dependence ranging from 30% to 70%5 (Table 1-7). Such studies have
demonstrated differences in heritability by gender, although this finding may relate to
the smaller on average sample sizes of female twin-study cohorts. A potential
confounder of the twin study design is the assumption of equal environments320.
Family studies statistically quantify whether a phenotype is present in related members
of a family more than would be expected by chance. Alcohol dependence is clearly a
familial phenotype as the siblings of alcohol-dependent individuals have a higher
likelihood of alcohol-dependence than would be expected from a random
population363,461. For example, in the USA the siblings of an individual with alcohol
dependence have a lifetime chance of becoming dependent themselves of 49.7% for
male siblings and 22.4% for female siblings32; this rate is significantly higher than in
control siblings. By design, family studies measure the familiality of a phenotype and
provide no information regarding the heritability of a phenotype as family members are
typically exposed to the same environmental factors.
Adoption studies are able to exclude the confounding shared environment by
comparing the concordance between the phenotypes of adopted away offspring with
the phenotypes of biological and adoptive parents. Heritability may be estimated if the
concordance in phenotype between adopted away offspring and biological parents is
higher than would be expected by chance. There are no adoption studies that solely
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focus on the alcohol dependence phenotype per se instead focusing on less specific
alcohol misuse phenotypes. The three major adoption studies of alcohol-use
phenotypes are the Danish Adoption Cohort, the Stockholm Adoption Cohort and the
Iowa Adoption Cohort (Table 1-8) with the majority of analyses demonstrating
moderate heritability estimates.
Twin, family and adoption studies provide considerable evidence for significant
familiality and heritability of the alcohol dependence and alcohol misuse phenotypes.
Despite this, many of the individual studies are non-comparable due to differences in
phenotypic classification or analytical methodology between studies. Heritability
estimates often differ by gender and are typically larger in cohorts that only contain
males. A large meta-analysis of over fifty twin, family and adoption studies of alcohol
misuse phenotypes indicated that heritability estimates of alcohol dependence
exceeding 40% to 60% may be inflated and that there is significant heterogeneity in the
results of most studies with the true heritability estimate closer to 30% to 36%446. It is
clear that both genetic and environmental risk factors, and their interplay, have a
substantial role in alcohol-dependence and alcohol-misuse phenotypes.
Table 1-7 Twin studies of alcohol-dependence
Location Diagnosticcriteria
Monozygotic twins Dizygotic twins HE
(%) Sourcen Sex C(%) N Sex
C
(%)
Sweden Chronicalcoholism 27 M 71 60 M 32 72
Kaij,
1960210
Finland Alcoholism 172 M 26 557 M 12 30 Partanen,1966326
UK Alcoholism
15 M 33 20 M 30 8 Gurling,
198116013 F 8 8 F 13 -16
USA Alcoholism 271 M 26.3 444 M 11.9 36 Hrubrec,1981185
Finland Alcoholism
69 M 13 175 M 5.7 24 Koskenvuo,
19842287 F 0 20 F 0 0
Sweden Alcoholism 95 M 12.6 187 M 9.1 14 Allgulander,19918
USA DSM-III AD
39 M 59 47 M 36.2 46 Pickens,
199133324 F 25 20 F 5 54
USA Alcoholdependence 203 F 26.2 154 F 11.9 34
Kendler,
1994218
USA DSM-IV AD 378 M 31.7 436 M 19.3 28 Prescott,1999342
Australia Alcoholdependence
396 M 38.9 231 M 19.9 40 Heath,
1997172932 F 20.9 534 F 9.2 22
USA Alcoholism 710 M 53.2 588 M 43.2 20 True,1996435
USA Alcoholdependence
28 M 40 26 M 13 48 Prescott,
200534348 F 17 58 F 24 10
Abbreviations: n – number, C – concordance, HE – heritability estimate, M – male, F – female,
UK – United Kingdom, USA – United States of America, AD – alcohol dependence, DSM-III –
diagnostic and statistical manual of mental disorders third edition.
Table modified from Walters, 2002446
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Table 1-8 Adoption studies of alcohol use phenotypes
Cohort DiagnosticCriteria
Proband subjects Control subjects
HE
(%) Year Source
n Sex Outcome n Sex Outcome
Danish
Adoption
Cohort
Alcoholism 55 M 18.2 78 M 5.1 42 1973
Goodwin,
1973147Problem
drinking 55 M 9.1 78 M 14.1 -16 1973
Alcoholism 6 F 33.3 90 F 52.2 -18 1977 Goodwin,1977148
Stockholm
Adoption
Cohort
Alcohol abuse 89 M 39.4 892 M 13.1 42 1978 Bohman,197840
Alcohol abuse 172 F 7 741 F 2.6 20 1981 Bohman,198141
Severe alcohol
abuse 307 M 7.8 555 M 4.9 12 1981
Cloninger,
198167
Alcohol abuse 108 M 24.1 469 M 12.8 24 1996
Sigvarsson,
1996396
Alcohol abuse 114 F 0.9 546 F 1.3 -2 1996
Iowa
Adoption
Cohort
Alcoholism 23 M 13 69 M 1.4 52 1980 Cadoret,198047
Alcohol abuse 39 B 48.7 404 B 13.9 5 1986 Cadoret,198649
Alcohol abuse 49 B 70.6 34 B 55.1 32 1994 Cadoret,199448
Abbreviations: n – number, HE – heritability estimate, M – male, F – female, B – both.
Table modified from Walters, 2002446
GENOME-WIDE STUDIES
There are two main approaches for the identification of risk loci/genes from the human
genome: linkage studies and genome-wide association studies.
The earliest technique to be developed was the linkage study, which is typically
performed in phenotypically well-characterized individuals from a single or several
families in which the phenotype of interest is familial. This technique relies on the
genotyping of hundreds of variants dispersed across the genome to capture the
patterns of crossing-over during the recombination events of meiosis. Linkage occurs
when the alleles of two more variants co-occur (i.e. are non-randomly inherited) in
members of the family that have the phenotype of interest. Linkage is statistically
quantified by calculating the logarithm of odds ratio score (LOD), a statistical estimate
of whether two genes, or a gene and a disease, are linked to one another. A LOD
score greater than 3 is indicative of linkage between a genomic region and a
phenotype297. For phenotypes with Mendelian patterns of inheritance, this technique
allows the accurate identification of causal genes. For complex disease phenotypes,
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this technique has limitations, especially when the phenotype of interest is of adult
onset such as alcohol dependence.
Several genome-wide linkage scans have been performed when studying alcohol use
and alcohol dependence (Table 1-9). The genomic regions implicated by studies in
alcohol dependence have been inconsistent with modest LOD scores suggesting that
risk variants for alcohol dependence are of small effect size. However, the genomic
locations with the modest linkage evidence contain plausible candidate loci such as the
alcohol-dehydrogenase gene cluster, and the GABA receptor gene cluster.
Table 1-9 Genome-wide linkages studies of alcohol use phenotypes
Phenotype Families Regions*
Candidate
Genes in
region
Ethnicity Cohorts Country Source
Alcohol
dependence 713 — — EUR UCSF USA
Gizer,
2011143
Alcohol
dependence
symptoms
1690 — — EUR — Australia Hansell,2010165
Alcohol
dependence 238
10q23.3–
24.1 — AFR — USA
Gelernter,
2009138
Alcohol
dependence;
Alcohol Use
474 4q22-32 — EUR IASPSAD Ireland Prescott,2006344
Alcohol
dependence 158 — — EUR SMOFAM USA
Wilhelmsen,
2005456
Consumption 330 — — EUR FraminghamHeart Study USA
Wyszynski,
2003468
Alcohol
dependence 100 ~chr4 ADH1B NA — USA
Ehlers,
2004112
Alcohol
dependence 172
chr11p,
chr4p
ADH cluster,
TH NA — USA
Long,
1998262
Alcohol
dependence 105 — — EUR — USA
Reich,
1998364
Abbreviations: SMOFAM – Smoking in Families Study; IASPSAD – Irish Affected Sib-Pair Study
of Alcohol Dependence, UCSF – University of California San Francisco, EUR – European, AFR
– African, NA – Native American, USA – United States of America. *LOD score > 3
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Genome-wide association studies (GWAS) are the paradigm successors of linkage
studies. GWAS involve the extensive parallel genotyping of hundreds of thousands of
genomic markers, typically single nucleotide polymorphisms (SNPS), which cover the
majority of common genetic variation across the human genome. GWAS are
performed in large, generally unrelated, populations in which either qualitative or
quantitative phenotypic data have been collected. These data are analysed for
significant differences in allele or genotype frequencies resulting in genetic association
when an allele is associated with a phenotype at a specified significance threshold.
A typical GWAS involves the statistical testing of hundreds of thousands of partially
independent genetic variants for association with a phenotype. This multiple testing
increases the likelihood of false positive association signals. To account for this, a
variant is typically deemed significantly associated with a phenotype when the
significance value is less than a certain threshold (P < 5x10-8), known as the genome-
wide significance threshold. The genome wide significance threshold equates to there
being 1 million independent tests when accounting for common genetic variation and
its linkage disequilibrium patterns105. Before a variant is deemed associated with a
phenotype or trait it generally requires independent verification through replication
analysis in a separate population or cohort59. It follows that the numbers of samples
needed for an effective GWAS are very large.
Several GWAS of alcohol-use and alcohol-dependence phenotypes have been
undertaken (Table 1-10). Many of these have been collaborative studies,
predominantly from the USA, in which large cohorts of alcohol-dependent cases and
population controls have been collected. In most instances the cohorts recruited in the
USA have been phenotypically heterogeneous, containing samples of multiple
different, or mixed, ancestries with a high proportion of the cohort having comorbidities
such as drug dependence32. Many of the smaller GWAS of alcohol dependence have
failed to identify genome-wide significant associations. Meta-analyses and studies in
populations with greater phenotypic surety have identified genome-wide significant
associations between variants in genes responsible for alcohol metabolism, for
example ALDH2 and ADH1B in East Asian ancestry populations and ADH1B and
ADH1C in European, African and East Asian ancestry populations.
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Table 1-10 Genome-wide association studies of alcohol use phenotypes
Pheno
Cases Controls
Genes* Ethnicity Cohorts Country Source
n Sex n Sex
AD 7,677 B 6,992 B ADH1B, ADH1C,METAP, PDLIM5 EUR, AFR
GCD,
SAGE USA
Gelernter,
2014139
AD 621 B 750 B ADH1B, ALDH2 EA - SouthKorea
Park,
2013325
AD 1,333 M 2,168 M ADH1B-ADH1C EUR - Germany Frank,2012130
AD 2,090 B 2,026 B KIAA0040 EUR, AFR SAGE,COGA USA
Zuo,
2012483
CONS 2,834 M - - ALDH2 EA - SouthKorea
Baik,
201117
CONS 47,501 B - - AUTS2 EUR AlcGen Several EUNations
Schumann,
2011384
AUD 2,062 B 3,393 B - EUR OZALC Australia Heath,2011173
AD/ND 1,823 B 2,763 B - EUR NESDA,OZALC
Holland,
Australia
Lind,
2010254
AD 1,192 B 692 B - EUR, AFR COGA USA Edenberg,2010108
AD 1,897 B 1,932 B - EUR, AFR SAGE USA,Germany
Bierut,
201034
AD 1,511 M 2,354 M PECR EUR - Germany Treutlein,2009433
Abbreviations: Pheno – phenotype, AD – alcohol dependence, CONS – alcohol consumption,
AUD – alcohol-use disorder, N – number, M – Male, B – Both males and females, EUR –
European, AFR – African, EA – East Asian, COGA – Collaborative study on the genetics of
alcoholism, SAGE - Study of Addiction: Genetics and Environment, OZALC - Australian twin-
family study of alcohol use disorder, NESDA – Netherlands Study of Depression and Anxiety,
AlcGen – Alcohol-GWAS consortium, GCD – GWAS discovery samples, USA – United States of
America.  *P value ≤ 5 x10
-8
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CANDIDATE GENE STUDIES
To date there have been over three-hundred candidate genetic association studies of
alcohol-dependence and related phenotypes (Figure 1-15). The majority of candidate
gene studies have failed to identify statistically significant genetic association or have
been inconsistent7 on replication analysis; this failure to replicate is a notable feature of
the candidate gene approach179. Candidate gene studies have identified some
replicable associations predominantly between functional variants in gene encoding
enzymes responsible for alcohol metabolism such as rs1229984 (Arg48His) in
ADH1B245 in European33, African33 and East Asian245 ancestry populations and rs671
(Glu504Lys) in ALDH2 in East-Asian246 ancestry populations. The combination of
genetic and functional analyses has proven complementary for the study of candidate
genes, as is the case for the several GABA genes, which encode subunits of GABA
receptor. The likely importance of variation in GABA genes is highlighted by positive
genetic associations in GABRA2107 and the strong phenotypic effects on alcohol
consumption resulting from functional mutations in the murine orthologue Gabrb113.
Figure 1-15 The number of genetic association studies of alcohol dependence
The number of journal articles for a given year identified in the PubMed database305 searching
for genetic association studies of alcohol dependence in humans excluding GWAS and meta-
analyses. Pubmed search term: “genetic association study Alcohol dependence NOT (GWAS
OR Family OR Linkage OR Meta-analysis)”
1.4.2 - ALCOHOL-RELATED LIVER DISEASE
Alcohol-related liver disease is precipitated by alcohol misuse241. However, there is
considerable variation in individual risk likely relating to a combination of genetic and
environmental factors. Case/control genetic association studies of alcohol-related
cirrhosis must avoid confounding by comparing groups that have experienced the
same environmental exposure (i.e. long-term harmful alcohol consumption) and either
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have established alcohol-related cirrhosis or else have no liver disease. Both groups
are difficult to identify with certainty, as this would usually require examination of liver
histology, which is uncommon in clinical practice. This may partially explain why the
study of alcohol-related liver disease genetics has received less attention than the
study of genetics in other forms of liver disease.
ENVIRONMENTAL FACTORS
Increasing alcohol consumption is the principle contributory epidemiologic factor in
alcohol-related cirrhosis241, although there are equivocal findings regarding the degree
to which the pattern of consumption and the amount of alcohol consumed contribute to
risk. Lelbach’s seminal work demonstrated a dose-response relationship between
alcohol consumption and cirrhosis risk240. A number of large prospective cohort
studies24,28,214,226,404 and a systematic review362, have since validated this relationship
from which it seems likely that above a threshold alcohol dose there is a dose-
dependent increase in risk. Findings between studies are highly variable, which may
relate to the difficulties in determining accurate alcohol consumption levels and
differences in the ascertainment of alcohol-related cirrhosis (e.g. clinical diagnosis,
biopsy, cause of death). There is a greater degree of contention as to whether the
pattern of consumption (e.g. regular daily drinking or irregular bingeing) influences risk.
Animal models would suggest that irregular bingeing is more harmful to the liver394 and
some epidemiological studies demonstrate findings that are in agreement with this85.
However, many more epidemiological studies find the opposite of this15,240,404 (i.e. daily
consumption is associated with increased risk of cirrhosis). Studies of drinking patterns
may be confounded by failing to account the total amount of alcohol consumed when
directly comparing regular and irregular drinkers359, as is the case for all but one15
study.
There are many other potential environmental factors, which relate either directly or
indirectly to alcohol consumption. Two large prospective studies have identified that
the type of alcoholic beverage, namely the consumption of wine, is associated with
reduced cirrhosis risk in comparison to the consumption of beer15,23. The consumption
of alcohol with food may also reduce the risk for developing cirrhosis28 and a high fat
and a low carbohydrate and protein diet may increase risk373. Several studies have
suggested a link between coffee consumption and protection from the development of
cirrhosis219. Smoking also seems to be an independent risk factor for the development
of alcohol-related cirrhosis81,226. Many risk factors have been associated, although
determining causality is more challenging due to the potential for confounding.
Constitutional differences influence the risk of developing alcohol-related cirrhosis. It is
well established that women are at an increased risk of developing alcohol-related
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cirrhosis295, even when differences in alcohol consumption levels are accounted for437.
This gender difference relates to the on average proportionally higher body fat content
composition of women. Body-fat content in in both genders, is associated with an
increased risk of developing alcohol-related cirrhosis304; this is potentially due to a
synergistic interaction between alcohol consumption and weight167. It seems likely that
the features of the metabolic syndrome that drive the progression of NAFLD, may also
contribute to alcohol-related liver disease pathogenesis357. A similar feature may also
occur in other forms of liver disease, where, in combination with alcohol consumption
infection with hepatitis C or hepatitis B virus is associated with a synergistic interaction
to increase risk298.
HERITABILITY AND GENETIC RISK FACTORS
Epidemiological studies of alcohol dependence heritability and familiality are limited to
a few studies. A single cohort has been used to estimate the heritability of alcohol-
related cirrhosis in study of a population of 15,924 male twin pairs185,194 from which it
was determined that the concordance of alcohol-related cirrhosis was three times
higher in monozygotic twins (14.6%) than dizygotic twins (5.4%). A subsequent
analysis of this large twin dataset data, with over a decade of additional clinical follow-
up has replicated this finding358. Between both analyses, heritability estimates ranged
from 21% to 67%. Otherwise, there is a single familial study of alcohol-related
cirrhosis452 in which patients with alcohol-related cirrhosis were more than twice as
likely to self-report that their father had liver disease and alcohol problems than control
alcohol misusers without significant liver injury.
There are marked differences in alcohol-related cirrhosis risk based on ethnicity. In the
United Kingdom non-Muslim men of South Asian ancestry present with alcohol-related
cirrhosis at a younger age and at a higher than expected frequency in comparison to
their white British counterparts living in the same area102. In the United States, a
similar observation has been observed where individuals of Hispanic ancestry present
with alcohol-related cirrhosis up to 10 years before white/Caucasian populations when
controlling for confounding issues244.
Perhaps the best existing paradigm for the role of a genetic variation in the context of
alcohol-related cirrhosis risk is for the variant rs671, which encodes a non-synonymous
substitution (Glu504Lys) in ALDH2. The 504Lys allele of rs671 results in a catalytically
inactive ALDH2 enzyme that has a limited capacity to clear acetaldehyde, resulting in
the so-called ‘alcohol flushing reaction’. Carriers of this allele may become averse to
alcohol consumption and hence the possession of this allele is highly protective against
the development of alcohol-related cirrhosis. In a meta-analysis of all published
studies a significant and robust association was identified between possession of this
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variant and the development of several alcohol-related harms including cirrhosis (PMETA
= 6 x10-19, Odds Ratio (OR) = 0.25, 95% confidence interval (CI) [0.19–0.34])246.
Although this variant is associated with protection from alcohol-related cirrhosis there
are several notable features of this association that are salient to the complexities of
this phenotype: first, this variant only occurs in individuals of East Asian ancestry and
thus only influences risk in these populations; second, this variant mediates alcohol
consumption per se rather than alcohol-related liver disease and thus indirectly
protects against alcohol-related liver disease; and finally, the variant also influences the
risk of other types of injury related to harmful alcohol use. This strong genetic
association at ALDH2 highlights the potential for confounding in genetic association
studies of alcohol-related liver disease where a genetic variant, which directly
influences alcohol consumption, may indirectly associate with the alcohol-related liver
disease.
Based on the wide variety in inter-individual risk for developing alcohol-related cirrhosis
and the heritability of this phenotype shown in twins, it is widely held that alcohol-
related cirrhosis risk is modulated through polygenic and complex inheritance in the
presence of environmental risk factors86,411.
GENOME-WIDE STUDIES
There have not been any genome wide linkage studies or GWAS of alcohol-related
liver cirrhosis or related phenotypes. This contrasts with all other major types of liver
disease, in which over thirty GWAS have been performed sometimes with different
aspects of the disease studied (Table 1-11). From these studies of other forms of liver
disease, it is clear that genetic variation plays a substantial role and may impact
clinically relevant aspects of disease progression. For example, a variant in IL28B has
large effect on antiviral treatment response and may have clinical utility in determining
treatment options136,355,417,421. Similarly, in NAFLD12 a major finding has been the
robust association between the variant rs738409 in PNPLA3 with several aspects of
the disease phenotype including steatosis, fibrogenesis and the development of HCC.
In most cases, the loci identified via GWAS have been followed by replication
genotyping in independent cohorts and functional studies to understand mechanisms of
pathogenesis.
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Table 1-11 Genome wide association studies of liver disease phenotypes
References Phenotype Summary
Romeo et al., 2008370
Chalasani et al., 201052
Speliotes et al., 2011405
Kawaguchi et al., 2012217
Kitamoto et al., 2013225
Feitosa et al., 2013124
Kozlitina et al., 2014229
Non-alcohol-
related fatty
liver disease
Several GWAS have examined features of NAFLD
including liver fat content; histological NAFLD and other
clinically determined phenotypes. The variant rs738409
in PNPLA3 has been robustly associated with NAFLD
and related phenotypes. Several other loci have been
identified with varying degrees of support. The
functional variant rs58542926 in TM6SF2 from an
extended LD block has been validated as a risk variant
in several studies
Mells et al., 2011289
Liu et al., 2010 260
Nakamura, 2012301
Liu et al., 2012258
Primary biliary
cirrhosis
These studies have been performed in large European
and East-Asian ancestry cohorts. The majority of
identified loci are involved in innate immunity, including:
HLA region, STAT4, DENND1B, CD80, IL7R, CXCR5,
TNFRSF1A, CLEC16A and NFKB1
Kamatani et al., 2009212
Mbarek et al., 2011286
Nishida et al., 2012310
Zhang et al., 2010477
Jiang et al., 2013199
Li et al., 2012248
Chan et al., 201157
Chen et al., 201362
Qu et al., 2016351
Png et al., 2011338
Hepatitis B
A number of features of hepatitis B infection have been
investigated via GWAS in primarily East-Asian and
European ancestry cohorts, including: chronic infection,
hepatitis B related HCC, and vaccine response. Studies
of chronic infection are limited to a single GWAS in
Asian ancestry populations, identifying risk and
protective haplotypes at the HLA-DP locus. A greater
number of GWAS have investigated hepatitis B related
HCC in in diverse global populations validating loci
including 1p36.22, STAT4, HLA-DG genes. In an
Indonesian cohort, the genes implicated in vaccine
response are largely found in the gene rich HLA Class III
interval
Ellinghaus et al., 2013114
Folseraas et al., 2012127
Melum et al., 2011290
Liu et al., 2013260
Primary
sclerosing
cholangitis
Primarily in European ancestry cohorts, several primary
GWAS and re-analyses have confirmed over 10
established risk loci including the HLA region, 3p21,
2q35, IL21, CARD9, REL, GPR35 and TCF4. These
analysis reveal a significant shared genetic risk with the
comorbidity ulcerative colitis
de Boer et al., 201288 Autoimmunehepatitis
Only a single GWAS has been performed in this less
common form of liver disease. The several identified
loci: HLADRB1*0301, HLA-DRB1*0401, SH2B3,
CARD10, overlap with those identified in other forms of
autoimmune liver disease
Rauch et al., 2010355
Kumar et al., 2011232
Hoshida et al., 2012183
Patin et al., 2012328
Miki et al., 2013441,
Ge et al., 2009136
Tanaka et al., 2009421
Suppiah et al., 2009417
Hepatitis C
Several features of hepatitis C infection have been
investigated in primarily East-Asian and European
ancestry cohorts, including: HCV induced cirrhosis, HCV
induced HCC, viral clearance in chronic HCV and
antiviral treatment response. There is a strong role of
genetic variants in the HLA region. Variants in MICA
may influence HCV progression to HCC. Variants in
MERTK/TULP1 associate with fibrogenesis and variants
in SAG fibrosis score. The variant rs12979860 IL28B
strongly predicts antiviral treatment response and may
have utility in clinical decision-making.
Abbreviations: HCC – Hepatocellular Carcinoma; NAFLD – Non-alcohol-related Fatty Liver
Disease LD – Linkage Disequilibrium; HLA – Human Leukocyte Antigen; HCV – Hepatitis C
Virus
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CANDIDATE GENE STUDIES
A number of candidate gene studies have been performed in cohorts of patients with
alcohol-related liver disease (Table 1-12). The selection of candidate genes has most
often resulted from hypotheses based on known biological mechanisms of liver injury
and almost invariably studies have genotyped protein altering variants (e.g. non-
synonymous or promoter variants). These include variants in genes implicated in:
alcohol metabolism482 such as alcohol dehydrogenase (ADH1B, ADH1C), aldehyde
dehydrogenase (ALDH2), or cytochrome P450 (CYP2E1); fibrogenesis such as matrix
metalloproteinases412 (MMP3); the deposition of lipids such as apoliprotein ε175
(APOE), phosphatidylethanolamine N-methyltransferase207 (PEMT) or microsomal
triglyceride transfer protein (MTTP); DNA damage and carcinogenesis such as X-ray
repair cross-complementing protein 1372 (XRCC1); the accumulation of iron in the liver
such as the human hemochromatosis protein158 (HFE); immune response such as
cluster of differentiation 14195 (CD14), tumour necrosis factor alpha156 (TNFα), cytotoxic
T-lymphocyte-associated protein 4442 (CTLA4) or the nuclear factor kappa-B subunit280
(NFKB1); and, oxidative stress such as mitochondrial superoxide dismutase 290
(SOD2) or glutathione S-transferase282 (GSTM1, GSTT1, GSTP1).
Most of the genetic association studies of alcohol-related liver disease have proven
negative, or negative following meta-analysis (Table 1-13). At least three genes that
have undergone meta-analysis may contain genuine risk variants: the promoter variant
rs361525 (-238) in TNFα, which is associated with alcohol-related liver disease when 
compared population controls281; the GSTM1 null allele, which is associated with
alcohol-related liver disease when compared with no-liver disease controls282; and,
heterozygosity for the variant rs1800562 (Cys282Tyr) in HFE and risk of developing
HCC in alcohol-related cirrhosis when compared with alcohol-related cirrhosis patients
with no HCC200. Several factors may explain the inconsistency: first, the small sample
sizes of early studies are likely to have limited statistical power; second, the differences
in phenotypic criteria (e.g. fibrosis, cirrhosis, liver fat, inflammation) and different
comparisons (e.g. population controls or no liver disease controls) between studies;
and finally confounding resulting from genetic associations with alcohol-use
phenotypes279,482.
The candidate gene approach, has proven most successful with the identification and
validation of the robust associations between the variant rs738409 (Ile148Met) in
PNPLA3 and alcohol-related cirrhosis377,428 and alcohol-related HCC. This variant,
which was originally identified by a GWAS of NAFLD370, will be discussed in detail in
later sections of this work.
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Table 1-12 Genetic association studies of alcohol-related liver disease phenotypes
Source Case/controlcomparison Patients Cases Controls Gene Variant
Risk
allele P-value
Järveläinen et
al., 2001195
Cirrhosis vs.
CON
Finnish
men 48 178 CD14
rs2569190
(-159) T <0.005
Grove et al.,
1997156
Cirrhosis vs
CON
British
118 145
TNF-a
rs361525
(-238)
NA NS
Steatohepatitis
vs CON 58 145 A <0.05
Cirrhosis vs
CON 118 145
rs1800629
(-308) NA NS
Grove et al.,
2000157 ALD vs. CON British 287 227 IL-10
rs1800872
(-627) A <0.0001
rs1800896
(-1117) A <0.05
Savolainen et
al., 1996380
Cirrhosis vs.
NLI
Finnish
men 72 54 GSTM1 Null allele Null allele <0.05
Oliver et al.,
2005316 ALD vs. CON Spanish 165 185 TGF-β1
rs1800470
(+869) NA NS
rs1800471
(+915) NA NS
rs1800469
(-509) NA NS
Hernández-
Nazará et al.,
2008175
Cirrhosis vs.
CON Mexican 86 133 APOE
rs7412 (Arg112Cys)
rs429358 (Cys158Arg)
APOE*2: Cys112, Cys158
APOE*3: Cys112 Arg158
APOE*4:Arg112, Arg158
APOE*2 <0.01
Rossit et al.,
2002372
Cirrhosis vs.
CON
South-
eastern
Brazil
97 96 XRCC1
rs1799782
(Arg194Trp) NA NS
rs25487
(Arg399Gln) Gln <0.01
Degoul et al.,
200190
Cirrhosis vs
CON French 13 79 SOD2 rs4880 (Ala16Val) Ala <0.001
Marcos et al.,
2009280
Cirrhosis vs.
NLI Spain 96 161
NFKB1 rs28720239(94ins⁄delATTG) NA NS
NFKBIA rs696 NA NS
PPARG rs1801282(Pro12Ala) NA NS
Grove et al.,
1998158
ALD vs.
Population
controls
British 242 117 HFE
rs1799945
(His63Asp) NA NS
rs1800562
(Cys282Tyr) NA NS
Jun et al.,
2009207 ALD Korean
82 113 PEMT rs7946(Val175Met) NA NS
82 95 MTTP rs3816873 (Ile128Thr) T <0.05
Stickel et al.,
2008412
Cirrhosis vs.
NLI
British;
German 689 334 MMP3
rs35068180
(5A ⁄6A) NA NS
Valenti et
al.,2004442 ALD vs. NLI Italian 183 43 CTLA-4
rs231775
(Thr17Ala) Ala <0.05
Takamatsu et
al., 2000419
Cirrhosis vs.
NLI Japanese 77 30
IL-1B
rs1143634
(+3953) NA NS
rs16944
(-511) NA <0.005
Cirrhosis vs.
CON Japanese 77 218
rs1143634
(+3953) NA NS
rs16944
(-511) NA <0.05
Takamatsu et
al, 1998418 ALD vs. CON
Japanese
men 102 46 IL1RN
rs2234663
(86bp VNTR) NA p<0.001
Abbreviations: ALD – Alcohol-related liver disease; CON – Population controls; NLI- Alcohol
misusing no liver injury controls; NA – Non-available; NS – Non-significant
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1.5 - AIMS OF THESIS
The overriding aim of this thesis was to determine the contribution of genetics factors to
alcohol-related cirrhosis risk. To address this aim, the focus of this research was to
contribute to a hypothesis generating genome-wide association study, with the
subsequent identification, validation and characterization of identified loci. In particular,
this work focuses on the functional and genetic characterization of PNPLA3 through a
detailed study of variants in this gene in the UCL cohort and functional characterization
of the PNPLA3 protein through structural studies.
The specific aims of this thesis are:
1. To perform the first genome-wide association study of alcohol-related cirrhosis,
in collaboration with several research groups, focusing on the identification and
validation of novel loci.
2. To identify novel alcohol-related cirrhosis risk loci through an extended
genome-wide association analysis including data from additional cohorts.
3. To refine the role of rs738409 in PNPLA3 on alcohol-related cirrhosis risk
beyond genetic association per se.
4. To characterise the PNPLA3 protein and the functional effects of the non-
synonymous genetic variant rs738409 (Ile148Met) through structural and
functional analysis.
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CHAPTER 2 GENOME-WIDE
ASSOCIATION STUDY OF ALCOHOL-
RELATED CIRRHOSIS
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2.1 - OVERVIEW
This chapter details the first genome-wide association study of alcohol-related cirrhosis
demonstrating genome-wide significant associations in three loci: patatin-like domain
containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2) and
membrane-bound O-acyltransferase domain-containing protein 7 (MBOAT7). These
data are summarized in a recent publication44.
2.2 - BACKGROUND
A GWAS requires the genotyping of hundreds of thousands of genetic variants,
typically SNPs, in cohorts that often contain many thousands of samples.
Consequently, there are many potential sources of error. The commonest types of
error are sample mishandling errors, population stratification and the presence of low
quality genotypes and DNA samples in a dataset11. A quality control process is
typically effected before association analysis during which low quality genotypes and
samples are removed from the data.
Novel risk loci are identified in a GWAS by statistical tests where the frequencies of
alleles or genotypes are compared by a phenotype or trait of interest. Because of the
stringent significance levels required in a GWAS, statistical power is a key issue in the
study and analytical design120. Many variables influence the statistical power of GWAS
such as the genetic architecture of a phenotype, the inheritance model that is tested
(dominant, recessive, allelic, genotypic) and the number of variants genotyped and the
presence of confounding factors in the study population. The techniques of imputation
and meta-analysis can maximise statistical power in a GWAS389.
Genotype imputation is the process through which genotypes are inferred through
known linkage disequilibrium patterns in the human genome184. The genetic variants
present on most GWAS bead-chips are, by-design, in linkage disequilibrium with the
majority of other un-genotyped genetic variants that are present in the human genome.
This ‘coverage’ of the human genome increases with a greater number of variants that
are genotyped by a GWAS bead-chip and is further increased by using imputation.
The increased variant coverage provided by imputation increases the statistical power
of a GWAS, where simulations have demonstrated that imputation can boost power by
around 10%406. Another prime use for imputation is the comparison of distinct GWAS
datasets, which often have discordant variant genotypes. Imputation can allow
datasets to be consolidated either through meta-analysis or the harmonisation and
merging of raw genome-wide genotyping data.
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Imputed genotypes are probabilistic and consequently contain a degree of uncertainty,
which if not accounted for may lead to error. When comparing the concordance
between imputed and direct genotypes error rates vary331. The uncertainty of imputed
genotypes can be accounted for by using allele dosages rather than the binary allele
coding used in association analysis, which is applied by the software SNPTEST278.
The quality of imputation is largely dependent on a high-quality reference dataset such
as the Haplotype Map project data192 or the 1000 genomes project data1.
Meta-analysis is a statistical technique in which the results from multiple studies are
analysed together119 and is often applied in GWAS of the same phenotype or trait. It
has particular utility when there are different GWAS datasets that cannot be
harmonised and merged due to substantial population differences. Both fixed effects
and random effects meta-analyses may be applied. Sometimes statistical
heterogeneity, or the differences between study results that exceeds expected
variance, occurs between studies for a number of variant associations. Heterogeneity
may arise in a GWAS due to differences in ancestry or phenotypic classification
between cohorts or differences in the genotyping subsequent processing of data.
Despite the possibility of heterogeneity, the increased number of samples undergoing
analysis increases statistical power.
2.3 - AIM
To perform the first genome-wide association study of alcohol-related cirrhosis.
2.4 - MATERIALS AND METHODS
This study was by design, split into two stages: (i) a discovery stage in which two
primary cohorts underwent genome-wide association analysis identifying candidate
loci; and, (ii) a validation stage in which the top-hit variants from the discovery stage
were directly genotyped in two independent validations cohorts (Figure 2-1). Following
the primary discovery and validation analyses, post-hoc analyses were performed.
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Figure 2-1 A schematic of the two-stage genome-wide association study design
2.4.1 - DISCOVERY COHORT
The discovery cohort was comprised of two groups containing patients recruited in the
UK and Germany (Table 2-1). These groups contained the DNA samples that
underwent genome-wide association analysis for the identification of significantly
associated variants for replication in the validation cohort.
Table 2-1 Demographics features of the discovery cohort
Discovery Cohort
Germany United Kingdom
Cases
(n=410)
Controls
(n=1080)
Cases
(n=302)
Controls
(n=346)
Median age years
(IQR) 53 (47-61) 42 (36-48) 53 (47-60) 49 (42-56)
Gender (% Male) 71 100 68 77
Median BMI
(IQR)* 26.2 (22.8-29.3) 24.8 (22.7-27.5) 24.8 (22.8-26.8) 24.6 (22.8-26.6)
Diabetes Type II
(%)* 24 4.0 0** 0**
Abbreviations: n – number; IQR – inter-quartile range; BMI – Body mass index. **Diagnosis of
type II diabetes was an exclusion criteria in the UK cohort
GERMAN DISCOVERY SAMPLES
The patients from Germany were recruited from 2000 until 2013 according to uniform
criteria across all centres. Alcohol consumption data were self-reported via interview by
a trained professional. All patients underwent careful clinical examination, standard
laboratory testing and abdominal ultrasound. Patients were excluded from the study if
they had any other cause of chronic liver disease, such as chronic viral hepatitis,
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autoimmune liver disease or genetic haemochromatosis. Genomic DNA was extracted
from peripheral blood samples according to standard procedures and quantified using
the PicoGreen dsDNA Quantitation Kit (Invitrogen Corporation, Carlsbad, California).
Cases with alcohol–related cirrhosis
Alcohol-related cirrhosis status was determined by either liver biopsy or unequivocal
clinical and laboratory evidence. The clinical parameters for determining the alcohol-
related cirrhosis included abnormal liver function test results, the confirmation of
cirrhosis-related complications including encephalopathy, ascites or oesophageal
varices and sonographic and/or radiological evidence for the presence of cirrhosis.
These patients were recruited from Gastroenterology and Hepatology Departments in
University affiliated hospitals in Germany, Austria and Switzerland.
Controls with no significant liver injury
The samples classified as no-significant liver injury controls were defined as alcohol-
dependent patients without cirrhosis as determined by biopsy or the clinical
parameters. These patients were recruited in Psychiatric facilities in Germany and
Switzerland.
UK DISCOVERY SAMPLES
Subjects with self-reported English, Scottish, Welsh or Irish descent were recruited
from the Centre for Hepatology at the Royal Free Hospital, London. All patients had a
history of prolonged alcohol misuse and fulfilled DSM-IV criteria for a diagnosis of
alcohol dependence. All patients were examined by two experienced, senior clinicians
for signs liver injury. Blood was screened (antibodies to hepatitis A, B, C, D and E,
cytomegalovirus, Epstein–Barr virus, herpes simplex and varicella; mitochondrial,
nuclear, smooth muscle and liver kidney autoantibodies; iron, total iron binding
capacity, ferritin; copper, caeruloplasmin; alpha one antitrypsin and tissue
transglutaminase) and patients were excluded if they had any other potential causes of
liver injury such as chronic viral hepatitis, autoimmune liver disease, genetic
hemochromatosis, Wilson's disease, α1 antitrypsin deficiency or celiac disease.  
Patients were also excluded if they had a body mass index (BMI) >30 and were
diabetic. All patients underwent abdominal ultrasound and/or abdominal X-ray
computed tomography/magnetic resonance imaging; all underwent routine upper
gastro-intestinal endoscopy; histological examination was undertaken whenever
possible.
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Alcohol–related cirrhosis
The UK alcohol-related cirrhosis cases comprised of 302 patients. In 224 (74%), the
diagnosis of cirrhosis was made on the basis of a sustained history of prolonged
hazardous drinking; the presence of alcohol-dependence and histological examination
of liver tissue. In the remaining 78 (26%) cirrhosis status was determined on the basis
of a sustained history of prolonged hazardous drinking; the presence of alcohol-
dependence and compatible historical, clinical, laboratory, radiological and endoscopic
features.
No significant liver injury
The UK no-significant liver injury controls comprised of 346 patients. In 122 (35%), the
absence of significant liver injury was confirmed on biopsy. The remainder had no
historical or clinical features suggestive of significant liver injury at presentation or
during prolonged follow-up. Notably, 26 (11%) had isolated hyperbilirubinaemia, most
likely reflecting the presence of Gilbert’s syndrome. The remainder had normal serum
bilirubin levels and all had normal plasma albumin concentrations and clotting profiles.
The serum GGT activity was raised in the majority. The serum ALT activity was within
the laboratory reference range in the majority and when elevated rarely exceeded twice
the upper laboratory reference level; none had evidence of parenchymal liver injury or
portal hypertension on imaging; upper gastrointestinal endoscopy was normal in those
in whom it was performed.
2.4.2 - VALIDATION COHORT
The validation cohorts contained those samples that underwent replication genotyping
of the top-hits identified in the discovery phase of the GWAS. Genome-wide
genotyping was not performed in any of these samples. This was comprised of two
cohorts containing patients recruited from Belgium and Germany (Table 2-2).
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Table 2-2 Demographics of the validation cohort
Validation Cohort
Germany Belgium
Cases
(n=529)
Controls
(n=761)
Cases
(n=619)
Controls
(n=161)
Median age years
(IQR) 54 (47-62) 46 (39-53) 55 (49-61) 47 (41-55)
Gender (% male) 72 83 70 69
Median BMI
(IQR)* 26.0 (23.0-29.2) 24.3 (21.7-27.0) 25.8 (22.7-29.8) 22.8 (20.6-25.7)
Diabetes Type II
(%)* 18.1 11.3 18.2 2
Abbreviations: n – number; IQR – inter-quartile range; BMI – Body mass index
**Diagnosis of type II diabetes was an exclusion criteria in the UK cohort
BELGIAN VALIDATION COHORT
The 780 Belgium samples comprised patients with a long-term history of alcohol
misuse recruited between 2002 and 2014 in the cities of Brussels and Haine-Saint-
Paul. The number of alcohol-related cases and the number of males was
disproportionately high in this cohort.
Alcohol-related Cirrhosis
The Belgian alcohol-related cirrhosis cases comprised 619 patients with alcohol-related
cirrhosis determined by either liver biopsy or unequivocal clinical and laboratory
evidence for the presence of cirrhosis. The clinical parameters for determining alcohol-
related cirrhosis included abnormal liver function test results, the confirmation of
cirrhosis-related complications including encephalopathy, ascites or oesophageal
varices and sonographic and/or radiological evidence for the presence of cirrhosis.
No-significant Liver Injury
The Belgian no-significant liver injury controls were heavy drinkers with excessive
alcohol intake (≥60 g/day) and without clinically evident cirrhosis.  They all received a 
diagnosis of alcohol-dependence based on DSM-IV criteria. These controls were
screened with transient elastography and/or liver biopsy to exclude the presence of
alcohol-related cirrhosis.
GERMAN VALIDATION COHORT
The German validation alcohol-related cirrhosis cases and alcohol-misusers with no-
significant liver injury were recruited by identical criteria as for the German discovery
cohort. This cohort was predominantly male (Table 2-2).
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ETHICAL APPROVAL
In the discovery and validation cohorts none of the cases or controls had been used in
any previous GWAS studies of alcohol-related cirrhosis. The protocols used for
recruitment in the UK, German and Belgian cohorts in each cohort were approved by
institutional review boards and all included subjects consented to inclusion into the
study.
2.4.3 - DISCOVERY ANALYSIS
DISCOVERY GWAS ARRAY BASED GENOTYPING
DNA samples underwent overnight whole genome amplification, followed by
fragmentation by nuclease digestion and then purification via isopropanol precipitation.
DNA was hybridized on to an Illumina BeadChip, which contains many thousands of
covalently joined locus specific DNA sequences. Following hybridisation, the bead-
chip underwent single base extension, using fluorescent labelled nucleotides allowing
genotype detection190.
DISCOVERY GWAS DATA PROCESSING
The German and UK discovery cohorts underwent genome-wide genotyping using the
same quality control and data processing protocols. All samples included in the
discovery cohorts were genotyped on Illumina Bead Chips (Illumina, San Diego, USA)
(Table 2-3). Genotype probabilities were determined from the raw fluorescence
intensity data using the software BEAGLECALL43. The genotype data were converted
into the PLINK349 compatible binary PED file format using fcGENE371. As the German
case and control populations were genotyped on three different platforms this has a
potential to result in systematic differences between datasets and hence intersection
strategy was applied to these genotype whereby only the genotypes that were present
on all of the genotyping platforms were utilised for subsequent analysis202. For this
merging and harmonisation process, all variants in these datasets were aligned to the
positive strand of the human reference genome build 19 (Genome Reference
Consortium GRCh37).
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Table 2-3 The genome-wide genotyping bead-chip arrays used on the discovery cohort
Group Number Array
German Cases 410 Illumina OmniExpress array (Version 12v1_j)
German Controls
329 Illumina Human610Quad
407 Illumina HumanHap550 BeadChip
383 Illumina Human660w Quad BeadChip arrays
UK Cases and
Controls 648 Illumina OmniExpress (version 24v1-0_a)
Following the initial stages of quality control samples underwent further quality control11
performed using PLINK349 (version 1.07) and the R189 programming language.
Samples were excluded from further analysis based on: (i) genotyping success of less
than 97%; (ii) outlying autosomal heterozygosity of more or less 3 standard deviations
from the mean 3 standard deviations from mean; (iii) a kinship coefficient greater than
18.5% between two samples; and, (iv) discordance between self-reported gender and
sex-chromosome inferred gender.
Samples were also excluded if cryptic non-European ancestry was identified from the
genome-wide genotyping data. To perform this, the UK and German datasets were
merged with the HapMap phase III dataset192, which contains the ancestrally
informative genotypes for several populations that are representative of the major
human ancestral groups (European, East Asian, South Asian, African). The merged
HapMap and UK/German data underwent multidimensional scaling analysis in
PLINK349. These sources of variation were plotted in R352, in which samples that
deviated from the average similarity (median ± 3 standard deviations) of the HapMap
reference European ancestral group were excluded.
Discovery Cohort Imputation
The genome-wide genotyping data for both the UK and German discovery cohorts
underwent imputation. Both the UK and German discovery cohort genotypes were
converted into the Oxford GENS format using fcGENE371. Imputation was performed
using IMPUTE2184 (version 2.3.1). The 1000 genomes phase 3 autosomal dataset and
the 1000 genomes phase 1 maternal X chromosome dataset were used as the source
of reference haplotypes for imputation1. Following the imputation any genotypes with
high imputation uncertainty (IMPUTE2 info-score < 0.8), or low minor allele frequency
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(< 1%) or by deviation of the allele frequencies from the Hardy-Weinberg equilibrium (P
< 1x10-6) were removed from the data and not included in association analysis.
DISCOVERY GWAS ASSOCIATION ANALYSIS
The quality controlled and imputed UK and German genome-wide genotyping data
underwent association testing using the software SNPTEST (v2.5) using an additive
frequentist model277. In both of these dataset, the genomic inflation factor was
estimated from the P-values.  If population stratification was evident (λGC > 1.1) the
analysis was adjusted by calculating the top three principal components of genetic
variation using EIGENSTRAT345. These top two principal components were included
as covariates. After this, the genomic inflation factor was re-estimated to verify that P-
value inflation was resolved. The association results were visualized using Manhattan
plots were created using the qqman package436 and Quantile-Quantile plots (QQ plots)
were created in the Haplin package in R352. Regional plots of the association results in
the context of genomic location, inter-variant linkage disequilibrium and local-
recombination rates were created using the Locuszoom server347.
Association results from the independent UK and German discovery dataset underwent
fixed-effect meta-analysis using the software META (v1.5.0). The analysis was
restricted to markers present on both datasets. The combined results were analysed
for genomic inflation and any deviation from the null was adjusted using genomic
control for each dataset in META97. The heterogeneity between studies was quantified
using the I2 statistic176. The results data were processed to identify the 10 unique ‘top-
hits’ that were defined as the strongest association signals present in independent loci
(separated by at least a 500 kB genomic distance).
2.4.4 - VALIDATION ANALYSIS
GENOTYPING
The top-hits from the discovery analysis were directly genotyped in the German and
Belgian validation cohorts. In the German and Belgian validation and population
control cohorts genotyping was performed using Taqman genotyping (Applied
Biosystems, Foster City, Ca, USA). The TaqMan assay fluorescence data was read
using a 7900 HT TaqMan sequence detector system (Applied Biosystems).
ASSOCIATION ANALYSIS
The top-hit variants identified in the discovery stage underwent single marker
genotyping in the German and Belgian validation cohorts. The raw genotype data were
converted into binary PED format and underwent logistic regression in PLINK349. The
genetic association results for the 10 top-hits form the discovery stage of analysis
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underwent fixed-effect meta-analysis with the genetic association results from the
validation stage using the software META (version 1.5.0).
2.4.5 - POST-HOC ANALYSIS
Three separate analyses were performed post-hoc. The first was a genetic association
analysis of genome-wide significant associated variants adjusted for clinical and
demographic variables. The second was a selective pathways analysis to determine
whether pathways annotated to the genes containing genome-wide significant
associations with alcohol-related cirrhosis, contain a greater number of genetic
associations than would be expected by chance. The third was an analysis of genetic
associations in the GWAS discovery dataset of variants in candidate genes that have
already been tested for association of alcohol-related cirrhosis in independent cohorts.
ADJUSTED ANALYSIS
Age, sex, BMI and type II diabetes status data were available in the majority of patients
in the discovery validation cohorts (Table 2-4). In the German discovery cohort, 71% of
cases and 70% of controls had BMI data and 97% of cases and 74% had known type II
diabetes status. In the UK discovery cohort 80% of cases and 53% of controls had
BMI data and none had type II diabetes (this was a cause for exclusion). In the
German validation cohort, 50% of cases and 40% of controls had BMI information and
76% of cases and 64% had known type II diabetes status. In the Belgian validation
cohort, 85% of cases and 91% of controls had available BMI information and 93% of
cases and 99% of controls had known type II diabetes status. In these sample, logistic
regression association was performed conditioning on these variables as covariates in
SNPTEST and PLINK. Otherwise, associate analyses were the same as those
performed in the primary analyses albeit on a smaller sample size.
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Table 2-4 The demographics of the samples in the adjusted meta-analysis
Variable
Discovery Cohorts
Germany United Kingdom
Cases
(n=213)
Controls
(n=691)
Cases
(n=243)
Controls
(n=182)
Median age years
(IQR)
55
(49-61)
41
(35-48)
56
(48-61)
50
(43-48)
Gender (% Male) 100 100 66 76
Median BMI (IQR) 26.9(23.6-29.4)
24.9
(22.8-27.5)
24.8
(22.8-26.8)
24.6
(22.8-26.6)
Diabetes Type II
(%)* 26.3 4.9 0 0
Variable
Validation Cohorts
Germany Belgium
Cases
(n=272)
Controls
(n=417)
Cases
(n=533)
Controls
(n=144)
Median age years
(IQR)
54
(48-61)
47
(41-53)
55
(49-61)
47
(41-56)
Gender (% male) 77 81 70 58
Median BMI (IQR)* 26.1(23.0-29.3)
24.3
(21.7-27.0)
25.8
(22.7-29.8)
22.8
(20.6-25.7)
Diabetes Type II
(%)* 22.1 14.7 18.9 2
Abbreviations: n – number; IQR – inter-quartile range; BMI – Body mass index
* A diagnosis with type II diabetes was an exclusion criteria in the UK discovery cohort
PATHWAYS ANALYSIS
Top-hits identified through the primary analysis underwent a biological literature review
to determine the gene and the biological context of the genes function. A top biological
pathway for each gene was annotated. All other genes present in these annotated
pathways were selected from the REACTOME biological pathways database76. These
genes were used to select out all of the variants present in the UK GWAS dataset that
occur within 20 kB of the genes boundaries that occur in these biological pathways.
Using these data, a set of SNPs was selected for each biological pathway and these
SNPs underwent adaptive permutation based set test analysis on the primary logistic
regression dataset (default settings) (PLINK version 1.9)349 to determine an empirical P
value to test whether each pathways has a greater number of genetic associations than
would be expected through chance.
CANDIDATE GENE ANALYSIS
Variants that have been genotyped in previous candidate gene studies (Table 1-13;
Table 1-12) were extracted from the GWAS Discovery meta-analysis results data and
tabulated.
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2.5 - RESULTS
2.5.1 - DISCOVERY ANALYSIS
UK DISCOVERY SAMPLE
In the UK discovery cohort, raw genotype data was available for 716,503 SNPs in 672
individuals. The number of which was reduced to 609,879 SNPs in 648 individuals
after quality control. This dataset of directly genotyped variants underwent imputation
generating a final dataset with 7,871,013 imputed and directly genotyped variants in
648 individuals.  There was no evidence of population stratification (λGC = 1.01). The
variants rs738409 and rs738408 associate with alcohol-related cirrhosis below
genome-wide significance (P < 5x10-8). Several variants associate at suggestive levels
of significance (P < 5x10-5) including rs2294915, rs12585483, rs4823173, rs6885856,
rs1324922, rs11149248, rs1021831, rs12483959, rs13099969, rs35096230,
rs12495649, rs12485518, rs12638570 and rs12484700. Of these, nine are located in
the PNPLA3 locus and the remainder are in five independent genomic regions on
chromosomes 3, 5, 12 and 13 (Table 2-5).
Table 2-5 Top-association statistics in the UK sample
Chromosome Gene/Locus Variant Position P-value OddsRatio
95%
Confidence
Interval
22 PNPLA3 rs738409 44324727 2.51 x 10-8 2.12 [1.63-2.77]
22 PNPLA3 rs738408 44324730 2.51 x 10-8 2.12 [1.63-2.77]
22 PNPLA3 rs2294915 44340904 2.19 x 10-7 1.98 [1.53-2.56]
13 Intergenic rs12585483 83298475 7.05 x 10-6 0.59 [0.47-0.74]
22 PNPLA3 rs4823173 44328730 7.33 x 10-6 1.93 [1.45-2.57]
5 Intergenic rs6885856 34587844 7.42 x 10-6 1.70 [1.35-2.14]
13 Intergenic rs1324922 83306586 7.57 x 10-6 0.59 [0.47-0.74]
13 Intergenic rs11149248 83304898 7.90 x 10-6 0.59 [0.47-0.74]
12 Intergenic rs1021831 128141516 7.96 x 10-6 0.53 [0.4-0.7]
22 PNPLA3 rs12483959 44325996 8.42 x 10-6 1.93 [1.45-2.58]
3 Intergenic rs13099969 79881007 8.70 x 10-6 1.74 [1.36-2.22]
3 Intergenic rs35096230 79881660 8.70 x 10-6 1.74 [1.36-2.22]
3 Intergenic rs12495649 79890801 8.70 x 10-6 1.74 [1.36-2.22]
3 Intergenic rs12485518 79893872 8.70 x 10-6 1.74 [1.36-2.22]
3 Intergenic rs12638570 79879521 9.78 x 10-6 1.73 [1.36-2.22]
22 PNPLA3 rs12484700 44327273 9.81 x 10-6 1.92 [1.44-2.56]
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GERMAN DISCOVERY SAMPLE
In the German discovery cohort, genotype data was available for 298,405 variants in
1,490 individuals and after imputation this increased to 6,866,424 variants. The
genomic inflation factor (λGC = 1.15) suggests the presence of moderate population
stratification. To counter this, all logistic regression based association analyses
included the top principal component as a covariate. A total of 126 variants associate
with the alcohol-related cirrhosis at genome-wide significance (P< 5x10-8); nearly all of
these associations occur within a 500 kB window surrounding the PNPLA3. An
additional 130 variants associated at suggestive levels (P < 5x10-5) in five independent
genomic regions. When association results for the PNPLA3 locus are plotted in the
context of local recombination rates and nearby genes (Figure 2-2) the association
signal peaks near a region of high recombination in the third exon of PNPLA3 and
extends over a region of high linkage disequilibrium encompassing both the PNPLA3
and the neighbouring SAMM50.
Figure 2-2 A locus plot of genetic associations in PNPLA3 in the German discovery
group
This locus plot of the shows the associations at PNPLA3 shows  −log10 of the P values for each 
variant plotted against their genomic position (human genome build 19). SNPs are coloured to
reflect correlation with the most significant SNP, with red denoting the highest linkage
disequilibrium, (r2 >0.8) with the lead SNP. Estimated recombination rates from the 1000
Genomes Project1 European populations are plotted in blue to reflect the local linkage
disequilibrium structure. Gene annotations were obtained from the UCSC Genome Browser
and the plot was generated using LocusZoom347
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DISCOVERY META-ANALYSIS
There was no evidence of population stratification in the combined meta-analysis (λGC =
1.01) (Figure 2-3). A number of variants in PNPLA3 were associated at the level of
genome-wide significance and of these rs738409 was the most significant. In addition
several independent regions of interest were identified which were associated at
suggestive levels of significance (Table 2-6). One of these variants, rs739846 in
SUGP1, occurs in a genomic region of strong linkage disequilibrium. This region of
strong linkage disequilibrium contains the functional269 variant rs58542926 (Glu167Lys)
in TM6SF2 and has previously been associated with NAFLD229,261. As this variant
appears to be the most plausible causal variant at this locus, it was also genotyped in
the validation cohort and underwent meta-analysis.
Table 2-6 Fixed effects meta-analysis results from the UK and German discovery
cohort
Chr SNP Locus Allele AlleleFrequency PMETA I
2 Odds Ratio
[95% CI]
22 rs738409 PNPLA3 G 0.27 1.17 × 10-28 60 2.39[2.05-2.78]
19 rs739846 SUGP1/TM6SF2 A 0.08 7.54 × 10-7 0 1.92[1.48-2.50]
19 rs58542926* SUGP1/TM6SF2 T 0.08 2.86 × 10-6 0 1.87[1.44-2.43]
2 rs62190923 TM4SF20 G 0.21 1.31 × 10-6 0 0.64[0.54-0.77]
8 rs7812374 Intergenic T 0.58 1.46 × 10-6 0 0.70[0.60-0.81]
5 rs6556045 Intergenic A 0.06 2.51 × 10-6 0 2.11[1.55-2.87]
1 rs6605237 Intergenic T 0.27 5.43 × 10-6 0 1.46[1.24-1.71]
4 rs17886348 IL21 T 0.08 7.64 × 10-6 60 1.79[1.39-2.31]
6 rs7769670 PDE7B A 0.14 7.84 × 10-6 0 1.58[1.29-1.93]
8 rs7845021 Intergenic C 0.61 1.02 × 10-5 0 0.73[0.64-0.84]
19 rs626283 TMC4/MBOAT7 C 0.44 1.07 × 10-5 0 1.36[1.19-1.57]
* rs58542926 included in analysis as this variant is thought to be functionally implicated in liver
disease pathogenesis
Abbreviations: CHR – chromosome; SNP – single nucleotide polymorphism; CI – confidence
interval; I2 – heterogeneity index
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Figure 2-3 A Manhattan and Quantile-Quantile plot of the combined UK-German GWAS
meta-analysis
Top image: Manhattan plot of German GWAS results. The blue horizontal line indicates
suggestive genetic association (P < 5x10-5) and the read horizontal line indicates genome-wide
significant genetic association (P < 5x10-8). Bottom image: A QQ plot of the observed versus
the expected P-values for the German GWAS results where the red line indicates the expected
distribution of results under the null hypothesis. The grey outline shows the 95% confidence
interval of the expected distribution of P-values. The dotted line represents a marginal
significance threshold (P ≤ 0.05) 
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2.5.2 - VALIDATION ANALYSIS
All selected variants were genotyped successfully and genotype distributions were in
Hardy-Weinberg equilibrium in both cases and controls (P>0.05). There was no
heterogeneity between any of the variants genotyped in both the discovery and
validation cohorts (I2 < 0.25). The variants in three of the top-hit loci replicated in the
validation cohort, these were rs738409 in PNPLA3, rs10401969 and rs58542926 in the
TM6SF2/SUGP1 locus and rs626283 in the MBOAT7/TMC4 locus (Table 2-7).
Table 2-7 Validation of the top SNPs identified in the validation cohort
Chr SNP
Validation Cohort Discovery and ValidationCohorts
PVALIDATION Odds Ratio[95% CI] PMETA
Odds Ratio
[95% CI]
22 rs738409 4.59 × 10-22 2.03[1.76-2.35] 1.54 × 10
-48 2.19
[1.97-2.43]
19 rs10401969* 1.24 × 10-4 1.57[1.25-1.97] 7.89 × 10
-10 1.71
[1.44-2.04]
19 rs58542926 7.34 × 10-5 1.59[1.26-1.99] 1.33 × 10
-9 1.70
[1.43-2.02]
2 rs62190923 0.73 1.03[0.87-1.22] - -
8 rs7812374 0.69 0.97[0.85-1.11] - -
5 rs6556045 0.16 1.20[0.93-1.56] - -
1 rs6605237 0.80 0.98[0.84-1.14] - -
4 rs17886348 0.99 1.00[0.77-1.30] - -
6 rs7769670 0.37 1.09[0.90-1.33] - -
8 rs7845021 0.19 1.09[0.95-1.26] - -
19 rs626283 2.29 × 10-5 1.33[1.17-1.53] 1.03 × 10
-9 1.35
[1.23-1.49]
*The lead SNP rs739846 failed genotyping for technical reasons and therefore rs10401969 was
used as a replacement (r2 = 1.0). Abbreviations: CHR – chromosome; SNP – single nucleotide
polymorphism; CI – confidence interval. Table published in Buch et al., 201544
The variant rs626283 sits in an extended region of linkage disequilbrium which covers
several genes including MBOAT7, TMC4, CNOT3 and LENG1 (Figure 2-4: Image A).
The most significantly associated SNP, rs626283, occurs in an intergenic region
between the 3’ promoter of TMC4 and the 5’ untranslated region of the MBOAT7. The
SUGP1/TM6SF2 variants rs10401969, which was genotyped as a proxy for rs739846,
and rs58542926 sit in another extended 500 kB region of high linkage disequilibrium on
chromosome 19 which includes several other genes including NCAN, MAU2,
GATAD2A and CILP2 (Figure 2-4: Image B). The functional variant rs58542926 in
TM6SF2 was less strongly associated with alcohol-related cirrhosis than the intronic
variant rs10401969 in SUGP1145.
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Figure 2-4 Fine-mapping analysis of the genome-wide significant loci
For the variants which replicate in the validation analysis locus plots are given for: A –
TMC4/MBOAT7; and, B – TM6SF2/SUGP1.  The −log10 (P values) are plotted against SNP 
genomic position based on the human genome build 1937. SNPs are coloured to reflect
correlation with the most significant SNP, with red denoting the highest linkage disequilibrium,
(r2 >0.8) with the lead SNP. Estimated recombination rates from the 1000 Genomes Project
(Europeans populations) are plotted in blue to reflect the local linkage disequilibrium structure.
Gene annotations were obtained from the UCSC Genome Browser.
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2.5.3 - POST-HOC ANALYSIS
ADJUSTED ANALYSIS
In the discovery and validation cohorts the logistic regression based allelic association
was adjusted for age, sex, BMI and type II diabetes status. This analysis was
performed as per the main GWAS with a discovery and replication phase but with 809
fewer samples due to missing variable information. There was no evidence for
population stratification. The only variant to contain genome-wide significant
associations was rs7390409 in PNPLA3. All of the other top-hit variants remain
associated, although none reached genome-wide significance.
Table 2-8 Post-hoc association analysis adjusted for gender, age, BMI and type II
diabetes status
Locus Chromosome SNP ID
Unadjusted Adjusted
P-value Odds Ratio[95% CI] P-value
Odds Ratio
[95% CI]
PNPLA3 22 rs738409 4.59 × 10−22 2.03[1.76–2.35] 4.05 × 10
−13 2.12
[1.73–2.59]
TM6SF2 19
rs10401969 1.24 × 10−4 1.57[1.25–1.97] 0.020
1.43
[1.06–1.94]
rs58542926 7.34 × 10−5 1.59[1.26–1.99] 0.022
1.43
[1.05–1.94]
MBOAT7 19
rs626283 2.29 × 10−5 1.33[1.17–1.53] 3.81 × 10
−4 1.41
[1.17–1.70]
rs641738 1.30 × 10−5 1.35[1.18–1.54] 2.11 × 10
−4 1.43
[1.18–1.72]
Table from Buch et al., 201544
Abbreviations: CI – confidence interval
PATHWAYS ANALYSIS
Three pathways from the REACTOME database76 were selected to be representative
for TM6SF2, PNPLA3 and MBOAT7 (Table 2-9). The variants present in the genes
which constitute each pathway were annotated to three gene sets in the UK dataset.
Both the arachidonic acid metabolism pathway and the glycerophospholipid
biosynthesis pathway contain a greater number of genetic associations than would be
expected by chance (P < 0.05) (Table 2-10).
CANDIDATE GENE ANALYSIS
Three independent loci contain variants that associate below marginal significance
(PMETA ≤ 0.05): ADH1C, CYP2E1 and GSTP1. In both ADH1C and CYP2E1, the two
associated variants (rs698; rs1693482 and rs3813867; rs2031920 respectively) are
known to be in strong linkage disequilibrium1. There is significant heterogeneity for the
genetic association for these variants, between the UK an German results data in this
fixed effects meta-analysis.
70
Table 2-9 The genes in each candidate pathway
Gene Pathway Other Genes in Pathway
TM6SF2
Lipid digestion, mobilization,
and transport
(REACT_602.8)
A2M, ABCA1, ABCG1, ABCG5, ABCG8, ABHD5, ALB, AMN,
APOA1, APOA2, APOA4, APOA5, APOB, APOC2, APOC3,
APOE, APOF, BMP1, CAV1, CEL, CETP, CLPS, CUBN, FABP1,
FABP12, FABP2, FABP3, FABP4, FABP5, FABP6, FABP7,
FABP9, HSPG2, LCAT, LDLR, LDLRAP1, LIPC, LIPE, LPA, LPL,
MGLL, MTTP, NPC1L1, P4HB, PLIN1, PLTP, PLTP, PNLIP,
PNLIPRP1, PNLIPRP2, PPP1CA, PPP1CB, PPP1CC, PRKACA,
PRKACB, PRKACG, SAR1B, SCARB1, SDC1
MBOAT7
Arachidonic acid
metabolism
(10.3180/REACT_147851.3)
ABCC1, AKR1C3, ALOX12, ALOX12B, ALOX15, ALOX15B,
ALOX5, ALOX5AP, CBR1, CYP1A1, CYP1A2, CYP1B1,
CYP2C19, CYP2C8, CYP2C9, CYP2J2, CYP2U1, CYP4A11,
CYP4A22, CYP4B1, CYP4F11, CYP4F2, CYP4F22, CYP4F3,
CYP4F8, CYP8B1, DPEP1, DPEP2, DPEP3, EPHX2, FAM213B,
GGT1, GGT5, GPX1, GPX2, GPX4, HPGD, HPGDS, LTA4H,
LTC4S, MAPKAPK2, PLA2G4A, PTGDS, PTGES, PTGES3,
PTGIS, PTGR1, PTGS1, PTGS2, TBXAS1
PNPLA3
Glycerophospholipid
biosynthesis
(10.3180/REACT_121401.2)
ACHE, AGPAT1, AGPAT2, AGPAT3, AGPAT4, AGPAT5,
AGPAT6, AGPAT9, BCHE, CDIPT, CDS1, CDS2, CEPT1, CHAT,
CHKA, CHKB, CHPT1, CPNE1, CPNE3, CPNE6, CPNE7,
CRLS1, DGAT1, DGAT2, EPT1, ETNK1, ETNK2, GNPAT,
GPAM, GPAT2, GPCPD1, GPD1, GPD1L, HADHA, HADHB,
LCLAT1, LPCAT1, LPCAT2, LPCAT3, LPCAT4, LPGAT1, LPIN1,
LPIN2, LPIN3, MBOAT1, MBOAT2, MBOAT7, MGLL, PCYT1A,
PCYT1B, PCYT2, PEMT, PGS1, PHOSPHO1, PISD, PITPNB,
PLA2G10, PLA2G12A, PLA2G16, PLA2G1B, PLA2G2A,
PLA2G2D, PLA2G2E, PLA2G2F, PLA2G3, PLA2G4A, PLA2G4B,
PLA2G4C, PLA2G4D, PLA2G4E, PLA2G4F, PLA2G5, PLA2G6,
PLB1, PLBD1, PLD1, PLD2, PLD3, PLD4, PLD6, PNPLA2,
PNPLA3, PNPLA8, PTDSS1, PTDSS2, PTPMT1, SLC44A1,
SLC44A2, SLC44A3, SLC44A4, SLC44A5, TAZ
Table 2-10 Post-hoc gene set-based association test results
Pathway SNPNumber
Number
Significant
(P < 0.05)
Empirical
Significance (P)
Top independent
Associations
Lipid digestion,
mobilization, and transport 4884 222 0.85 -
Arachidonic acid
metabolism 4450 291 0.0091
rs5751902,rs45535831,
rs11078528, rs17205398,
rs3801150, rs73734172
Glycerophospholipid
biosynthesis 9958 469 0.0022
rs738408, rs16972418,
rs11414481, rs6439081,
rs1883350
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Table 2-11 Post-hoc analysis of candidate gene variants
Chr Gene Variant Position(hg19)
Risk
allele PMETA
Odds
ratio 95% CI PHET I
2
1 IL-10 rs1800872(-627) 206946407 T 0.30 0.91 [0.93-1.07] 0.20 37.9
1 IL-10 rs1800896(-1117) 206946897 C 0.27 0.92 [0.93-1.04] 0.013 83.9
2 IL-1B rs1143634(+3953) 113590390 A 0.31 0.92 [0.93-1.04] 0.013 83.9
2 IL-1B rs16944(-511) 113594867 A 0.46 1.06 [1.05-0.97] 0.027 79.7
2 CTLA-4 rs231775(Thr17Ala) 204732714 G 0.39 1.06 [1.05-0.95] 0.48 0.0
3 PPARG rs1801282(Pro12Ala) 12393125 G 0.45 0.93 [0.94-1.04] 0.082 66.9
4 ADH1C rs698(Ile350Val) 100260789 C 0.038 0.86 [0.88-1.07] 0.052 73.5
4 ADH1C rs1693482(Arg272Gln) 100263965 T 0.038 0.86 [0.88-1.07] 0.055 72.9
4 MTTP rs3816873(Ile128Thr) 100504664 C 0.61 1.04 [1.04-0.97] 0.33 0.0
5 CD14 rs2569190(-159) 140012916 A 0.070 1.13 [1.12-0.94] 0.15 52.7
6 HFE rs1799945(His63Asp) 26091179 G 0.94 0.99 [0.99-1] 0.71 0.0
6 HFE rs1800562(Cys282Tyr) 26093141 A 0.87 1.03 [1.02-0.99] 0.19 42.0
6 TNF-a rs1800629(-308) 31543031 A 0.26 1.12 [1.09-0.92] 0.0079 85.8
6 TNF-a rs361525(-238) 31543101 A 0.38 0.87 [0.91-1.02] 0.053 73.4
6 SOD2 rs4880(Ala16Val) 160113872 A 0.22 0.92 [0.93-1.07] 0.32 0.0
10 CYP2E1 rs3813867(Pst-I) 135339605 C 0.011 0.58 [0.73-0.84] 0.052 73.5
10 CYP2E1 rs2031920(Rsa-I) 135339845 T 0.014 0.60 [0.74-0.85] 0.046 75.0
11 GSTP1 rs1695(Ile105Val) 67352689 G 0.024 1.19 [1.16-0.85] 0.75 0.0
14 NFKBIA rs696 35871093 T 0.97 1.00 [1.0-1.0] 0.15 50.5
17 PEMT rs7946(Val175Met) 17409560 C 0.73 1.03 [1.02-0.98] 0.36 0.0
19 TGF-β1 rs1800471(+915) 41858876 G 0.61 0.93 [0.95-1.02] 0.74 0.0
19 TGF-β1 rs1800470(+869) 41858921 G 0.75 0.98 [0.98-1.02] 0.37 0.0
19 TGF-β1 rs1800469(-509) 41860296 A 0.95 1.00 [1.0-1.0] 0.28 14.7
19 XRCC1 rs25487(Arg399Gln) 44055726 T 0.82 1.02 [1.01-0.99] 0.84 0.0
19 XRCC1 rs1799782(Arg194Trp) 44057574 A 0.25 0.85 [0.89-1.03] 0.29 9.8
19 APOE rs429358(Cys158Arg) 45411941 C 0.52 0.93 [0.95-1.03] 0.63 0.0
19 APOE rs7412(Arg112Cys) 45412079 T 0.87 0.98 [0.98-1.01] 0.087 65.9
Abbreviations: Chr – chromosome; hg19 – human genome 19; CI – confidence interval; PMETA-
Fixed effects meta-analysis genetic association significance; PHET – Heterogeneity test
significance value
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2.6 - DISCUSSION
Three independent genome-wide significant associations were identified in the
genes/loci: PNPLA3, TM6SF2/SUGP1 and MBOAT7/TMC4. PNPLA3 contained the
most significantly associated variant and had the largest odds ratio of the variants with
genome-wide significant associations. This variant has already been identified as a
risk variant for alcohol-related cirrhosis in several association studies413,428,431. This
GWAS confirms the robustness of this association and demonstrates it prominent
effect in comparison to other variants in these cohorts. Two other independent loci
also contain variants that associate with alcohol-related cirrhosis at genome-wide
significance, localising to the genes TM6SF2/SUGP1 and MBOAT7/TMC4.
The genetic association at the TM6SF2/SUGP1 locus was confirmed through the
genotyping of the two variants rs58542926 and rs10401969. The variant rs58542926
occurs in TM6SF2, which is located on chromosome 19 at the coordinates 19,375,174-
19,384,074 (human genome build 19) and encodes the 351 amino acid length protein
Transmembrane 6 superfamily member 2 (TM6SF2). This variant is non-synonymous
and is predicted to result in a glutamate to lysine amino-acid substitution at position
167 (Glu167Lys) in the encoded protein. This variant has already been associated with
NAFLD through exome-wide association analysis229 and replication genotyping261.
TM6SF2 is predominantly expressed in the liver and small intestine and at a sub-
cellular level, localises to the endoplasmic reticulum and the intermediate compartment
of human liver cells. Functional experimentation has demonstrated that TM6SF2 is a
regulator of liver fat metabolism. The rs58542926 is also functional where carriage of
either the opposing effects on the secretion of triglyceride-rich lipoproteins from the
liver influencing either NAFLD or cardiovascular disease risk269. It is thought that
TM6SF2 is required for normal very-dense lipoprotein secretion and that one of the
rs58542926 variants alleles alter TM6SF2 function resulting in the accumulation of
lipids in the liver229.
There is strong functional evidence implicating rs58542926 as a pathogenic variant in
NAFLD and it therefore seems likely that this is the causal variant, which also
contributes to alcohol-related cirrhosis risk. However, the variant rs10401969 in
SUGP1 associates with greater significance. A potential cause of this discrepancy
could be pleiotropy (Figure 2-5). In support of this hypothesis, there are several
genome-wide significant hits in this locus with a diversity of non-liver related
phenotypes such as bipolar disorder299 and schizophrenia366 suggesting that this region
may harbour several sources of genetic variation which could independently contribute
to distinct phenotypic effects. Techniques such as Bayesian fine-mapping410 could be
useful to delineate the presence of multiple independent genetic associations.
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Figure 2-5 Forms of pleiotropy between genetic variants and phenotypes at a locus
A - Biological pleiotropy at the allelic level: the causal variant affects both phenotypes; B – Co-
localizing association (biological pleiotropy): the observed genetic variant is in strong LD with
two causal variants in the same gene that affect different phenotypes; C - Biological pleiotropy
at the gene level: two independent causal variants in the same gene affect different phenotypes;
D - Mediated pleiotropy: the causal variant affects P1, which lies on the causal path to P2, and
thus an association occurs between the observed variant and both phenotypes; E - Spurious
pleiotropy: the causal variant affects only P1, but P2 is enriched for P1 owing to misclassification
or ascertainment bias, and a spurious association occurs between the observed variant and the
P2; F - Spurious pleiotropy: the observed variant is in LD with two causal variants in different
genes that affect different phenotypes. Abbreviations: P1 – Phenotype 1; P2 – Phenotype 2; LD
– Linkage Disequilibrium; GWAS - Genome-wide Association Study. Figure from Solovieff et
al., 2013402
The genetic associations at the MBOAT7/TMC4 locus were confirmed through the
genotyping of the variant rs626283. This variant occurs in an intergenic region of high
linkage disequilibrium between the genes MBOAT7 and TMC4 and is a known
expression quantitative trait loci for MBOAT7191. This provides a hypothetical functional
mechanism through which it may influence cirrhosis risk. MBOAT7 is located on
chromosome 19 at the coordinates 54,677,106-54,693,733 and encodes the 472 amino
acid length protein, membrane bound o-acyltransferase domain containing 7. This
protein has several aliases: BB1, LRC4, LENG4, LPIAT, MBOA7, OACT7 and hMBOA-
7. It is predicted to contain several transmembrane regions and is thought to be an
integral membrane protein. It also has in vitro lysophospholipid acyltransferases
activity with a substrate preference for arachidonic acid and because of this may be
important for regulating free arachidonic acid levels and leukotriene synthesis in
neutrophils141. Other members of the MBOAT7 enzyme family play critically important
roles in the remodelling phospholipids in cell membranes as part of the Lands'
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cycle180,237 (Figure 2-6). The Land cycle also generates eicosanoids and
endocannabinoids that may play important roles in the inflammatory processes which
drive liver disease progression towards cirrhosis420. Genome-wide significant
associations in MBOAT7 have also been reported by other GWAS where the variants
rs2576452 and rs8736 are significantly associated with the ratio of arachidonate and its
metabolite 1-arachidonoylglycerophosphoinositol in the blood393. Notably, these
quantitative trait loci occur in the same promoter region between TMC4 and MBOAT7
as the variant that is most significantly associated with alcohol-related cirrhosis
providing a functional mechanism through which this variant may influence liver
disease pathogenesis.
Figure 2-6 Phospholipid metabolism in the Lands cycle
Fatty acids of phospholipid are liberated by phospholipase A2 and converted to eicosanoids.
Lysophospholipids are also precursors of a different class of lipid mediators including PAF, LPA,
and endocannabinoids. Lysophospholipids are converted to phospholipids in the presence of
acyl-CoA by lysophopsholipid acyltranseferases. X indicates several polar head groups of
phospholipids. Abbreviations: PAF – Poly Unsaturated; LPA - Lysophosphatidic Acid. Image
from Hishikawa et al., 2008180
In contrast to many other GWAS, this study is of modest sample size. For example,
GWAS cohorts for the study of schizophrenia are comprised of tens of thousands of
DNA samples from which, over a hundred independent unique loci and risk variants
have been identified381 (many have odds ratio < 1.5). If such variants of a similar effect
size contribute to alcohol-related cirrhosis risk, as would be predicted by a polygenic
risk model, then the current work is largely underpowered to detect these genetic
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associations. It is likely that there are still many alcohol-related cirrhosis risk loci that
may be identified through genome-wide association analysis with sufficiently large
sample sizes452.
This GWAS accounts for the vast majority of the common genetic variation in the
genomes of two Northern-European ancestry populations and thus risk variants
identified in this study may not be relevant in other ancestral populations. However,
there are several reasons to suppose that this is not the case: (i) it is already known
that rs738409 in PNPLA3 is associated with both NAFLD and alcohol-related liver
disease risk in diverse ancestral populations55,370; and (ii) both rs626283 in MBOAT7
and rs58542926 in TM6SF2 are common variants, in all major ancestral populations1.
Although this GWAS covers the majority of common genetic variation, it lacks coverage
of copy number variants and rare variants (minor allele frequencies < 1%). Studies of
lower frequency variation require increasing levels of statistical power and hence either
large sample sizes or an analysis which is limited to a sub-set of variants. Copy
number variation analysis typically requires the recalling of the raw fluorescence
intensity data using a specialised calling algorithm471. Reanalysing these data, using
such different methodologies, or with enlarged cohorts and other datasets, could
account for these other sources of genetic variation and identify new cirrhosis risk loci.
There is a potential for GWAS to be confounded by population sub-structure whereby
factors, unrelated to the phenotype of interest lead to spurious genetic associations.
For example, the German no-liver disease controls used in the discovery analysis were
primarily recruited for the purposes of a GWAS of alcohol-dependence433 and thus may
be of less phenotypic surety than those recruited from the UK, which were recruited at
a hepatology clinic. To minimize error several precautions were undertaken: (i)
patients of ambiguous ancestry were excluded via multi-dimensional scaling analysis
with reference to the diverse HapMap192 populations; (ii) the genomic inflation factor
(λGC) and the top-principal components were calculated in the data to detect and
account for population stratification; (iii) an adjusted analysis was performed
accounting for several variables which have potential to confound the genetic
association with alcohol-related cirrhosis; and, (iv) allele frequencies were separately
compared for variants of interest between cirrhosis cases and both no-liver disease
controls and population controls. All of these measures indicated a homogeneous
dataset, with phenotypic surety, in which the confounding of the association signal was
limited.
Three gene sets, representative of three lipid metabolic pathways were tested for an
overabundance of genetic associations in the UK dataset. The arachidonic acid
metabolic pathway and the glycerophospholipid pathway gene sets both contained a
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greater number of genetic associations with cirrhosis than would be expected by
chance. It has long been known that disturbances in lipid processing374 and
metabolism51 occur in chronic alcohol misuse, which contribute to the development of
hepatic steatosis252 and liver injury264. Serum arachidonic acid levels are known to be
reduced in patients with cirrhosis204 suggesting a link between this pathways analysis
and experimental observation. However, this pathways analysis was selective rather
than encompassing limiting the scope of these findings. Pathways analysis is a
developing area of GWAS study447 and there is clear potential for future studies to
perform more detailed pathways analysis to validate these findings.
For the variants present in 17 previously studied alcohol-related liver disease candidate
genes, there was limited evidence to support genetic associations with alcohol-related
cirrhosis in the UK and German discovery cohorts. Variants in the ADH1C, CYP2E1
and GSTP1 loci were marginally associated with cirrhosis (P < 0.05); however, there
was significant heterogeneity in the meta-analysed data for the variants in both ADH1C
and CYP2E1. As a fixed effects model was used to calculate these significance
values, it is therefore likely that they overestimate the true significance. The only
marginally associated variant without heterogeneity, rs1695 in GSTP1, encodes a non-
synonymous substitution (Ile105Val) in the protein glutathione S-transferase pi 1. A
recent meta-analysis identified significant genotypic associations between the Val/Val
and Val/Ile genotype of rs1695 and alcohol-related cirrhosis (P = 0.03, OR = 2.04 955
CI [1.09-3.80])282. In this previous meta-analysis, other variants encoding null alleles of
other glutathione-s-transferases, GSTM1 and GSTT1, were also tested for association
with risk. However, these null alleles are encoded by large insertion deletion variants
and therefore were not covered by panel genotyping or imputation; it remains unknown
whether these variants contribute to cirrhosis risk in the study population.
In summary, this first GWAS of alcohol-related cirrhosis demonstrates three genome-
wide significant risk variants in the genes PNPLA3, TM6SF2 and MBOAT7. These
findings confirm previously identified genetic risk factors and identify novel risk loci. It
is likely that increasing the number of patients studied via GWAS analysis has the
potential to discover novel risk loci.
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CHAPTER 3 EXTENDED GENOME-WIDE
ASSOCIATION STUDY
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3.1 - OVERVIEW
Alcohol-related cirrhosis is a complex disease phenotype, likely with polygenic genetic
risk factors. To maximise statistical power and validate new risk loci additional cohorts
will be required. This chapter details an extended GWAS including an additional 850
severe-alcoholic hepatitis cases recruited through the Steroids or Pentoxifylline for
Alcoholic Hepatitis Trial (STOPAH). The GWAS data for 322 STOPAH cases
underwent harmonisation and merging with the UCL alcohol-related cirrhosis GWAS
dataset. This expanded dataset underwent genetic association analysis followed by a
meta-analysis with the genetic association results from the German alcohol-related
cirrhosis GWAS dataset. Variants of interest underwent replication genotyping in an
independent cohort of 528 STOPAH severe alcoholic hepatitis cases and 873 UCL
alcohol dependent controls.
3.2 - BACKGROUND
Severe alcoholic hepatitis is a clinically evident form of alcohol related liver disease
resulting from chronic alcohol misuse, which frequently co-occurs with alcohol-related
cirrhosis285. It has a poor short-term prognosis and treatment options for it are limited
with current guidelines59,285 recommending two pharmaceuticals: the glucocorticoid
based prednisolone and the phosphodiesterase inhibitor pentoxifylline (Figure 3-1).
There have been several clinical trials of these treatment options, however, some
studies are conflicting and hence controversy exists regarding their efficacy 399. A
recent systematic network review suggests that both drugs either alone or in
combination reduce short-term (4 weeks) mortality although no treatment reduces
medium term (3-12) mortality399. The largest study included in this systematic network
review was the UK based STOPAH trial129. Germane to the subject of GWAS, the DNA
samples from a significant proportion of the STOPAH cohort have been extracted and
one third of these have undergone genome-wide genotyping as part of the first, and
ongoing, GWAS of severe alcoholic hepatitis.
Figure 3-1 the chemical structures of prednisolone and pentoxifylline
The GWAS of alcohol-related cirrhosis validated three independent loci: PNPLA3,
TM6SF2 and MBOAT7. However, it is likely that there are undiscovered alcohol-
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related cirrhosis risk variants, as is consistent with a polygenic model of genetic risk.
The joint analysis of independent GWAS datasets has the potential to increase
statistical power and identify novel loci. There are two approaches through which
independent GWAS datasets may undergo joint genetic association analysis: (i) the
merging of independent GWAS datasets before undergoing genetic association
analysis; or, (ii) the meta-analysis of the genetic association results from independent
GWAS datasets. The use of these approaches are not mutually exclusive.
The merging of GWAS datasets is a complex process involving joining datasets
containing the genotype information for hundreds of thousands of genetic variants, in
potentially thousands of individuals; this process has the potential to introduce
substantial error unless stringent quality control procedures are adhered too385,484.
Joint analysis is particularly useful when a significant proportion of the same DNA
samples overlap between different datasets. Before merging, dataset compatibility
must be assessed by a number of criteria, primarily: (i) is the phenotypic information
sufficiently similar between datasets to allow accurate and equivalent comparison; (ii) is
sample demography equivalent between datasets; and, (iii) is between GWAS panel
genotype concordance sufficient to cover the majority of common variation. The
process of dataset merging requires that all concordant variants present in both
datasets are aligned to the same DNA strand, have the same reference genomic
coordinates and have the same allele-coding schema. Ambiguous SNPs in particular
have a significant potential to confound the harmonisation process. Following merging,
a dataset may be treated as if a primary dataset and undergo genome-wide imputation
and genetic association analysis.
Meta-analysis is a statistical method for systematically combining the results of
different studies to provide a single summary result; it is widely used in GWAS119. It is
advantageous as it allows datasets to be co-analysed when merging of datasets is
unsuitable (e.g. significant ancestral differences between cohorts, primary genotype
data is unavailable…). Before such an analysis can occur, dataset compatibility must
be assessed, primarily: (i) is phenotypic information sufficiently similar between
datasets to allow accurate and equivalent comparison; (ii) is there significant statistical
heterogeneity between the results of each GWAS dataset; (iii) does each genetic
association file contain equivalent measures of genetic association (e.g. allelic,
dominant or recessive models) and effect size (e.g. OR or beta, 95% confidence
interval or standard error); and, (iv) are the variants in each genetic association results
dataset concordant. The latter criterion is generally not an issue as most GWAS
contain imputed genotype data and therefore have high overlapping genotype
coverage and the universal alignment of allele codes to the forward strand. A more
significant issue is statistical heterogeneity, or variance between results data.
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Heterogeneity is widely quantified using the Cochran’s Q statistic68. From this statistic,
a significance value may be calculated that indicates the probability of their being
heterogeneity in the data between the samples. It is also possible to calculate a
percentage measure of the total variation between studies176, known as the I2. The
presence of significant heterogeneity influences the choice of meta-analytical using
either a fixed effects or random effects model. Fixed effects models are the widely
used for GWAS meta-analysis. However, in the presence of between-study
heterogeneity, this model may underestimate confidence intervals and overestimate
significance values87. Random effects models alternately assume variance between
results datasets and are appropriate in the presence of statistical heterogeneity.
3.3 - AIM
The primary objective of this study was to merge the GWAS dataset for the STOPAH
severe alcoholic hepatitis cases with the UCL alcohol-related cirrhosis GWAS dataset
and to perform an enlarged genome-wide association analysis focussing on the
identification and verification of novel loci.
3.4 - MATERIALS AND METHODS
This study was by design, split into two stages: (i) a discovery analysis in which an
enlarged UCL/STOPAH GWAS dataset underwent genome-wide association analysis
followed by meta-analysis with the German GWAS dataset results; and (ii) a validation
stage in which novel variants identified during the discovery analysis underwent
replication/validation genotyping in the validation STOPAH cases and UCL controls
(Figure 3-2).
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Figure 3-2 The study design plan of the extended genome-wide association study
3.4.1 - COHORTS
UCL COHORT
The UCL cohort used in this analysis, comprised of 1,521 alcohol dependent samples
that were used in either the discovery or the validation analysis: (i) there were 302
alcohol-related cirrhosis cases and 346 no-significant liver injury controls that
underwent genome-wide genotyping in the discovery analysis; and (ii) there were 873
alcohol-dependent samples without clinically evident alcohol-related liver disease that
were used as controls in the validation analysis (Table 3-1).
STOPAH COHORT
The STOPAH cohort comprised solely of cases with severe alcoholic hepatitis and
were recruited as per a published protocol427. All of these cases had a long history of
alcohol misuse and compatible clinical, and/or biopsy features of severe alcoholic
hepatitis. Subjects that had a prolonged history of jaundice (>3 months) or whose liver
biochemistry was not suggestive of alcohol-related hepatitis (ALT >300 international
units per litre, AST >500 international units per litre) were excluded. All of these cases
were British, although their ancestral information was limited to a broad classification of
self-reported ethnic group (e.g. white, South Asian, black etc.). All cases that were of
none white ancestry were excluded so in total, 850 severe alcoholic hepatitis cases
were included from the STOPAH cohort.
DNA samples were extracted from whole blood using a commercially available Blood
DNA extraction mini kit (QIAGEN, Manchester, UK). These samples were split into two
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groups that were used in the discovery and validation analyses: (i) the STOPAH
exploratory group comprising of 322 severe alcoholic hepatitis cases which were used
in the in the discovery analysis (Table 3-1); and, (ii) STOPAH validation group
comprising of 528 severe alcoholic hepatitis cases which were used in the validation
analysis (Table 3-2).
Table 3-1 Demographic features of the UCL and STOPAH discovery group
Analysis UCL STOPAH
Group Case Controls Case
Number 302 346 322
Genome-wide
genotyping Yes Yes Yes
Median age
years (IQR) 53 (46-60) 48 (41-55) 48 (41-55)
Gender
(% male) 67.6% 76.6% 67.4%
Proven
alcohol-related
cirrhosis (%)
100% 0 37.8%
Table 3-2 Demographic features of the UCL and STOPAH validation group
Analysis UCL STOPAH
Group Controls Case
Number 873 528
Genome-wide
genotyping No No
Median age
years (IQR) 45 (39–52) 49 (42 - 57)
Gender
(% male) 65.4% 60.8%
Proven
alcohol-related
cirrhosis (%)
0 48.4%
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3.4.2 - DISCOVERY ANALYSIS
GWAS DATASETS
UCL Alcohol-related Cirrhosis GWAS Dataset
The UCL exploratory cohort comprised of alcohol-related cirrhosis cases and no-
significant controls that underwent genome-wide genotyping as part of the first alcohol-
related cirrhosis GWAS (chapter 2). This dataset contains the genotype information for
609,879 variants in 346 alcohol-related cirrhosis cases and 302 no-significant liver
injury controls.
STOPAH-UCL Severe Alcoholic Hepatitis GWAS Dataset
The STOPAH severe alcoholic hepatitis GWAS dataset forms part of an ongoing
GWAS of severe-alcoholic hepatitis. The samples in this dataset include 322 severe
alcoholic hepatitis cases from the STOPAH cohort and 311 no-significant liver injury
controls from the UCL cohort; these controls were the same as those used in the initial
alcohol-related cirrhosis GWAS (Figure 3-3). All samples were genotyped on an
Illumina Core Exome array (Illumina, San Diego, USA) at the Welcome Trust Sanger
Institute. At the Welcome Trust Sanger Institute, raw fluorescence intensities
underwent genotype calling using two algorithms: the zCall algorithm for rare variants
(allele frequency < 1%)146 and the proprietary GenCall algorithm (Illumina, San Diego,
USA) for all other variants. This raw genotype data underwent quality control including
per sample quality control (gender checks, duplicate sample checks, heterozygosity
(±3 standard deviations from mean), relatedness (ߨො ≥ 0.185) and removal of tri-allelic 
variants) and per variant quality control (genotyping success rate, Hardy-Weinberg
equilibrium (PHWE ≤ 1 x 10-6)), case/control differences in genotyping rates and removal
of redundant genotypes for those genotyped more than once). This data was stored in
binary PLINK format.
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Figure 3-3 The overlap in no-significant liver injury controls
This Venn diagram shows the proportion of shared controls between the UCL alcohol-related
cirrhosis GWAS dataset and the STOPAH severe alcoholic hepatitis GWAS dataset
GWAS DATASET PROCESSING
Data Harmonisation
The STOPAH GWAS dataset was harmonised with the UCL alcohol-related cirrhosis
GWAS dataset using the software Genotype Harmonizer (version 1.4.15)89. The
naming of variants in all datasets were standardized to those the UCL dataset schema.
Variants that were none concordant between datasets and those that did not meet
selected criteria (minor allele frequency < 0.01, minimum linkage disequilibrium with at
least 3 neighbouring variants r2 < 0.3) were removed from the merged dataset.
Duplicate Quality Control
Duplicate samples were identified in both the UCL and STOPAH harmonised datasets;
these samples were extracted and merged in PLINK (version 1.9)58. Variants with
conflicting genotypes between duplicate samples or any sample with a conflicting
genotyping rate (< 98%) or differential missing genotype rates (Pmissing < 5x10-4) were
excluded.
Data Merging
The harmonized datasets were merged using default settings in PLINK (version 1.9).
All STOPAH samples and UCL alcohol-related cirrhosis samples were coded as cases
and the UCL no-liver disease samples were coded as controls. The harmonised,
merged dataset underwent sample level quality control. This included identical by
descent estimation to infer relationship and calculation of autosomal heterozygosity to
identify abnormal samples. Related samples that were no closer than second cousins
(πෝ ≥ 0.185) and samples with abnormal autosomal heterozygosity (±3 standard 
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deviations from the group autosomal heterozygosity mean) were excluded from the
dataset. A principal components analysis was performed on a linkage-disequilibrium346
pruned dataset to visually confirm genetic homogeneity within the merged dataset.
Imputation
The merged and quality controlled UCL/STOPAH dataset underwent haplotype
phasing using SHAPEIT (version v2.r790)312. The phased data underwent imputation
using Impute2 (version 2.3.2)277 using the 1000 genomes phase 3 haplotype data as a
reference1. Standard parameters were used for imputation (buffer = 250 kb, effective
size = 20,000 and input threshold = 0.9) sequentially on 500 megabase interval chunks
of each autosome. The output GENS files were concatenated and converted into the
Oxford BGEN format using QCTOOL (version 1.4) excluding variants of poor
imputation quality (info score < 0.3) and low minor-allele frequency (< 1%).
GENETIC ASSOCIATION ANALYSIS
Discovery Association Analysis
Genetic association analysis was performed on the merged UCL-STOPAH dataset
using SNPTEST (version 2.5.1) under a frequentist additive model on genotype
dosages (i.e. method expected). Subsequent analyses of genetic association results
were performed using R (version 3.2.2) using the GENABEL package for genomic
inflation factor estimation and the ggplot2 package for data visualization.
Meta-Analysis
The UCL/STOPAH GWAS genetic association results dataset underwent a fixed-effect
meta-analysis with the German alcohol-related cirrhosis GWAS dataset using the
software META (version 1.3.2)278. The German GWAS genetic association data
contained the results for 6,866,425 imputed and directly genotyped variants that had
undergone allelic logistic regression based association test conditioning on gender and
the top-principal component (chapter 2) (Table 3-3).
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Table 3-3 Demographics of the German discovery group
German Cohort
Analysis Meta Meta
Group Alcohol-related cirrhosisCases
No-significant liver injury
controls
Number 410 1080
Genome-wide
genotyping Yes Yes
Median age
years (IQR) 53 (47-61) 42 (36-48)
Gender
(% Male) 71 100
Proven alcohol-
related cirrhosis
(%)
100% 0
Abbreviations: IQR – inter-quartile range
3.4.3 - VALIDATION ANALYSIS
SNP SELECTION AND GENOTYPING
Variants were selected for validation genotyping based on three criteria:
(i) The genetic association P-value is below the marginal significance threshold
(PMETA ≤ 1x10-5)
(ii) The variant is in an independent locus (i.e. is not in linage disequilibrium
with any other variant undergoing validation genotyping)
(iii) The locus has not been identified in the previous alcohol-related cirrhosis
GWAS
Those identified variants were genotyped in-house using the K-Biosciences allele
specific PCR (KASPAR) (LGC Genomics, Hoddesdon, UK) genotyping platform and
custom designed primers. If the variant was unsuitable for PCR based genotyping
(e.g. due to the location in a highly repetitive region of nucleotide sequence) then a
nearby variant in strong linkage disequilibrium was genotyped as a proxy. The PCR
amplification and detection of fluorescence data was performed on a LightCycler® 480
Real-Time PCR machine (Roche Molecular Diagnostics, Burgess Hill, UK). Genotype
calling was performed automatically using proprietary software (Roche Molecular
Diagnostics, Burgess Hill, UK)367 with some minor manual editing of genotype calls.
ANALYSIS
The raw genotype data underwent quality control (e.g. removal of conflicting samples,
removal of duplicates) and was converted into PED and MAP using a custom designed
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R package, KASParclean. Further quality controls and genetic association tests
including tests of Hardy-Weinberg equilibrium, differential genotype missing rate tests
were performed using PLINK58 (version 1.9).
Concordance analysis
A proportion of samples from both the STOPAH and UCL cohort, with imputed
genotype data, underwent direct genotyping to validify the accuracy of imputed
genotype calls. The concordance between imputed and direct genotype data was
directly assessed using a custom package79 in R (version 3.2.2) from which a
concordance value was determined. The correlation between this concordance value
and the imputation accuracy (Impute2 info score) was asses using linear regression.
Genetic association analysis
Genetic association tests were performed by comparing the allele frequencies between
the validation STOPAH severe alcoholic hepatitis cases and the validation UCL
alcohol-dependent controls. The discovery genetic association was performed in
PLINK58 (version 1.9) using an allelic logistic regression model conditioning on gender
as a covariate. Validation genetic association data were converted into an appropriate
format and underwent both a fixed effects and random effects meta-analysis using the
software META278 (version 1.3.2).
3.5 - RESULTS
3.5.1 - GWAS DATASET PROCESSING
Before imputation, there were genotypes for 233,076 variants in the UCL/STOPAH
GWAS dataset, (Figure 3-4); these represent those variants that are concordant
between the original UCL and STOPAH GWAS datasets. In the 308 overlapping
controls with no significant liver injury, the mean conflict rate between the genotype
calls was 16 conflicts per variant (0.0069%) all of which occurred in 446 variants. In
total, 15 variants (Pthreshold < 5 x 10-4) had significantly different missing genotype rates.
An autosomal heterozygosity check identified five samples with abnormal autosomal
heterozygosity; these samples were removed from the merged dataset. Identity-by-
descent analysis identified a single case that was independently recruited into both the
STOPAH and UCL studies. Following these stages of quality control, there were
genotypes for 232,616 variants in 932 samples (Figure 3-4).
A post-quality control principal components analysis did not reveal significant
stratification issues in the dataset (Figure 3-5). The merged UCL/STOPAH dataset
was split into separate files by each autosome and underwent imputation producing
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genotype information for 81,454,666 variants. The majority of this information was
either redundant or of poor quality as when crudely filtering on imputation quality and
minor allele frequency (info score < 0.3; minor allele frequency < 1%) only 9,613,508
variants were retained in the dataset (Figure 3-4). Of these, 7,882,973 (81.9%)
variants were of sufficient imputation quality for genetic association analysis (impute2
info score ≥ 0.8). 
Figure 3-4 A schematic of the stages of the discovery analysis
The UCL and STOPAH GWAS datasets were underwent harmonisation and merging. A
number of controls overlapped between these datasets. The merged dataset underwent quality
control followed by imputation including autosomal variants only.
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Figure 3-5 Principal component plot in the UCL-STOPAH merged dataset
The top three principal components are compared for each sample by plotting on X-Y scatter
plot and colouring by phenotype status (female = green, male = blue) or phenotype status. The
clustering of points into a single group, and is suggestive of a homogeneous dataset.
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3.5.2 - DISCOVERY ASSOCIATION ANALYSIS
In the discovery association analysis, there were 621 alcohol-related liver disease
cases and 345 no-significant liver injury controls. There was not any indication for
population stratification (Figure 3-6) as measured by the genomic inflation factor (λGC =
1.04, standard error = 3.05x10-6). The PNPLA3 locus contains the greatest number of
significantly associated variants including several genome-wide significant hits (P ≤ 
5x10-8) (Figure 3-7). In total 146 variants had a P-value below the marginal
significance threshold (P ≤ 1x10-5). These variants occurred in 19 distinct loci, although
only eight contained multiple supporting variants below the marginal significance
threshold (Table 3-4, Figure 3-7). Two of these occur in genes: rs10601886 in RTCA
and rs2226856 in DLG2.
Figure 3-6 Quantile-quantile plot of the genetic association results in the extended
UCL/STOPAH dataset
This plot shows the distribution of P-values in the entire dataset (black dots) and excluding P-
values from the PNPLA3 locus (blue dots). The red line represents the expected distribution of
P-values under the null hypothesis and the grey area represents a 95% confidence interval for
the expected distribution.  The genomic inflation factor, λGC is estimated from all of the P-values.
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META-ANALYSIS
In the discovery association meta-analysis, the UCL/STOPAH discovery genetic
association results from the 621 alcohol-related liver disease cases and the 345 no-
significant liver injury controls were meta-analysed with the German discovery genetic
association results from 410 alcohol-related cirrhosis cases and 1080 no-significant
liver injury controls. In total, 6,440,581 variants were concordant, and suitable for
meta-analysis, between the UCL/STOPAH and the German datasets (Figure 3-9). The
distribution of P-values in the meta-analysis was not indicative of systematic deviation
from the expected distribution of P-values (Figure 3-8) (λGC = 1.04, standard error =
5.73x10-5). In total, 191 variants from 11 distinct loci were associated below the
marginal significance threshold (PMETA ≤ 1x10-5). The PNPLA3 locus contained 155 of
the top hit variants including a number below the genome-wide significance level (P ≤ 
1x10-8). None of the variants in the remaining 10 loci surpassed the genome-wide
significance threshold. Several of the most significant variants were analysed
previously, including rs3747207 (PNPLA3), rs58489806 (TM6SF2), rs626283
(MBOAT7) and rs73321291 (intergenic between DUSP1 and ERGIC1). In total six
variants met the criteria for validation analysis, that is, they occurred in independent
loci, were below the marginal significance threshold and were unique to this analysis.
These variants occur in genomic regions that have been associated with diverse traits
through GWAS including lipid and cholesterol metabolism (Table 3-6).
Figure 3-8 Quantile-Quantile plot of the meta-analysis P-values
This plot shows the observed versus the expected distribution of P-values on a –log10 scale. It
shows the distribution of all variants tested in the meta-analysis (black points) and with the
variants from the PNPLA3 locus removed (blue points). The red line shows the expected
distribution of P-values when there is no systematic deviation from the expected distribution of
P-values with a 95% confidence interval (grey box).  The estimated genomic inflation factor, λGC
was derived from all of the P-values in the data
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3.5.3 - VALIDATION GENOTYPING
A total of 873 UCL controls and 528 STOPAH cases from the UCL/STOPAH validation
group underwent direct genotyping, concordance analysis and genetic association
analysis for those variants identified in the discovery meta-analysis.
Genotyping
All of the selected variants except for rs6768997 were suitable for validation
genotyping. Rs6768997 occurs on a repetitive short interspersed nuclear element and
is therefore unsuitable for PCR based genotyping so instead, the nearby variant
rs9861686 was selected as a proxy. These variants underwent KASPAR genotyping
using allele specific primer PCR amplification (Table 3-7). Visual inspection of
genotyping cluster plots demonstrates distinct clustering of the three possible
genotypes for each variant and the negative controls (Figure 3-10). All of the variants
were in Hardy-Weinberg equilibrium in the entire validation group and in both case
control groups (PHWE > 0.01).
Concordance analysis
The samples with both imputed and direct genotype data underwent analysis to
determine their concordance (Table 3-8; Figure 3-12). The genotypes for the majority
of variants were highly concordant between the imputed and direct genotype data
(concordance > 97%), however, the variants rs28350 and rs36056997 had a lower
concordance. There was a clear linear relationship (R2 = 0.99) between the Impute2
information score of the imputed genotype data and the measured concordance rate
between the imputed and genotyped data (Figure 3-11).
Genetic association analysis
In the validation group, for the several variants genotyped none of the allele
frequencies differ between cases and controls (Table 3-9). When this validation data is
meta-analysed with the discovery UCL/STOPAH and German genetic association data,
it introduces significant heterogeneity (PHET ≤ 0.05).  Despite none of these genetic 
associations being significant, all variants share the same directionality of effect as in
both the extended UCL/STOPAH and German genetic association datasets.
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Table 3-7 Nucleotide sequences of the primers used for validation genotyping of the six
most significantly associated variants
SNP Name Sequence
rs4027132
Allele specific (G) GAAGGTCGGAGTCAACGGATTCTCTGGCTATGACAAATTCAAAGTTCAAA
Allele specific
(GA) GAAGGTGACCAAGTTCATGCTGGCTATGACAAATTCAAAGTTCAAG
Reverse 1 CTTCTCAAGTCCTCCTAAATAAATGTTTAA
Reverse 2 CACTCTTTCTTCTCAAGTCCTCCTAAATA
rs9861686
Allele specific (A) GAAGGTGACCAAGTTCATGCTAAAATGTCATTTAATATCTAAGCCTCTGAATA
Allele specific (G) GAAGGTCGGAGTCAACGGATTAATGTCATTTAATATCTAAGCCTCTGAATG
Reverse 1 GCATAATCACACATTGCTCTGTGCTATTT
Reverse 2 CATTGCTCTGTGCTATTTACAAATAGGTTT
rs28350
Allele specific (A) GAAGGTGACCAAGTTCATGCTGTTGCCTAGACAATGGCATATTAAATCA
Allele specific (G) GAAGGTCGGAGTCAACGGATTGCCTAGACAATGGCATATTAAATCG
Reverse 1 CTGGAAGATTTATTACATTCCCTTGTTCTA
Reverse 2 CATTCCCTTGTTCTATAGATCAAGGACAA
rs153409
Allele specific (C) GAAGGTCGGAGTCAACGGATTCATATCATGTGGTCTTTGCAGTACG
Allele specific (T) GAAGGTGACCAAGTTCATGCTCCATATCATGTGGTCTTTGCAGTACA
Reverse 1 AATTAGCCACAGGCCTTGTCTGTATTATA
Reverse 2 GGCCTTGTCTGTATTATACACCTTAAGAA
rs11082773
Allele specific (A) GAAGGTGACCAAGTTCATGCTAAGATTTCAAACTCCTAACAGCCAGAT
Allele specific (G) GAAGGTCGGAGTCAACGGATTTCAAACTCCTAACAGCCAGAC
Reverse 1 CCAGGCTTGGTGAAAAAGAAATGAATGAA
Reverse 2 GGTAGTTAGTCCAGGCTTGGTGAAA
rs36056997
Allele specific (C) GAAGGTCGGAGTCAACGGATTGTAAGTACCTGCTCTTATACAAGGAC
Allele specific (A) GAAGGTGACCAAGTTCATGCTGTAAGTACCTGCTCTTATACAAGGAA
Reverse 1 TCCAGTTCTGAGAAGTCCTCTAAGATTT
Reverse 2 GAGAAGTCCTCTAAGATTTCCAGTTGATT
99
Figure 3-10 Fluorescence cluster plots of validation genotyping experiments
Each scatter plot represents the recorded fluorescence at two different wavelengths for a single
KASPAR genotyping experiment containing 384 DNA samples. Each point represents a single
genotype coloured by clustering (red, green and blue) from which genotyping is inferred.
Negative controls (grey) should have limited fluorescence and cluster together towards zero.
Samples with poor clustering were classified as unknown (pink).
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Table 3-8 A concordance comparison of direct and imputed genotype data
Chromosome Variant
Number of
genotypes
compared
Concordance*
2 rs4027132 917 1.00
3 rs9861686 922 0.98
3 rs28350 919 0.91
5 rs153409 890 0.97
18 rs11082773 910 0.99
20 rs36056997 918 0.82
*Pearson’s correlation coefficient
Figure 3-11 Linear regression plot of genotyping concordance versus Impute2 info score
From a linear regression of Impute2 info scorer versus genotype concordance a line of best fit
(blue line) with its 95% confidence interval (grey polygon)
101
Figure 3-12 Comparing the concordance between imputed and direct genotype data
Each plot shows the discrete direct genotype values converted into genotype dosage format
(0=homozygote allele 1, 1=heterozygote, 2= homozygote allele 2) (x-axis) plotted versus the
continuous imputed genotype dosage values (y-axis) for the six variants that underwent
validation genotyping. Each genotype data point is coloured on a continuous scale (from red to
green) by its percentage concordance between the imputed and direct genotype data
102
Ta
bl
e
3-
9
Th
e
re
su
lts
of
a
ge
ne
tic
as
so
ci
at
io
n
an
al
ys
is
in
th
e
va
lid
at
io
n
gr
ou
p
95
%
Co
nf
id
en
ce
In
te
rv
al
[0
.9
5-
1.
30
]
[0
.8
4-
1.
19
]
[0
.8
4-
1.
29
]
[0
.8
3-
1.
14
]
[0
.7
5-
1.
14
]
[0
.8
9-
1.
22
]
*A
lle
lic
as
so
ci
at
io
n
te
st
pe
rfo
rm
ed
us
in
g
lo
gi
st
ic
re
gr
es
si
on
w
he
n
co
nd
iti
on
in
g
on
ge
nd
er
as
a
co
va
ria
te
O
dd
s
Ra
tio
1.
11
1.
00
1.
04
0.
98
0.
92
1.
05
P* 0.
18
0.
98
0.
71
0.
76
0.
46
0.
58
M
in
or
Al
le
le
Fr
eq
ue
nc
y
Co
nt
ro
ls
43
.2
%
26
.9
%
15
.6
%
41
.5
%
16
.8
%
43
.2
%
Ca
se
s
45
.9
%
26
.9
%
16
.2
%
40
.9
%
15
.7
%
44
.3
%
G
en
ot
yp
e
Co
un
ts
Co
nt
ro
ls
16
9/
38
3/
28
2
67
/3
17
/4
53
17
/2
30
/5
99
15
1/
40
2/
29
5
29
/2
20
/5
80
16
4/
40
4/
27
9
Ca
se
s
10
5/
25
9/
14
7
40
/1
96
/2
77
15
/1
36
/3
63
78
/2
72
/1
73
13
/1
34
/3
63
10
3/
25
3/
16
2
M
aj
or
Al
le
le
A G G C A G
M
in
or
Al
le
le
G A A T G G
A
Va
ria
nt
rs
40
27
13
2
rs
98
61
68
6
rs
28
35
0
rs
15
34
09
rs
11
08
27
73
rs
36
05
69
97
Ch
ro
m
os
om
e
2 3 3 5 18 20
103
Ta
bl
e
3-
10
Th
e
re
su
lts
of
a
m
et
a-
an
al
ys
is
in
cl
ud
in
g
th
e
va
lid
at
io
n
ge
ne
tic
as
so
ci
at
io
n
da
ta P
VA
LI
D
A
TI
O
N
0.
26
0.
63
0.
49
0.
79
0.
48
0.
50
P U
C
L/
ST
O
PA
H
1.
05
X1
0-
3
3.
93
X1
0-
4
8.
81
X1
0-
5
9.
17
X1
0-
4
3.
51
X1
0-
5
9.
82
X1
0-
5
P G
ER
M
A
N
Y
5.
90
X1
0-
4
5.
09
X1
0-
3
2.
70
X1
0-
3
1.
63
X1
0-
3
2.
78
X1
0-
3
3.
95
X1
0-
3
He
te
ro
ge
ne
ity I2
58
.3
8
81
.5
3
71
.3
0
73
.1
5
72
.3
2
74
.8
6
P 0.
09
0.
00
0.
03
0.
02
0.
03
0.
02
P M
ET
A
1.
40
X1
0-
5
3.
45
X1
0-
3
2.
18
X1
0-
3
0.
13
3.
84
X1
0-
5
0.
01
9
2.
48
X1
0-
4
0.
04
0
1.
07
X1
0-
5
0.
01
6
7.
57
X1
0-
5
0.
02
7
Ef
fe
ct
s
M
od
el
Fi
xe
d
R
an
do
m
Fi
xe
d
R
an
do
m
Fi
xe
d
R
an
do
m
Fi
xe
d
R
an
do
m
Fi
xe
d
R
an
do
m
Fi
xe
d
R
an
do
m
Va
ria
nt
rs
40
27
13
2
rs
98
61
68
6
rs
28
35
0
rs
15
34
09
rs
11
08
27
73
rs
36
05
69
97
Ch
ro
m
os
om
e
2 3 3 5 18 20
104
3.6 - DISCUSSION
The merging of datasets genotyped on different panels has the potential to confound
GWAS484. These analyses utilised strict quality control procedures and state of the art
software89 to remove errors resulting from dataset harmonisation and merging. The
quality control also included an analysis using the overlapping control samples
genotyped on two arrays for the identification of discordant genotypes. In the final
UCL/STOPAH dataset, genotype concordance was high, and there was variant
coverage over all of the autosomes. Principal components analysis demonstrates that
there are no significant differences between samples in the merged dataset.
The PNPLA3 locus contained both the greatest number of significant genetic
associations and the most significant overall genetic associations. The genetic
association at the variant rs738409 was 100-fold more significant in the merged
dataset in comparison to the UCL dataset alone (PUCL = 2.51 x 10-8 versus PUCL/STOPAH =
1.68 x 10-30), a finding consistent with the increased number of cases. Other variants
identified from the discovery analysis were nearing genome-wide levels of significance
such as the candidate gene DLG. Other GWAS have also associated the DLG2 locus
with energy intake in childhood obesity69 and the sera levels of certain
glycerophospholipid species94.
This extended GWAS confirms the primacy of PNPLA3 as a risk locus as it was the
only locus to contain genome-wide significant associations in both the expanded
UCL/STOPAH GWAS analysis and the German association analysis. Notably,
rs3747207 was the most significantly associated variant in PNPLA3. This variant,
which occurs in an intergenic region between the second and third exons, had a
marginally greater association signal than rs738409 which has been identified as the
primary variant driving associations at this locus370,413,428 (Prs3747207 = 1.46 x 10-30,
Prs738409 = 1.68 x 10-30). These two variants are close to each other (130 bases) and in
perfect linkage disequilibrium (r2 = 0.99, D’ = 1.01). This slight discrepancy may have
resulted from the lower imputation information score of rs374207 in both the German
dataset (Impute2 info score: rs738409 = 0.943 vs rs3747207 = 0.934) and the
UCL/STOPAH dataset (Impute2 info score: rs738409 = 0.951 vs rs3747207 = 0.946).
The meta-analysis identified several novel loci containing variants nearing genome-
wide significance. Of these, there was an intriguing novel loci containing several highly
associated variants (rs11082773, PMETA = 4.11x10-7) between the endothelial lipase
gene, LIPG and the acetyl-Coenzyme A acyltransferase 2 gene, ACAA2 (Figure 3-13).
This region is a quantitative trait loci for the expression high-density lipoprotein (HDL)
cholesterol16,60,450,457 and the nearby endothelial lipase gene may be functionally
involved in this mechanism196. The ACAA2 gene encodes the enzyme acetyl-
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Coenzyme A acyltransferase 2 which catalyses the last stage of the mitochondrial fatty
acid beta oxidation spiral177. Other validated alcohol-related cirrhosis risk loci such as
PNPLA3, MBOAT7 and TM6SF2 are also involved in lipid metabolic pathways making
this locus an intriguing candidate for further analysis.
For the most significantly associated variants, the imputed and direct genotypes were
compared in a large number of samples. The concordance between the imputed and
direct genotypes was high for most variants (concordance > 97%) highlighting the
accuracy of imputation. There was a near perfect correlation between the imputation
information measure and the concordance between direct and imputed genotype data.
The imputation information measure is used by the frequentist association test
performed in SNPTEST, to account for missing information in imputed data in genetic
association calculations277. Hence, even when the imputation information score was
lower, as was the case for rs36056997, this was unlikely to introduce bias to the
genetic association test.
Validation genotyping did not provide supporting evidence for the novel genetic
associations identified in the extended GWAS meta-analysis. Independent replication
is the gold standard59 for validating a genetic association, although non-replication
alternately does not refute a genetic association per se150. There are several potential
causes of non-replication such as complex genetic architecture153, insufficient statistical
power150, or phenotypic differences between datasets230. There is evidence to suppose
that phenotype definitions in the replication cohort differed from those used in the
primary GWAS datasets as the genotyping significant heterogeneity into the meta-
analysis summary results119. There are phenotypic differences between the STOPAH
cohort cases and the UCL alcohol-related cirrhosis cases. First, a large number of the
severe alcoholic cases were of unidentified alcohol-related cirrhosis status whereas all
of the UCL cases had confirmed alcohol-related cirrhosis. Second, there was less
ancestral information for samples in the STOPAH cohort, bar self-reported white British
status, giving a greater potential for population stratification.
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Figure 3-13 A locus plot of the genetic association signal near LIPG and ACAA2
The −log10 (P values) are plotted against SNP genomic position based on the human genome
build 19. Variants are coloured to reflect correlation with the most significant SNP, with red
denoting the highest linkage disequilibrium, (r2 >0.8) with the lead SNP. Estimated
recombination rates (blue line) from the 1000 Genomes Project (hg19/genomes March 2012
release, EUR population) reflect the local linkage disequilibrium structure. Gene annotations
were from the UCSC Genome Browser. The plot was generated using LocusZoom 347.
Many of the same criticisms levied at the original GWAS pertain here also (e.g.
merging of different datasets, lack of coverage of CNVs and rare variants). Another
limitation of this analysis is the non-autosomal coverage of the sex chromosomes or
the mitochondrial DNA. These genomic regions were not included in this analysis due
to the increased challenges of harmonizing, merging and imputing haploid variants.
There are well-known differences in alcohol-related liver disease risk by gender 295, and
therefore the sex chromosomes may contain important loci that contribute to disease
risk. The mitochondria are also linked to liver disease because they are intimately
involved in the oxidative stress mechanisms which contribute to the pathogenesis of
alcohol-related liver disease182. Therefore, mitochondrial DNA may also contain
important alcohol-related liver disease loci. Despite these limitations, there is high
confidence in the data quality of this enlarged meta-analysis because it still identifies
the confirmed loci: PNPLA3, TM6SF2 and MBOAT7 as top-hits. The functionality of
the novel top-hit loci, especially in the region near LIPG/ACAA2, provide intriguing
evidence that genes involved in lipid metabolic pathways are important in the
pathogenesis of alcohol-related cirrhosis and the broader alcohol-related liver disease
phenotype.
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In summary, this extended GWAS revealed several novel variants nearing genome-
wide significance levels while variants in PNPLA3, TM6SF2 and MBOAT7 also
remained as the most significant associations. Despite showing the same directionality
in all instances, none of these variants replicated. One of the loci identified via this
analysis was between the genes LIPG and ACAA2, is also a validated cholesterol level
quantitative trait locus11,52,410,416 and hence shares a similar pathway to the validated
risk loci TM6SF2. Genetic variation in PNPLA3 and in particular, the variant rs738409,
remained as the most significant association in this dataset.
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CHAPTER 4 GENETIC VARIATION IN
PNPLA3 AND ALCOHOL-RELATED
CIRRHOSIS RISK
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4.1 - OVERVIEW
The variant rs738409 in PNPLA3 has the largest effect on alcohol-related cirrhosis risk
of any variant so far identified. While the robust genetic associations at this locus have
been addressed, much still remains to be clarified. In this chapter the consequences of
the carriage of rs738409 are further explored by determining: (i) if it is a risk factor for
the development of alcohol dependence per se; (ii) if it is associated with other
important phenotypic features of alcohol-related cirrhosis such as age at presentation,
survival and the development of HCC; and (iii) its contribution to the population
attributable risk of cirrhosis in the British and Irish ancestry population of England.
4.2 - BACKGROUND
4.2.1 - PNPLA3
PNPLA3 occurs on the long arm of chromosome 22 towards the end of the 22q13.2
region. The reference sequence for PNPLA3 contains nine exons and spans nearly 24
kilo-bases. It has five known transcripts and three of these do not code for proteins;
the transcript ENST00000216180 encodes the reference protein sequence126
(Supplementary Sequence 1). The transcription of PNPLA3 is detected primarily in the
liver but also in kidney, adipose, cerebral, duodenal and skin tissue121.
A review of transcription factor binding motifs in the PNPLA3 promoter region from the
ENCODE dataset (Figure 4-1)116 demonstrates several nutritionally regulated
transcription factor binding motifs and others which recruit the core machinery for
transcription such as SREBP and retinoid X receptor binding motifs. As with any
transcribed gene, it also contains all of the sequence necessary to recruit the core
transcription machinery such as RNA polymerase II (POLR2A) and myc-associated
factor X (MAX). Several of these transcription factors are known to regulate PNPLA3
expression via a feed-forward loop188.
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Figure 4-1 Transcription factor binding sites and regulatory elements in PNPLA3
Several transcription factor binding sites that are involved in nutritional regulation are found in
the promoter region of PNPLA3. Abbreviations: chr – chromosome; SNP – single nucleotide
polymorphism; ENCODE - The Encyclopaedia of DNA Elements; POL2RA – RNA polymerase
II; JUND - jun D proto-oncogene; MAX - myc-associated factor X; RXRA - Retinoic acid receptor
RXR-alpha; FOSL2 - FOS-Like Antigen 2; CEBPD - CCAAT/Enhancer-Binding Protein Delta;
SREBP1 - Sterol regulatory element-binding transcription factor 1. Image obtained from the
UCSC genome browser216
4.2.2 - GENETIC VARIATION IN PNPLA3 AND LIVER DISEASE
PNPLA3 was first identified as a nutritionally regulated mRNA transcript in adipose
tissue22 and following from this the earliest genetic association studies of PNPLA3 were
undertaken in obesity related phenotypes. In the first candidate gene study of
PNPLA3, several SNPs were found to marginally associate with obesity risk201.
Interest in the role of genetic variation in PNPLA3 escalated when a GWAS in patients
with NAFLD identified highly significant association between the variant rs738409 in
PNPLA3 and liver fat content and measures of liver inflammation370. This variant,
rs738409, encodes a cytosine to guanine substitution on the forward strand of
chromosome 22 at the position 43,928,847 on human genome build 19 (hg19)1 and is
common with the minor allele (rs738409[G]) having frequencies varying from 10-50% in
global populations (Figure 4-2).
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Figure 4-2 Map of rs738409 genotype frequencies
The variant rs738409 is common in all global populations with minor allele frequencies ranging
from as low as ~10% to as high as ~50%. Data source: 1000 genomes, 20121.
Following from the initial GWAS, several independent studies have confirmed
significant associations between rs738409 and NAFLD as well as several related
phenotypes and traits (Table 4-1). In the largest GWAS of NAFLD to date, rs738409
conferred the largest effect on the chance of developing advanced stage NAFLD
(P=3.60x10-43, OR 3.26 95% CI [2.11–7.21])405. There is an increasing awareness of
the effect of rs738409 as an independent risk factor in the development of HCC in
NAFLD169,398 and its potential use in prognostic models161.
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4.2.3 - PNPLA3 IN ALCOHOL-RELATED LIVER DISEASE
NAFLD and alcohol-related liver disease share clinical, histological and pathogenic
features266,473. Following from this, several groups have genotyped rs738409 and other
variants in PNPLA3 to investigate genetic associations with alcohol-related liver
disease phenotypes (Table 4-3).
The seminal genetic association between rs738409 and alcohol-related cirrhosis was
reported in a mixed European/Native American Mestizo population from Mexico in
which 15 SNPs around PNPLA3 were genotyped428. On conditional analysis, the most
significant association was observed between the rs738409 and the presence of
clinically diagnosed alcohol-related cirrhosis. This association has replicated in a
modest number of independent cohorts. In the first of these, a highly significant allelic
association was reported between rs738409 and alcohol-related cirrhosis in a
population from the UK388. A further two studies have also demonstrated significant
associations between this variant and alcohol-related liver disease risk. The first of
these studies reported a strong association rs738409 and biopsy proven alcohol-
related cirrhosis in a predominantly male German population413 while the second study
demonstrated association with the broader phenotype of alcohol-related liver injury in a
Belgian population431. In all studies the minor allele (rs738409[G]) encoding the
148Met allele was found to increase risk of alcohol-related cirrhosis.
It seems likely that the genetic association between rs738409 and alcohol-related
cirrhosis are independent of the comorbid phenotype, alcohol dependence413.
However, the case/control comparisons required to validify this hypothesis have not
been tested in the majority of genetic association studies55. The case/control
comparisons have been either between cases and population controls431 or between
cases and alcohol-misusers without significant liver injury388,428. As a case in point,
such a confounding genetic effect occurs for the genetic association between rs671
(Glu504Lys) ALDH2 and alcohol-related cirrhosis in East Asian ancestry populations,
which is primarily driven due to its association with alcohol-dependence/misuse. It
remains unclear whether the alcohol dependence phenotype is confounding genetic
association studies of rs738409 and alcohol-related cirrhosis.
Beyond influencing cirrhosis predisposition per se, rs738409 is also associated with
HCC following presentation with alcohol-related cirrhosis432 (Table 4-2). In particular,
carriage of the rs738409[G] allele increases HCC risk following the alcohol-related
development of cirrhosis (OR = 1.77)432.
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Table 4-2 The association between rs738409 and HCC risk
Study Odds Ratio[95% CI] P
Falletti et al.,
2011122
1.64
[0.98-2.73] 0.057
Guyot et al.,
2013161
2.23
[1.44-3.45] 3.05x10
-4
Hamza et al.,
2012164
1.67
[0.96-2.89] 0.067
Nischalke et
al., 2011309
2.68
[1.48-4.85] 0.0011
Trépo et al.,
2012430
2.51
[1.84-3.41] 4.30 x 10
-9
Meta-analysis 2.20[1.80-2.67] 4.71 x10
-15
Abbreviation: CI – confidence interval.
Data from Trépo et al., 2011432
There is emerging evidence that rs738409 is associated with the clinical presentation
with alcohol-related cirrhosis and its prognosis. This has been explored in a limited
way using the rs738409 genotype to stratify groups and following features of alcohol-
related liver disease such as presentation with cirrhosis from alcohol-misuse onset46,
time on a transplantation waiting list until death or liver transplant133 and presentation
with HCC and survival in alcohol-related cirrhosis443. It has been shown that carriers of
rs738409[G] cirrhosis risk allele: (i) present with cirrhosis after a shorter drinking
history; (ii) have a significantly increased risk of developing hepatocellular carcinoma
once they have cirrhosis; and, (iii) either die or develop decompensated cirrhosis after
a shorter time-period. There are several potentially confounding issues in these time-
to-event analyses, including lack of control of ancestral background443, potential
violations of the proportional hazards assumption133,151 and lack of inclusion of key
variables in multivariate time to event models133.
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4.3 - AIMS
There were three aims:
1. To investigate the association between the rs738409 and alcohol-related
cirrhosis when comparing both alcohol-dependent and non-dependent
populations controls via direct genotyping
2. To analyse the association between rs738409 and time to presentation with
cirrhosis and time to death using time to event modelling
3. To determine the population attributable risk for alcohol-related cirrhosis
resulting from carriage of rs738409 in the British population
4.4 - MATERIALS AND METHODS
4.4.1 - ALCOHOL-DEPENDENCE COHORT
The UCL alcohol-dependence cohort comprised of the DNA samples from 1513
individuals that were recruited when attending a variety of UK community and hospital-
based services providing support and treatment for alcohol use disorders, between
1997 and 2013 (Figure 4-3). A diagnosis of alcohol-dependence was made, by
experienced staff/trained research workers, using the DSM-IV10 or the ICD-10463
criteria. All participants were unrelated and of English, Scottish, Welsh or Irish descent
with a maximum of one grandparent of Northern-European but non-Jewish origin.
Details of alcohol history including the ages of onset of alcohol misuse, abuse and
dependence; the duration of hazardous drinking; average daily alcohol consumed in
grams and family history of alcohol abuse/dependence were recorded in the majority of
samples in this cohort.
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Figure 4-3 The sites at which alcohol-dependent subjects were recruited
A subset of 652 alcohol dependent individuals, recruited primarily from the Hepatology
service at the Royal Free Hospital, London were more extensively evaluated to
determine the presence and degree of any associated alcohol-related liver injury. The
clinical history, including further details of alcohol consumption, were recorded with
particular attention paid to previous encounters with medical practitioners, laboratory
and radiological investigations and hospitalizations and clinical episodes suggestive of
liver injury or decompensation including: jaundice, variceal haemorrhage, fluid retention
and neuropsychiatric disturbance. All patients were examined by two experienced,
senior clinicians for signs of alcohol misuse and liver injury and a detailed nutritional
assessment was undertaken, in the majority, by a senior dietitian. Blood was taken at
the time of presentation for standard liver function tests including plasma albumin,
serum bilirubin, ALP, AST, ALT, and GGT, full blood count, prothrombin time and the
INR; urea, creatinine and electrolytes; serological testing for antibodies to hepatitis A,
B, C, D and E, cytomegalovirus, Epstein–Barr virus, herpes simplex and varicella;
mitochondrial, nuclear, smooth muscle and liver kidney autoantibodies; iron, total iron
binding capacity, ferritin; copper, caeruloplasmin; alpha-one antitrypsin and tissue
transglutaminase. All patients underwent abdominal ultrasound and/or abdominal
computed tomography/magnetic resonance imaging scans, as indicated; all underwent
routine upper gastrointestinal endoscopy; histological examination was undertaken,
whenever possible, of liver biopsy material obtained by percutaneous, ultrasound
guided or transjugular routes; or else of explant or post-mortem liver tissue. Patients
were excluded if they had any other potential cause of liver injury e.g. chronic viral
hepatitis, autoimmune liver disease; genetic haemochromatosis; Wilson’s disease;
alpha-one antitrypsin deficiency or coeliac disease or if they had a body mass index
(BMI) > 30 and were also excluded from this group if they had a diagnosis of diabetes.
Based on this assessment two groups were defined from the larger cohort (Figure 4-4):
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Figure 4-4 Venn diagram of the UCL alcohol-dependence cohort samples stratified by
liver disease status
Alcohol–related cirrhosis
The alcohol-related cirrhosis group (n=321) comprised of individuals with either
clinically evident or biopsy proven alcohol-related cirrhosis. For these participants,
data regarding length of drinking history and self-reported daily alcohol consumption
were available from the date of recruitment. In 224 (69.8%) of this group, the diagnosis
of cirrhosis was made on the basis of a sustained history of prolonged, harmful
drinking; the presence of alcohol-dependence and histological examination of liver
tissue; in the remaining 97 (30.2%), the diagnosis was made on the basis of a
sustained history of prolonged, hazardous drinking; the presence of alcohol-
dependence and compatible historical, clinical, laboratory, radiological and endoscopic
features.
No significant liver injury
This population comprised of 332 individuals - all subjects were actively drinking at the
time of enrolment of which data were available regarding length of drinking history and
self-reported daily alcohol consumption were available from the date of recruitment.
The majority of these individuals had been hazardous drinking for over fifteen years. In
118 (36%) the absence of significant alcohol-related liver injury was confirmed on liver
biopsy. The remainder had no historical or clinical features suggestive of significant
liver injury either at presentation or during prolonged follow-up; 21 (6.3%) had isolated
hyper-bilirubinaemia, most likely reflecting the presence of Gilbert’s syndrome, but the
remainder had normal serum bilirubin levels; all had normal plasma albumin
concentrations and clotting profiles; serum GGT activity was raised in the majority;
serum ALT activity was within the laboratory reference range in the majority but when
elevated rarely exceeded twice the upper laboratory reference range; none had
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evidence of parenchymal liver injury or portal hypertension on imaging; upper
gastrointestinal endoscopy was normal in those in whom it was performed.
The majority of the individuals in the combined alcohol-related cirrhosis and no-
significant liver injury groups (n=633) also underwent genome-wide genotyping as part
of the first GWAS of alcohol-related cirrhosis (chapter 1)(Figure 4-5).
Figure 4-5 The overlap in samples between the genetic association study of PNPLA3 and
the GWAS of alcohol-related cirrhosis
POPULATION CONTROLS
The ancestrally matched population controls (n=1,249) were recruited from two
sources. The majority (n=780) were recruited from London branches of the National
Health Service blood transfusion service, from family doctor surgeries and from
amongst university students. Individuals were excluded if screening with the Schedule
for Affective Disorders and Schizophrenia identified a life-time history of depression,
bipolar disorder, schizophrenia or alcohol/drug use disorders. Thus, none of the
control subjects had a family history of bipolar disorder, schizophrenia or alcohol-
dependence; none currently drank above the current UK recommended weekly
maximum of 21 (168 g) units for men and 14 (112 g) units for women nor had done so
previously. All of the individuals providing blood donations had normal standard liver
function tests and were negative for hepatitis surface antigen and core antibody and
antibodies to HCV and HIV. The remaining population control samples (n=468) were
obtained from a separate cohort of controls of British ancestry, that were not screened
for psychiatric or alcohol use disorders; these were purchased from the European
Collection of Cell Cultures (Health Protection Agency Culture Collections, Salisbury,
UK).
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4.4.2 - SNP GENOTYPING
The variant rs738409 was genotyped in-house using the KASPAR (LGC Genomics,
Hoddesdon, UK) genotyping platform and custom designed primers (Table 4-4).
Amplification and detection was undertaken using a LightCycler® 480 Real-Time PCR
machine (Roche Molecular Diagnostics, Burgess Hill, UK). Genotype calling was
performed automatically using proprietary software367 with some minor manual editing
of genotype calls. Approximately 12% of samples, randomly selected a priori, were
genotyped in duplicate to ensure consistent genotype calling.
Table 4-4 Primers used for genotyping rs738409 in PNPLA3
SNP Name Sequence
rs738409
Allele specific (C) GAAGGTGAACCAAGTTCATGCTCCTTGGTATGTTCCTGCTTCATC
Allele specific (G) GAAGGTCGGAGTCAACGGATTCCTTGGTATGTTCCTGCTTCATG
Reverse 1 CGCCTCTGAAGGAAGGAGGGAT
Reverse 2 AAGGAGGGATAAGGCCACTGTAGAA
DATA PROCESSING AND ANALYSIS
Tests for primary allelic association, conditional logistic regression association analysis
and quality control measures such as tests of Hardy-Weinberg equilibrium and
missingness were performed using the software PLINK (version 1.9)58,349. A proportion
of samples from the UCL cohort, with imputed genotype data underwent direct
genotyping for rs738409. The concordance between imputed and direct genotype data
was directly assessed using a custom package79 in R (version 3.2.2) from which a
concordance value was determined.
4.4.3 - TIME-TO-EVENT ANALYSIS
DATASET
A proportion of the alcohol-dependence cohort recruited from the Royal Free Hospital,
London were retrospectively followed until 26st October 2015. The study enrolment of
these patients occurred from 23rd August 1996 until the 1st December 2011 (Figure
4-6). In all of these individual patients, several variables were collected including
gender, age, length of alcohol misuse (and the age of misuse onset) and self-reported
alcohol intake
The time-point at which this information was collected varied by liver disease status:
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1. Those patients classified with alcohol-related cirrhosis were phenotypically
categorised at the date of clinical presentation with cirrhosis.
2. Those patients classified with no-significant liver injury were phenotypically
categorised at the date of enrolment.
In those classified as alcohol-related cirrhosis, the data for several variables relevant to
liver function were recorded including LFTs and complications of liver dysfunction such
as variceal haemorrhage, ascites and hepatic encephalopathy. These clinical data
were used to derive the Pugh score348 and the MELD score213; these scores were
dichotomised as compensated or decompensated liver function in each patient at the
date of presentation with alcohol-related cirrhosis (MELD score >15: decompensated;
Pugh’s score >7: decompensated).
Figure 4-6 The total enrolment of patients by year from the Royal Free Hospital
The enrolment of alcohol dependent patients from the Royal-Free hospital occurred over a
period from 1996 until 2011
ANALYSIS
Entire dataset
Differences between the no-significant liver injury and the cirrhosis groups were
statistically compared at the date of enrolment/presentation. Dichotomous variables
(e.g. gender, decompensation status) were tested using a Pearson-Chi-squared test
and continuous variables (e.g. alcohol consumption, age) were tested using a two
sample t-test. The difference in mortality between these groups was also compared
using Kaplan-Meier time-to-event estimates215 from the date of birth until an event
(death or orthotopic liver transplant). The differences in morbidity between these
groups (i.e. presentation with cirrhosis) was compared by rs738409 genotype from the
date of birth. Kaplan-Meier time to event estimates were statistically compared using
the log-rank test.
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Cirrhosis patients
To detect potential confounding all variables were tested for association with rs738409
genotype at the date of clinical presentation with cirrhosis. To test association Pearson
Chi-Squared tests were used for dichotomous variables (e.g. gender, decompensation)
and Wald tests were used for continuous variables (e.g. alcohol consumption, age).
Univariate and multivariate time-to-event analysis were performed using a Cox
proportional hazards regression model73. Each variable was tested for association with
the time from presentation with cirrhosis until the date of death or orthotopic liver
transplant. Variables that were significantly associated with the time-to-event in the
univariate analysis (P<0.05) were entered into a multivariate Cox proportional hazards
regression model as covariates. The multivariate models, was tested for deviation from
Cox proportional hazards assumption using the method of Grambsch and Thernau151.
Covariates that were in violation of the proportional hazards assumption were entered
as time dependent strata in the Cox proportional hazards model (at the minimum strata
size in which the proportional hazards assumption is not violated in the model).
Several variables were analysed post hoc in the alcohol-related cirrhosis group. These
variables may have influenced the time-to-event but were not suitable for survival
modelling either because the factor occurred after presentation with cirrhosis (e.g.
development of HCC) or, where the information was incomplete in the majority of
samples (e.g. non-abstinence or the cause of death). The development of HCC and
patient abstinence following presentation with cirrhosis were analysed by rs738409
genotype status using Chi-Squared test for dichotomous variables and Wald tests for
continuous variables. The cause of death was incomplete in the vast majority of
samples and therefore was not statistically analysed.
No-significant liver injury patients
At the date of enrolment all variables were tested for association with rs738409
genotype to detect potential sources of confounding. Pearson Chi-Squared test were
performed for dichotomous variables (e.g. gender, decompensation) and Wald tests for
continuous variables (e.g. alcohol consumption, age). Univariate and multivariate time-
to-event analysis were performed using a Cox proportional hazards regression
model73. Each variable was tested for association with the time from presentation with
cirrhosis until the date of death or orthotopic liver transplant. Variables that were
significantly associated with the time-to-event in the univariate analysis (P<0.05) were
entered into a multivariate Cox proportional hazards regression model as covariates.
The multivariate model was tested for deviation from Cox proportional hazards
assumption using the method of Grambsch and Thernau151. Covariates that were in
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violation of the proportional hazards assumption were entered as time dependent strata
in the Cox proportional hazards model (at the minimum strata size in which the
proportional hazards assumption is not violated in the model).
Software
All time-to-event analyses were performed in R352 using the survival package426 and
several other packages were used for data manipulation, processing and plotting
including ggplot2, gridExtra, reshape and plyr. Tests for association between variables
collected and the date of presentation/enrolment and rs738409 were performed in
PLINK349.
4.4.4 - POPULATION ATTRIBUTABLE RISK
The population attributable risk (PAR) and its 95% confidence intervals were calculated
using effect size estimates from the allelic association of this variant when compared
between alcohol-related cirrhosis cases and no-significant liver injury controls in the
UCL cohort. The equation used for PAR estimation is suitable without the presence of
confounding in the genetic association368:
Abbreviations: PAR – population attributable risk; fcases – risk allele frequency in cases, RR –
relative risk
This calculation requires the relative risk (RR), a measure of the magnitude of an
association between an exposed and non-exposed group. However, case/control
genetic association tests cannot empirically quantify the RR and instead the OR a
related measure of is calculated as a measure of effect size in genetic association
studies. The OR and its 95% confidence intervals may be used as proxies for the RR
and its 95% confidence intervals72. However, this may lead to inflation of the true effect
size estimate and hence overestimation of the PAR. Because of this, RR estimates
were calculated from the OR and its 95% confidence intervals using the method of
Zhang and Yu478 were used to calculate a separate PAR based on this RR estimate:
Abbreviations: RR – relative risk; OR – odds ratio; fcontrols – alcohol-related cirrhosis incidence in
C-allele carriers
An estimate of the number of individuals affected by alcohol-related cirrhosis of British
and Irish ancestry in England was calculated using published data on the prevalence of
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alcohol-dependence in England and Wales288 and contemporaneous total population
estimates of alcohol dependence318. The effect of the PAR estimates were compared
at range of alcohol-related cirrhosis incidence rates in this population.
4.5 - RESULTS
4.5.1 - GENOTYPING
GENOTYPING ACCURACY
The KASPAR genotyping succeeded with a genotyping success rate > 95%. In the
proportion of samples genotyped in duplicate <1% were in conflict. Visual inspection of
genotyping cluster plots demonstrates distinct clustering of the three possible
genotypes for each SNP and also the negative controls (Figure 4-7). Rs738409
followed Hardy-Weinberg equilibrium (P > 0.01) in all of the comparator populations
used for association analysis. In the 628 alcohol-dependent cases with both imputed
and direct genotype data for rs738409, the results were highly concordant (96.9%)
(Figure 4-8) demonstrating the accuracy of the imputed data, which was used in the
GWAS.
Figure 4-7 A KASPAR genotyping cluster plot for rs738409
These images demonstrate the fluorescence data used to determine sample genotype for a
SNP where each point on the scatter plot represents the recorded fluorescence at two different
wavelengths. Genotypes are shown by coloured groups (red, green and blue) which are
assigned by a computational algorithm and manual editing. Grey samples represent negative
controls which should have limited fluorescence and cluster together. Pink samples represent
samples where the genotype cannot be ascertained from these genotype data and are hence
classified as unknown.
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Figure 4-8 Concordance between direct and imputed genotype data for rs738409
The discrete direct genotype values (x-axis) plotted versus the continuous imputed genotype
values (y-axis) for rs738409. Each genotype data point is coloured on a continuous scale (from
red to green) by its percentage concordance between the imputed and direct genotype data
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4.5.2 - GENETIC ASSOCIATION ANALYSIS
The variant rs738409 in PNPLA3 was genotyped in a total of 1513 alcohol dependent
cases and 1249 population controls. There were no significant differences in the allele
frequencies between the alcohol dependent cases and population controls (Table 4-5).
In the alcohol-dependent patients that were phenotypically classified by liver disease
status a total of 331 alcohol-related cirrhosis cases and 323 no significant liver injury
controls underwent genotyping. The rs738409[G] allele was strongly associated with
alcohol-related cirrhosis when compared against no-significant liver injury controls
(P=1.55x10-7; OR=2.01, 95% CI [1.55-2.61]).
Table 4-5 Allelic association analysis of rs738409 in the UCL cohort
Comparison Group Number P-values Odds Ratio[95% confidence interval]
Alcohol dependence
vs. population controls
Cases 1509
0.66 0.97[0.86-1.10]
Controls 1249
Cirrhosis vs.
population controls
Cases 323
8.19x10-7 1.62[1.34-1.96]
Controls 1249
Cirrhosis vs. no
significant liver injury
Cases 323
1.55x10-7 2.01[1.55-2.61]
Controls 331
*Calculated using an allelic Pearsons Chi-squared test
Figure 4-9 The genotype distribution and allele frequency of rs738409 in the UCL cohort
The genotype frequencies for each group of patients in the UCL cohort as bar plots with the
number of genotypes in each group given above each bar. The allele frequency of the major
and minor allele are given in the pie-charts above each bar plot group.
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4.5.3 - TIME-TO-EVENT ANALYSIS
Phenotypic data necessary for time-to-event data was collected in 437 patients with
alcohol-dependence recruited at the Royal Free hospital. The data necessary for time-
to-event analysis was complete in the majority of individuals (95.2%). There were a
greater number of men (70.9%) and at the date of enrolment or presentation with
cirrhosis: the mean age was 53.2 years; the mean length of drinking history was 25.2
years; the mean age of alcohol-misuse onset was 28.0 years; and, the mean self-
reported alcohol consumption was 190.9 units/week.
There were two phenotypically categorised groups: those with alcohol-related cirrhosis
and those with no-significant liver injury (Table 4-6). At the baseline (date of enrolment
or the date of clinical presentation with cirrhosis), there were significant differences
between these groups: the alcohol-related cirrhosis group were more likely to be
female, began misusing alcohol at an older age, had a higher frequency of the
rs738409[G] allele and had a reduced lifespan (Table 4-6). Patients with cirrhosis,
have on average, a ten-year shorter lifespan than those with no-significant liver injury
(Figure 4-10).
In all patients, the time from the date of birth until the date of clinical presentation with
cirrhosis was estimated and stratified by rs738409 genotype. Those patients that did
not present with cirrhosis were censored at the date of death or the final time point in
which they were last known to be alive. There were significant differences by rs738409
genotype (Plog-rank = 5.74x10-6) (Figure 4-11, Table 4-7) and on average carriers of the
rs738409[GG] genotype presented with cirrhosis approximately 10 years earlier than
those with the rs738409[CC] genotype.
Table 4-6 Base lines demographics of the time-to-event cohort by liver disease status
Variable Cirrhosis(n=254)
No-Liver Injury
(n=183) P-value
Gender (Male) 160 (66.9%) 135 (76%) 0.049*
Alcohol consumption (units/week) 186.1 197.7 0.3**
Age of Alcohol-misuse onset (years) 29.3 26.4 3.58x10-3**
Length of drinking history (years) 25.8 24.5 0.16**
rs738409 genotype
CC/CG/GG (%)
109/99/31
(45.6%/41.4%/12.9%)
114/61/2
(64.4%/34.5%/1.12%) 2.31x10
-6*
Median KM time-to-event estimate
(years) 64.3 75.5 1.95x10
-6***
The average is given for continuous variables and the count and frequency for discrete
variables. Abbreviations: KM – Kaplan-Meier. Statistical tests: * Pearson's Chi-squared test; **
Welch Two Sample t-test; ***Log-rank test
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Figure 4-10 Kaplan-Meier curve in all patients stratified by liver status
This Kaplan-Meier curve shows the estimated survival curves stratified by liver disease status
(cirrhosis or no-significant liver injury) from birth until and death or liver transplant
Abbreviations: NSLI – no-significant liver injury
Table 4-7 Median Kaplan-Meier time-to-event estimates from the date of birth until the
date of presentation with cirrhosis stratified by rs738409 genotype
Variable Strata Median time-to-event (years)[95% CI]
rs738409
genotype
CC 63.0 [60.1–66.7]
CG 61.4 [57.4–64.3]
GG 52.4 [51.1-57.6]
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Figure 4-11 Kaplan-Meier curve in all patients stratified by rs738409 genotype
This Kaplan-Meier curve shows the estimated time-to-event curves stratified by rs738409
genotype from the date of birth until the date of presentation with cirrhosis
CIRRHOSIS PATIENTS
Over the period of data collection, an event (death or orthotopic liver transplant)
occurred in 161 (68.6%) of the patients that presented with alcohol-related cirrhosis
and the 78 patients alive at the date of last observation were censored. Of all the
observed events, 142 (88.2%) were deaths and 19 were orthotopic liver transplants
(11.8%). The baseline clinical and demographic variables collected at the date of
presentation did not differ by rs738409 genotype (Table 4-8). Several variables
associated with this time-to-event (Table 4-8) including the carriage of the rs738409[G]
allele, which was associated with an increased the chance of death or liver
transplantion by 26% at any time-point.
Covariates deemed significantly associated in the univariate test (PUNIVARIATE < 0.05)
were entered as covariates into a multivariate Cox proportional hazards model. None
of the variables in this model deviated from the proportional hazards assumption.
Despite its significance, the MELD score was not included in the multivariate model for
two reasons: (i) because it is an approximate for the Pugh score; and, (ii) because the
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MELD score data was missing in a greater proportion (n=37 (15.5%)). In the
multivariate model, both gender and the Pugh score remained independently
associated with the time-to-event (PMULTIVARIATE < 0.05). Survival curves were
calculated in the alcohol-related cirrhosis group when stratified by those variables that
were significantly associated with the time-to-event (PUNIVARIATE < 0.05) (Figure 4-12,
Table 4-10). On average, death or liver transplant occured 5 years earlier for
individuals that are homozygote for the rs738409[GG] genotype than carriers of the
rs738409[CC] genotype.
Table 4-8 Baseline clinical and demographic features in patients with cirrhosis stratified
by rs738409 genotype
Variable CC(n=109)
CG
(n=99)
GG
(n=31) P-value
Sex
(male) 67 (61.46%) 69 (69.69%) 24 (77.4%) 0.19*
Pugh status
(decompensated) 40 (43.01%) 47 (51.08%) 14 (51.85%) 0.49*
MELD status
(decompensated) 31 (34.06%) 50 (35.29%) 10 (38.46%) 0.92*
Alcohol consumption
(units/week) 184.35 187.28 188.7 0.77**
Age at presentation
(years) 53.76 53.12 53.26 0.70**
Age of Alcohol-misuse
onset (years) 55.69 54.41 55.43 0.62**
Length of drinking
history (years) 26.22 25.14 26.77 0.91**
The mean is given for continuous variables and the count and frequency for discrete variables.
Statistical tests: *allelic Pearson's Chi-squared test; **Wald-test
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Table 4-9 Cox proportional hazards analysis of the time from presentation with cirrhosis
until death or orthotopic liver transplant using univariate and multivariate models
Covariate
Univariate Multivariate
Hazard
Ratio P-value Number
Hazard
Ratio P-value Number
Sex (male) 1.76 0.0016 239 1.57 0.018 212
Age at presentation
(years) 1.02 0.0051 239 1.02 0.075 212
Pugh score 5-7
(decompensated) 2.02 3.13x10
-5 212 2.01 4.3x10-5 212
MELD score ≤15 
(decompensated) 2.01 9.16x10
-5 202 - - -
rs738409 genotype
(CC=0, CG=1, GG=2) 1.26 0.040 239 1.15 0.24 212
Abstinence 0.86 0.68 110 - - -
Length of alcohol
misuse (years) 1.01 0.37 239 - - -
Alcohol consumption
(units/week) 1.00 0.79 239 - - -
Age of misuse onset
(years) 0.99 0.97 239 - - -
Table 4-10 Kaplan-Meier median time-to-event estimates for several variables
associated with the time to death or transplant from cirrhosis presentation
Variable Strata Median time-to-event in years[95% CI]
rs738409
genotype
CC 10.00[7.87–11.8]
CG 7.40[5.29–10.6]
GG 4.47[2.69-11.8]
Gender
Male 5.55[4.71-7.87]
Female 11.76[10.06-18.23]
Pugh Score
Compensated
(5-7)
10.06
[8.09-13.52]
Decompensated
(8-15)
4.59
[2.73-6.42]
MELD Score
Compensated
(≤15) 
9.82
[7.14-12.90]
Decompensated
(>15)
4.47
[2.71-7.10]
Age at
Presentation
(years)
≤54 
10.06
[8.09-12.40]
>54 5.61[4.47-8.71]
Abbreviations: MELD – Model of end-stage liver disease; CI – Confidence interval
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Figure 4-12 Kaplan-Meier survival curves in patients with cirrhosis
Kaplan-Meier survival curves from the date of presentation with cirrhosis until the date of death
or orthotopic liver transplant were stratified by the variables deemed significant (P < 0.05) in
univariate Cox-regression analysis with the at risk tables for each strata given below each plot.
Continuous covariates were stratified by their median value.
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Causes of Death
The cause of a death was identified in a small number of patients with cirrhosis (Figure
4-13). The predominant causes of death were liver failure and HCC. Many of the other
causes of death were associated with complications arising from cirrhosis (e.g. variceal
bleeds, renal failure).
Figure 4-13 The causes of death or liver transplant in patients with cirrhosis
HCC
In total 16 patients with alcohol-related cirrhosis group developed HCC. Several
clinical and demographic variables, including rs738409 genotype were statistically
compared by HCC status (Table 4-11). Patients with HCC were more likely to be male
and carriers of the rs738409[G] allele. The development of HCC was not significantly
associated with the time from presentation until death or liver transplant (P < 0.05)
although the development of HCC on average reduces the time until death or
transplant by 3.5 years in patients with cirrhosis.
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Table 4-11 Baseline clinical demographic features of patients with cirrhosis as stratified
by the subsequent development of hepatocellular carcinoma
HCC & Cirrhosis
(n=16)
Cirrhosis
(n=223) P value
Gender (Male) 15 (93.75%) 145 (65.02%) 0.037*
Pugh score 8-15
(decompensated) 8 (46.5%) 93 (66.7%) 0.29*
MELD score >15
(decompensated) 5 (34.5%) 66 (45.4) 0.68*
Alcohol consumption
(units/week) 164.7 187.7 0.22**
Age at clinical presentation
with cirrhosis (years) 56.6 53.2 0.06**
Length of alcohol-misuse
(years) 30.5 25.5 0.051**
rs738409 genotype
(CC/CG/GG)
3/7/6
(18.8%/43.8%/37.5%)
106/92/25
(47.5%/41.2%/11.2%) 0.0015***
KM median time to death or
OLTx (years) 5.2 8.5 0.21****
The mean is given for continuous variables and the count and frequency for discrete variables.
Abbreviations: KM – Kaplan-Meier, OLTx – orthotopic liver transplant. Statistical tests:
*Pearson's Chi-squared test; ** Welch Two Sample t-test; ***Allelic Pearson's Chi-squared test;
****Log-rank test
Abstinence
Alcohol use recidivism data following presentation with cirrhosis was available in a
minority of patients (n=110). None of the clinical, genetic or demographic variables
differed by abstinence status (Table 4-12).
Table 4-12 Test for association between several variables and alcohol use recidivism in
the alcohol-related cirrhosis time-to-event dataset
Abstinent
(n=63)
Non-abstinent
(n=47) P value
Gender (Male) 33 (52.3%) 28 (59.5%) 0.58*
Pugh (decompensated) 20 (40.8%) 21 (50.0%) 0.51*
MELD (decompensated) 17 (35.4%) 12 (29.2)% 0.70*
Alcohol consumption
(units/week) 178.6 177.7 0.96**
Age at cirrhosis
presentation (years) 51.9 50.7 0.59**
Length of drinking history
(years) 24.5 24.6 0.92**
rs738409 genotype
(CC/CG/GG)
38/16/9
(60.3%/25.4%/14.28%)
20/24/3
(42.5%/51.1%/6.38%) 0.43***
KM median time to event
(years) NA NA 0.61****
The mean is given for continuous variables and the count and frequency for discrete variables.
Abbreviations: KM – Kaplan-Meier. Statistical tests: * Pearson's Chi-squared test; ** Welch Two
Sample t-test; ***Allelic Pearson’s Chi-squared test; ****Log-rank test
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NO-SIGNIFICANT LIVER INJURY PATIENTS
Out of the 177 patients with no-significant liver, 57 (32.2%) died between the date of
enrolment and the last follow-up. The remaining 120 patients (67.8%) were censored
at the date of last observation. At the baseline (date of enrolment) there were no
differences by rs738409 genotype for the several clinical and demographic variables
collected (Table 4-13). Several variables were associated with the time-to-event
(Table 4-14) including carriage of the rs738409[G] allele, which was associated with a
decreased chance of death by 48% at any time-point. Other significantly associated
variables included the age at enrolment (4% increased chance of death for every
additional year of age at enrolment) and age of alcohol-misuse onset (3% increased
chance of death for every additional year of age of alcohol misuse onset).
The significantly associated variables (PUNIVARIATE < 0.05) were entered into a
multivariate Cox proportional hazards model. The age of enrolment covariate violated
the Cox-proportional hazards assumption; this violation was accounted for by stratifying
the model into tripartite strata by the age of enrolment. In the final model both
rs738409 allele status and the age at enrolment were associated with the time to event
(PMULTIVARIATE < 0.05) (Table 4-14) (Figure 4-14).
Table 4-13 Baseline demographics of the no-significant liver injury patients stratified by
rs738409 genotype
Variable CC(n=117)
CG
(n=64)
GG
(n=2) P-value
Sex
(male) 88 (75.2%) 49 (76.5%) 2 (100%) 0.71*
Alcohol consumption
(units/week) 197.2 198.2 270 0.74**
Age at enrolment
(years) 50.71 50.69 51.8 0.97**
Age of Alcohol-misuse
onset (years) 26.73 25.35 25.8 0.38**
Length of drinking
history (years) 23.97 25.34 26 0.96**
The mean is given for continuous variables and the count and frequency for discrete variables.
Statistical tests: *allelic Pearson's Chi-squared test; **Wald-test
136
Table 4-14 Cox proportional hazards time to death from enrolment analysis in the no-
significant liver injury group
Covariate
Univariate Multivariate*
Hazard
Ratio P-value Number
Hazard
Ratio P-value Number
Sex (male) 0.70 0.22 177 - - -
Age at enrolment (years) 1.04 0.0051 177 1.03 0.016 177
rs738409 genotype
(CC=0, CG=1, GG=2) 0.52 0.033 177 0.52 0.035 177
Length of alcohol misuse
(years) 1.02 0.24 177 - - -
Alcohol consumption
(units/week) 1.00 0.71 177 - - -
Age of misuse onset
(years) 1.03 0.051 177 0.97 0.41 177
*The multivariate model was stratified by tripartite strata at the age at enrolment to avoid
violations of the proportional hazards assumption.
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Figure 4-14 Kaplan-Meier survival curves in patients with no significant liver injury
Kaplan-Meier survival curves from the date enrolment until the date of death were stratified by
the variables deemed significant (P < 0.05) in univariate Cox-regression analysis with the at risk
tables for each strata given below each plot. Continuous covariates were stratified by their
median value.
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4.5.4 - POPULATION ATTRIBUTABLE RISK
The PAR estimates for rs738409 were derived from the OR of the allelic association
test between alcohol-related cirrhosis cases and no-significantly liver injury controls
(OR = 2.01, 95% CI [1.55-2.61]). This OR was used to calculate an estimate of the RR
of the genetic association (RRestimate = 1.69, 95% CI [1.41-2.01]). In this British and
Irish cirrhosis study population the PAR for the carriage of the rs738409[G] cirrhosis
risk allele was substantial accounting for around one fifth of the PAR when using the
OR (PAR%=24.23, 95% CI [14.06-20.09]) and when using an RR estimate
(PAR%=17.98%, 95% CI [11.39-24.21]).
In 2009, the recorded population of ethnic British and Irish adults (16-75+ years) living
in England was 35,597,700. In this population, 8.7% of men and 3.3% of women have
reported alcohol-dependence, totalling 2,109,229 alcohol-dependent individuals.
Based on a 20% incidence rate of alcohol-related cirrhosis in patients with alcohol
dependence 241,423, it is estimated that 421,846 individuals in England of British or Irish
ancestry, will develop alcohol-related cirrhosis over their lifetime. Based on this
estimate and the calculated population attributable risk for rs738409, if the rs738409[G]
allele was not present in the British and Irish population of England there would be
102,209 (95% CI [62,562-142,427]) fewer cases of alcohol-related cirrhosis in this
population (Figure 4-15). Calculations based on the relative risk estimate are lower
although still substantial.
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Figure 4-15 Population attributable risk estimates of alcohol-related cirrhosis by
rs738409 genotype at difference incidence levels
These images show the estimated number of alcohol-related cirrhosis cases that would not be
present if the rs738409[G] allele was absent from British and Irish ancestry population of
England and Wales. These estimates were derived from the odds ratio (image A) and a relative
risk estimate (image B). Both images show the estimated number of people (y-axis) at different
incidence levels of alcohol-related cirrhosis (x-axis) that would not be present in dependent
drinkers of British and Irish ancestry in England and Wales (black line) with the 95% confidence
interval of the estimate (grey outline). A range of likely alcohol-related cirrhosis incidence levels
in alcohol-dependent populations are highlighted (dashed red lines).
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DISCUSSION
Alcohol-related cirrhosis and alcohol-dependence are both influenced by genetic risk
factors. Hence, confounding may occur in genetic association studies without
appropriate case/control comparisons, namely comparing alcohol-related cirrhosis
cases with both population controls and alcohol-misusers with no-significant liver injury.
Through the direct genotyping of rs738409 in a large (n=2,762), ancestrally
homogeneous and well characterized cohort this analysis demonstrates that there is no
evidence for genetic association between rs738409 and alcohol dependence.
The variant rs738409 is firmly associated with alcohol-related cirrhosis risk55; this
finding is typified as this was the most significantly associated variant in the GWAS of
alcohol-related cirrhosis44. In the current work, the genetic association results for
rs738409 from the GWAS are replicated albeit through direct genotype data rather than
probabilistic imputed genotype data. The results are highly concordant with the
imputed data (rs738409 UK-GWAS imputed data: P=2.51x10-8, OR=2.12 95% CI [1.63-
2.77]; rs738409 direct genotyping data: P=1.55x10-7, OR=2.01, 95% CI [1.55-2.61]).
The subtle differences in significance and effect size between these data likely reflect
the slightly different samples used (Figure 4-5), differences in the genetic association
test resulting from the use of different analytical software, and also minor differences
between the empirical direct genotype data and the probabilistic imputed genotype
data. The effect size of the rs738409 association with alcohol-related cirrhosis is
greater in the comparison with long-term alcohol misusers with no-significant liver injury
(OR=2.01, 95% CI [1.55-2.61]) than with population controls (OR=1.62, 95% CI [1.34-
1.96]). This finding is likely due to increased relative statistical power, which derives
from using phenotypically, screened controls and is consistent with similar comparisons
in other cohorts55.
There is increasing awareness that rs738409 genotype may influence prognosis in
alcohol-related liver disease46,55,443. In the current work, rs738409 was investigated for
such effects in a sub-cohort of alcohol-dependent patients in which data was collected,
in some, over a twenty year period from the date of enrolment or clinical presentation
with alcohol-related cirrhosis until death or orthotopic liver transplant. The primary
phenotypic difference between patients was the presentation with alcohol-related
cirrhosis which was associated with a significantly worse prognosis than those with no-
significant liver injury. Notably, in this stratified cohort the rs738409[G] allele carriers
clinically present with alcohol-related cirrhosis at a younger age. This findings is in
agreement with a previous study which also demonstrates that carriers of the
rs738409[G] allele have an earlier age of alcohol-related cirrhosis onset46.
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The primary time-to-event analysis was from the date of presentation/enrolment until
death or orthotopic liver transplantation; this was performed separately in the alcohol-
related cirrhosis and no-significant liver injury sub-groups.
In the cirrhosis sub-group, several variables (Pugh score, MELD score, gender and
rs738409 allele status) were associated with the time from clinical presentation with
cirrhosis until death or orthotopic liver transplant. A primary finding from this analysis
was that of an increased hazard of death or orthotopic liver transplant (HR= 26% per G
allele) for each rs738409[G] allele carried. This finding did not remain significant in the
multivariate analysis and only decompensated liver disease status (as determined by a
Pugh score) and male gender were independently associated with the time-to-event.
As the multivariate analysis was performed with a reduced dataset this may have
reduced the statistical power to detect the association between rs738409 allele status
which was observed in the univariate analysis. This finding is consistent with the
association between the rs738409[G] allele and reduced transplantation free survival in
a population waiting for liver transplant133.
The presentation with alcohol-related cirrhosis may occur incidentally, due to referral
based on abnormal LFTs, or symptomatically due to the development of liver failure.
These differences in presentation result from the presence, or absence, of clinical
symptoms and therefore the date of presentation is subject to a lead time bias 445
(Figure 4-16). In disease modalities such as cancer77, where screening is a key
strategy to reduce mortality, lead time bias can result in an overestimation of survival
time. However, this was unlikely to have occurred in the present study as patients with
cirrhosis, at the baseline date of presentation, did not have significantly different
rs738409 allele frequencies by either the MELD or CTP scores.
Figure 4-16 Lead time bias
The occurrence of lead time bias results from the earlier detection of a disease, in comparison
to the typical symptomatic presentation, which may result in an overestimation of the perceived
survival time without affecting the course of the disease
The major causes of death in the alcohol-related cirrhosis sub-group were liver failure
and HCC. This is the first study to demonstrate a significant association between HCC
risk developing from alcohol-related cirrhosis and the rs738409 variant in a British and
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Irish ancestry cohort. This finding replicates those findings from several other
European ancestry cohorts432. HCC is associated with a worse prognosis in cirrhosis
and therefore, rs738409 genotype information may have clinical utility in identifying
those requiring greater HCC surveillance.
Unlike the other variables, the data regarding abstinence post-diagnosis with cirrhosis
was incomplete in the majority of patients with cirrhosis. In those patients in which this
information was obtained, it was not associated with the time until death or liver
transplant; a finding is incongruous with clinical guidelines444 and the findings from
several studies469. However, the quality of this data may be limited by several factors:
(i) abstinence data was missing for a majority of the sub-group; (ii) abstinence data
were dichotomised due to lack of information and were therefore less informative than
quantitative data (e.g. amount and length of alcohol consumption after cirrhosis
diagnosis); and, (iii) abstinence data was collected retrospectively and therefore has a
potential to be influenced by ascertainment bias.
In patients with no-significant liver time-to-event comparisons were performed from the
date of enrolment until death. Surprisingly in those with no-significant liver injury, the
rs738409[G] allele, which is associated with an increased risk of alcohol-related
cirrhosis, was associated with a decreased hazard ratio of a death (HR=0.52). This
finding remained significantly associated in the multivariate model with both the age at
enrolment and rs738409 as independent predictors of prognosis. This is the first report
of an association between the rs738409[G] alcohol-related cirrhosis risk allele and a
favourable prognosis in a population of alcohol-misusers with no-significant liver injury.
A hypothetical mechanism through which rs738409[G] may reduce mortality in alcohol-
misusers without alcohol-related cirrhosis is through lowering serum triglyceride levels
and hence cardiovascular disease risk257. In studies of rs738409 in NAFLD, carriers of
the rs738409[G] allele have lower mean serum triglycerides, a lower Framingham
cardiovascular risk score and lower prevalence of metabolic syndrome91. Functionally
the rs738409 variant may impact the secretion of triglycerides from the liver as in a
cohort of overweight/obese men this variant explained 46% of the variance in VLDL
triglyceride secretion from the liver into the plasma; the rs738409[G] allele was
associated with a reduced VLDL secretion capacity from the liver335. A similar, so-
called ‘catch-22 situation’, has already been suggested for such a two-way
disease/allele risk relationship between the alleles of the functional variant rs58542926
in TM6SF2 and either cardiovascular or liver disease risk209.
The primary time-to-event analyses were performed using the Cox proportional
hazards model73. This statistical model has several advantages over other time-to-
event analytical models such as the nonparametric Kaplan-Meier time-to-event
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estimates215 and their statistical comparison using the log-rank test or more complex
regression based parametric models. The primary advantage of the Cox proportional
hazards model is its ability to include data from several variables for multivariate
analysis while not requiring the detailed knowledge of a survival distributions as is
required for parametric models. However, there are two primary assumptions of this
model: first, the non-informative censoring assumption (i.e. the cause of censoring is
independent of the event); and second, the proportional hazards assumption (i.e. the
hazard functions of each variable are constant over the time interval). In the current
analysis all of the samples were censored at the date of last clinical observation and
where this information was unclear they were excluded from analysis reducing the
likelihood of non-informative censoring. Also, the proportional hazards assumption was
tested using the method of Grambsch and Thernau151 in which each variable is
statistically tested for deviation from the proportional hazards assumption and visually
described using weighted residual plots. Any variables that violated the proportional
hazards assumption were stratified until there was no evidence for non-proportional
hazards in the multivariate model reducing the likelihood of proportional hazards
violation.
The rs738409[G] allele is common in people of British and Irish ancestry (allele
frequency=22.1%) and has a relatively large effect on alcohol-related cirrhosis risk for a
common genetic variant on a complex disease phenotype (OR=2.01, 95% CI [1.55-
2.61]). Hence, it may have utility in identifying patients with increased risk of
developing alcohol-related cirrhosis; indeed, this idea has already been suggested428.
The allele frequency and OR values do not provide readily interpretable information for
understanding the effect of the variant on disease incidence at a population level. This
is the use of the PAR, which provides an indication of the percentage reduction in the
incidence rate of a disease if the risk factor were not present in a population. When
calculated from the OR, the rs738409[G] allele accounts for around one-fifth (PAR% =
20.49%, 95% CI [14.39%-26.57%]) of the population attributable risk for alcohol-related
cirrhosis in this British and Irish ancestry population, a figure that is comparable to a
another estimate in German ancestry population413. This estimate of the population
attributable risk is sizeable indicating that knowledge of rs738409 genotype may have
some use in the identification of individuals who are at increased risk of developing
alcohol-related cirrhosis.
In case/control genetic association studies the PAR is often calculated using the OR as
a proxy for the RR413. These two measures of effect size are not equivalent; the OR
nearly always overinflates the RR83,276. The scale of this over inflation is dependent on
the prevalence of the disease phenotype in a population and the scale of its true effect
size. For diseases with a low population frequency the RR and OR asymptotically
144
approach, and hence are equivalent; this is the rare disease assumption72 (Figure
4-17). As the RR, cannot be empirically determined from the case/control study design
employed in this analysis, several precautions were undertaken to minimize and
account for PAR inflation resulting from using the OR. First, PAR estimates were
derived from both the OR and an estimate of the RR using the method of Zhang and
Kai478 and second, 95% confidence intervals were generated for comparisons to
account for uncertainty in the estimate. As expected the PAR derived from the RR
estimate was lower than that derived from the OR yet nevertheless both demonstrate a
substantial PAR estimate and there would likely be nearly a fifth fewer alcohol-related
cirrhosis cases occurring in British and Irish ancestry populations if this variant were
not present.
Figure 4-17 The relationship between relative risk and odds ratios
At increasing disease incidence levels (from 1% to 50%) and increasing effect sizes the relative
risk and odds ratio become less equivalent. These data were calculated using the formula of
Zhang and Kai, 1998478
Oxymoronically, a major strength and weakness of this analysis was the case/control
study design386. Case/control studies require the retrospective selection of patients, in
this instance by liver disease status, and therefore are not a representative population
per se. Several features of this analysis minimized potential bias resulting from
case/control selection: (i) for time-to-event analysis patients with alcohol-related
cirrhosis and no-significant liver injury were analysed separately; (ii) variables were
analysed using both univariate and multivariate models, including several clinical and
demographic variables, to account for confounding; and (iii) phenotypic
characterization and follow up was performed independent from rs738409 genotype
145
status. The major strength of the case/control study design is that it maximises
statistical power. In the case of genetic association analysis particularly, this allows the
detection of robust genetic associations, which by other study designs, namely cohort
studies, could be impractical due to the overall population incidence of alcohol-related
cirrhosis and the long follow up period required for it to become apparent.
In summary, this analysis validates the robust association between rs738409 and
alcohol-related cirrhosis in the UCL cohort demonstrating the accuracy of imputed
genotype data. Through several case/control comparison in this large and well-
characterized cohort the association between rs738409 and alcohol-related cirrhosis is
demonstrated to be independent from comorbid alcohol-dependence risk. A time-to-
event analysis in patients with an without alcohol-related cirrhosis provides intriguing
evidence that carriage of the rs738409[G] allele worsens prognosis following clinical
presentation with cirrhosis yet improves prognosis in alcohol-misusers with no-
significant liver injury. These data indicate that rs738409 is a significant contributor to
the overall population attributable risk of alcohol-related cirrhosis in the UK as well as
influencing clinical outcomes such as prognosis and the development of HCC.
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CHAPTER 5 STRUCTURAL STUDIES OF
PNPLA3
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5.1 - BACKGROUND
5.1.1 - OVERVIEW
There is growing interest in the biological function of PNPLA3 due to genetic
associations between the variant rs738409 and forms of liver disease. This variant
results in an isoleucine to methionine amino acid substitution at the position 148 in the
protein sequence and has been shown to affect the proteins function. However, the
physiological role of PNPLA3 is unknown, as is the specific functional effect associated
with the rs738409[G] 148Met allele. Structural biology has the potential to increase
understanding of both the role of PNPLA3 and the functional effects of rs738409.
5.1.2 - THE PATATIN DOMAIN
PNPLA3 is transcribed and translated into the enzyme patatin-like phospholipase
domain containing 3 (PNPLA3)198. Other commonly used names for this enzyme
include adiponutrin (ADPN)233 and calcium independent phospholipase 2 epsilon
(iPla2-ε)198. PNPLA3 is a member of the patatin-like phospholipase domain containing
(PNPLA) family of proteins. This domains namesake is the non-specific lipid acyl
hydrolase, and major constituent of the potato, the patatin glycoprotein353. The patatin
glycoprotein has been structurally376 and functionally178,415 characterized demonstrating
that this domain has unique structural features. The amino-acid sequence motifs that
characterise this domain are highly conserved and ubiquitous in nature, occurring in
over three-thousand species of prokaryotes and over three-hundred species of
eukaryotes21.
The patatin domain is a member of the serine hydrolase superfamily of proteins. Many
enzymes in this superfamily catalyse important biochemical reactions such as
proteolysis and thioester bond cleavage263. Based on sequence homology information,
PNPLA3 belongs to a sub-group of this family known as the metabolic serine
hydrolases.  A characteristic feature this sub-group is the α/β hydrolase fold, which 
juxtaposes catalytic residues forming an enzymatic active site. The active site of this
superfamily is characterized by a catalytic serine residue, which functions as a
nucleophile resulting from its interaction with other catalytic residues present in the
active site; the core residues of serine hydrolases form either catalytic dyads or triads.
In patatin domain containing proteins, this catalytic site is characterized by a Ser-Asp
catalytic dyad. When performing catalysis the nucleophilic serine attacks acyl moieties,
such as the ester moiety of any triacylglycerol, cleaving it into two products: a molecule
with a hydroxyl moiety (e.g. glycerol) and an acyl moiety containing molecule such as a
fatty acid (e.g. oleic acid) (Figure 5-1).
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Figure 5-1 Mechanism of the nucleophilic serine active-site residue
The catalytic serine acts as a nucleophile attacking the thioester bond of a substrate molecule.
This forms an acyl-enzyme intermediate at the active site serine. This is followed by water-
induced saponification of the product, and regeneration of the free serine residue for entry into
the next reaction cycle. Image modified from Long et al., 2011263.
THE PNPLA FAMILY IN HUMANS
In humans, there are several proteins that contain patatin domains and these proteins
have diverse and essential roles in human physiology (Figure 5-2). However, not all of
these proteins have phospholipase activity as suggested by their naming convention,
as some members only possess lipase activity. Based on enzymatic activity and
sequence homology236,459 human PNPLA proteins have been categorised into two
subtypes namely the lipase type and the phospholipase A type.
All PNPLA proteins maintain the core catalytic residues in the patatin domain but
otherwise vary considerably. The lipase type enzymes (PNPLA1, PNPLA2, PNPLA3,
PNPLA4 and PNPLA5) mediate a diverse range of functions relating to lipid hydrolysis.
The enzyme PNPLA2, which is also known as adipose triglyceride lipase has a
prominent functional role as it catalyses a crucial step in triglyceride hydrolysis. It is
known to be physiologically important because loss of function mutations in PNPLA2
result in a form of neutral lipid storage disease with myopathy125. The other enzyme
sub-family (PNPLA6, PNPLA7, PNPLA8 and PNPLA9) have the capacity to hydrolyse
phospholipids into fatty acids and other lipophilic substances. The enzyme PNPLA6,
which is also known as neuropathy target esterase, is expressed in the nervous system
and exhibits significant phospholipase activity. It is known to be physiologically
important because loss of function mutations in PNPLA6 result in significant
neurological deficits and neurodegeneration429.
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Figure 5-2 Phylogenetic and structural comparison of human PNPLA family members
This schematic shows a phylogenetic tree of human PNPLA family members on the left-hand
side with the measure of support (0-1 scale) for the tree branching. On the right-hand side,
proportional linear models of the protein domain organisation are shown with their length in
amino-acids given with the location of the core patatin domain (red box), active site (vertical
line) and other regions of the protein (grey) highlighted. Image from Kienesberger et al., 2009223
5.1.3 - PNPLA3 STRUCTURE
PNPLA3 is transcribed into five putative splice variants126 of which two encode
sequences that are known to be translated into proteins. The reference protein
transcript for PNPLA3, encodes a protein containing a sequence of 481 amino acids.
The first 250 residues of PNPLA3 correspond to a patatin-like domain. The motifs that
characterise this domain include a catalytic dyad composed of a serine at position 47
and asparagine at position 166. Other notable motifs include a glycine rich nucleotide
binding motif (Gly-X-Gly-X-X-Gly)26 (Figure 5-3). PNPLA3 also contains a less
common Brummer-box motif, which may be essential for targeting the protein to
intracellular lipid droplets56. The remainder of the primary sequence towards the C-
terminus of the protein (residues 250-481) is of unknown function. Studies in ex vivo
models have demonstrated that this region contains protein sequence (between
residues 320 to 481) which localise PNPLA3 to lipid droplets300.
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Figure 5-3 The domain architecture of PNPLA3
The region from the N-terminal domain contains the core patatin domain. In this region there are
several amino acid motifs including a nucleotide binding motif, the catalytic dyad residue motifs
and a Brummer box motif.
There are no experimentally determined three-dimensional structural models of
PNPLA3. As a proteins function is implicit to its structure387 it is likely that significant
information could be obtained if this data were available. However, there are structural
models in the protein databank (PDB) of other patatin domain containing proteins that
have been obtained using the technique of X-ray crystallography30,376 (Figure 5-4).
Figure 5-4 The stages of protein structure determination by X-ray crystallography
The technique of X-ray crystallography is reliant on the formation of crystalline solids containing
proteins molecules; these structures are characterized by the highly ordered repetitive
arrangement of protein molecules in space. X-rays have a wavelength corresponding to the
length of covalent bonds in molecules and thus constructive or deconstructive interference
occurs when passed through a substance. In crystalline solids the regular lattice arrangement
allows for the production of non-random diffraction patterns. The diffraction pattern produced
contains information regarding the atomic structure of a protein molecule; however converting
these requires complex algorithmic mathematics guided by expert crystallographers to generate
an atomic model. Image obtained from Splettstoesser, 2015407
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The three dimensional structure of protein horse-leaf nettle patatin (Pat17) enzyme has
been used to classify the domain fold of the patatin domain 376. This structure has also
been used to predict the structure of the patatin domain of PNPLA3 using the in silico
technique of homology modelling459. This predicted model of PNPLA3 contains several
putative features of this domain such as its overall α/β hydrolase fold, the positioning of 
its catalytic dyad residues and a also a ‘lid’ region (Figure 5-3).
Figure 5-5 A predicted model of the patatin domain structure in PNPLA3
The regions predicted to fold as β-sheets and α-helices are shaded yellow and blue 
respectively. Side chains of the catalytic aspartate and serine residues are rendered in stick
format. The glycine-rich region is indicated by a red arrow and the putative “lid” region by a
white arrow. Image from Wilson et al., 2006459
5.1.4 - PNPLA3 FUNCTION
Nutritional Regulation
In comparison to PNPLA2 and PNPLA6, the physiological role of PNPLA3 is less well
understood. The discovery of PNPLA3 resulted from its regulation by nutritional
stimuli22 as high carbohydrate or protein diets up-regulate its expression and fasting
down regulates its expression198. In mice188 and human tissues103, PNPLA3 expression
is nutritionally regulated by a feed forward loop (Figure 5-6). PNPLA3 transcription is
observed in in the liver247 as well as in the retina336, skin and adipose tissue188. The
protein has been localised to these tissues as well and may also be secreted into the
blood plasma in minute quantities as a multimeric protein 460.
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Figure 5-6 A proposed feed forward loop nutritional regulatory mechanism of PNPLA3
Following carbohydrate feeding, the postprandial increase in circulating insulin levels up
regulates the liver X receptor (LXR) or the retinoid X receptor (RXR) which consequently
activate the transcription factor sterol regulatory element binding protein 1C (SREBP-1C). This
transcription factor binds to a sequence upstream of the first exon of PNPLA3 up-regulating
gene transcription. It is also a transcription factor for several other genes involved in fatty acid
synthesis. This results in an increase in free fatty acids which may also inhibit further PNPLA3
transcription forming a feedback loop. Abbreviations: LXR – Liver X receptor; RXR – Retinoid X
receptor; SREBP-1c – Sterol regulatory element binding protein 1c; CoA – Coe-enzyme A; ACC
– FAS – Fatty acid synthetase; ELOVL6 - Fatty Acid Elongase 6; SCD - Stearoyl-CoA
Desaturase. Image from Huang et al., 2010188.
Enzymatic studies of PNPLA3 function
The nutritional regulation of PNPLA3 and its significant sequence homology with
adipose triglyceride lipase (PNPLA2) suggest a functional role for the protein in lipid
metabolism. The PNPLA3 protein has been characterized in vitro by purifying the
enzyme233 and testing its activity through candidate approaches assaying synthetic or
hydrolytic activity towards selected lipid substrates.
The earliest study to test PNPLA3 activity in vitro purified the recombinant protein from
insect cells and demonstrated that it has triacylglycerol hydrolysis activity and the acyl-
CoA-independent transacylation activity198. Subsequent studies, have demonstrated
that it has hydrolytic substrate preference for oleic acid containing glycerolipids with
only limited activity against other lipid substrates such as phospholipids, cholesteryl
esters, and retinyl esters187. Notably, the triacylglycerol synthesizing transacylation
activity was not observed in this experiment. Recombinant PNPLA3 has also been
heterologously expressed and purified in E. coli from which the enzyme was shown to
have lipid synthetic activities but was primarily active as an lysophosphatidic acid
acyltransferase233. The phospholipids synthesised by this reaction are involved
inflammatory processes. PNPLA3 heterologously expressed and purified in yeast334
from which the purified enzyme demonstrates glycerolipid hydrolysis activity,
lysophosphatidic acid acyltransferase activity and retinyl palmitate hydrolase activity336.
The results from in vitro studies are diverse and sometimes conflicting. The enzymatic
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activity of PNPLA3 may involve the synthesis of lipids, primarily through transacylation,
and also hydrolytic activity through esterase and thioesterase activity, towards a host of
lipid substrates. It remains unknown whether any of these in vitro activities are
physiologically relevant.
Ex vivo studies of PNPLA3 function
PNPLA3 has been investigated in ex vivo models primarily via gene knockout or gene
over expression in cultured human cell lines. The first study to characterise loss of
PNPLA3 in a human adipocyte cell-line determined that this had no obvious effects on
glycerol or fatty acid release221. Studies investigating PNPLA3 function on retinol
metabolism in hepatic stellate cells have demonstrated that upregulation of PNPLA3
results in the extracellular release of retinol336. A more holistic analysis of PNPLA3
function in human hepatic stellate cells via protein overexpression followed by mass-
spectrometric analysis of cellular lipid content has identified alterations in the ratios of
triacylglycerol’s that contain saturated or monounsaturated fatty acid moieties375.
Visualization of PNPLA3 in human cell lines demonstrates that it localises to the
surface of lipid droplets56,300 and to a lesser extent the cell membrane170. From cellular
models, it is evident that PNPLA3 is likely involved in lipid metabolism as it binds to
lipid droplets and its expression levels correlate with alterations in cellular lipid content.
In vivo studies of PNPLA3 function
The human PNPLA3 protein and its orthologues have been studied in several
organisms but most extensively in zebrafish259, mice20 and rats234 in which gene
expression has either been ‘knocked down’ or ‘knocked-out’. In Zebrafish when
PNPLA3 expression is knocked down the effects are moderate and include reductions
in hepatic progenitor cell numbers, reduced liver size and alterations in gene
expression259. This loss of PNPLA3 does not influence the Zebrafish predisposition to
steatosis when exposed to alcohol or to acute liver injury when exposed to
acetaminophen. In Rats when PNPLA3 gene expression is knocked down there are
several phenotypic effects234 including a reduced predisposition to steatosis, reductions
in the levels of diacylglycerol and acyl-CoA intermediates and alterations in the ratio of
phosphatidic acid to lysophosphatidic acid. In mice when Pnpla3 is deleted there are
no obvious phenotypic effects20: the hepatic lipid content of wild-type and knock out
mice are equivalent as are rates of cholesterol and fatty acid synthesis and
triacylglycerol hydrolysis activity. From in vivo studies it seems evident that PNPLA3
functions in lipid metabolism, however, findings between different organisms are
conflicting.
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PNPLA3 ILE148MET
The variant rs738409 leads to a non-synonymous Ile148Met amino acid substitution in
PNPLA3. In orthologous PNPLA3 enzymes370 the isoleucine corresponding to position
148 in the human protein sequence is highly conserved. This sequence conservation
implies this residue is involved in protein function. However, it is difficult to reconcile
this functional effect when the physiological role of PNPLA3 remains unknown. For this
reason, the majority of the functional studies of the Ile148Met substitution have focused
on either gains or losses of particular measurable functions in either in vitro, ex vivo or
animal models.
In vitro studies of PNPLA3 Ile148Met
There has been contention regarding the lipid synthetic or hydrolytic activity of
PNPLA3. Following from this, in vitro studies have identified both gains and losses of
lipid synthesis or lipid hydrolysis resulting from the Ile148Met substitution. In vitro
studies have demonstrated that the 148Met variant of PNPLA3 has decreased ability to
catalyse triacylglycerol hydrolysis188; a decreased ability to catalyse retinol
hydrolysis336; but, an increased ability to catalyse lysophosphatidic acid acyl transfer233.
Ex vivo studies of PNPLA3 Ile148Met
In cell lines, transfection and over expression of the wild-type enzyme (PNPLA3 148Ile)
or the variant enzyme (PNPLA3 148Met) significantly alters the ratios of several lipids
suggesting that the substitution results in a loss of triacylglycerol remodelling
functionality375. In a hepatic stellate cell line, the transfection and overexpression of the
148Met mutant PNPLA3 results in the accumulation of retinol containing lipid
droplets336 also suggesting a loss of function.
In vivo studies of PNPLA3 Ile148Met
In animal models The knock-out of the murine orthologue Pnpla3 demonstrate no
obvious phenotypic difference in the histology of liver tissue or the levels of several key
lipids this suggesting that the complete loss of PNPLA3 is not deleterious per se20.
However, when PNPLA3 148Met is transiently overexpressed in mice it induces clear
histological features of liver disease and lipid deposition. It is likely that this effect
results from a loss of enzymatic activity in the patatin domain as chronic
overexpression of a catalytically dead PNPLA3 (Ser47Gly) result in a similar phenotype
to the 148Met variant247. Recently, the 148Met variant was introduced into the murine
orthologue Pnpla3400. Following the consumption of carbohydrate rich diet, Pnpla3
148Met mutant mice have increased hepatic lipid accumulation comparison to wild-type
counterparts with notable accumulation of the on lipid droplets400. From this model it
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appears that functional effects of PNPLA3 148Met enzyme requires both the
expression of a catalytically inactive PNPLA3 protein and its accumulation on lipid
droplets.
5.1.5 - PNPLA3 ILE148MET: STRUCTURE AND FUNCTION
A proteins structure is determined by its amino acid sequence387 and this structure is
implicit to biological function. Hence, alterations in the sequence of a protein alter its
structure, which may alter function and ultimately influence the pathogenesis of a
disease. The variant rs738409 in PNPLA3 is non-synonymous resulting in an
Ile148Met amino acid substitution in PNPLA3.
The structure of PNPLA3 has not been experimentally determined. The structure has
been investigated170,233,470, however, using homology model predictions derived from
the structure of the distantly related isozyme from S. cardiophyllum (Pat17)459 (Figure
5-5). These predicted models of the patatin domain (residues 1-180) of PNPLA3
suggest that the 148Ile residue is sterically close to Ser-Asp catalytic dyad (Figure 5-7)
and hence its substitution with 148Met may preclude the access of substrate to the
enzymes active site170.
Structural modelling has therefore provided a hypothesis as to how the Ile148Met
substitution alters PNPLA3 function and ultimately liver disease risk. The strength of
this hypothesis, however, is limited by the accuracy of structural modelling. Homology
models may provide an accurate overall topology of a protein structure. However, they
are rarely if ever accurate at the atomic level. Hence, alterations such as the atomic
positioning of residues in the active site of PNPLA3 are likely to contain substantial
error. Further, existing models of PNPLA3 only predict the structure of patatin domain
and provide no information about the remaining sequence (Figure 5-7). Without
experimental validation, it is clear that the structural mechanisms of the effects of the
Ile148Met substitution will remain hypothetical.
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Figure 5-7 A predicted model of the PNPLA3 active site
This model demonstrates the hypothetical positioning of the patatin domain catalytic dyad
(Ser47 and Asp166) and the position of Ile148 (left panel) and Met148 (right panel),
respectively. Protein traces are rainbow-colored from N to C terminus (blue to red). The dots
indicate a space-filling model corresponding to van der Waals atomic radii. Oxygen and sulphur
atoms are coloured red and yellow. Image from He et al., 2010170
5.2 - AIMS
The overarching aim of this study was to obtain the crystal structure of PNPLA3 and
study the effects of the Ile148Met amino-acid substitution on protein structure and
function. The largely empirical process of protein structure determination may be split
into several stages which guided the aims of this work (Figure 5-8).
Figure 5-8 Experimental stages to obtain a protein structure
The aims of the individual sectional work plan were:
(i) To perform a computational analysis of the PNPLA3 protein sequence to
identify likely features of the protein to aid design of heterologous protein
expression system
(ii) Create recombinant vectors for the expression of the human PNPLA3
protein, and/or its domains in a host organism/cell type
(iii) Refine a protein expression protocol for large scale purification of PNPLA3
(iv) Crystallise the protein
(v) Collect X-ray diffraction data and initialise structure determination.
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5.3 - PROTEIN SEQUENCE ANALYSIS
5.3.1 - OVERVIEW
The purification and crystallisation of proteins is a largely empirical process. There are
many experimental strategies to maximise the chances of obtaining a protein in a
suitable form for crystallographic analysis. A widely used approach for multi-domain,
proteins is the ‘divide and conquer’ strategy whereby different domains of a protein are
expressed in a recombinant expression system. This follows the hypothesis that
individual domains of a protein are more tightly folded and hence easier to express,
purify and subsequently crystallise. Structural modelling and other computational
techniques can provide information regarding the folding and likely domain organisation
of proteins such as PNPLA3115. In this section, the primary protein sequence of
PNPLA3 is analysed focussing on the identification of protein domains through
computational analysis via sequence alignment, structural modelling and other in silico
techniques. The primary aim of these analyses is the identification of protein regions
for recombinant protein expression experiments and protein crystallography.
Figure 5-9 Experimental stages to obtain a protein structure
5.3.2 - MATERIALS AND METHODS
PRIMARY SEQUENCE ANALYSIS
The primary sequence of PNPLA3 that was used in all protein sequence analyses
(Supplementary Sequence 1) was obtained from the National Center for Biotechnology
Information (NCBI) protein database (Accession: NP_079501). The expected physio-
chemical parameters of the protein such as the molecular weight, the isoelectric point
and the grand average hydrophobicity were calculated using the ProtParam tool 135.
The native disorder in the protein structure, was predicted using DISOPRED2 448 which
uses an algorithm to compare, and predict intrinsic disorder, based on data from over
750 empirically determined disordered protein sequences.
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SEQUENCE ALIGNMENT
The Basic Local Alignment Search tool (BLAST) is used to interrogate the similarity of
amino-acid or nucleotide sequences against reference sequence databases. The
BLAST software is used as either standalone package or via a server424 to interrogate
several publicly available nucleotide and protein databases. BLAST was utilised to
identify orthologues of PNPLA3, to evaluate PNPLA3 sequence conservation and to
identify homologous protein structures from the PDB sequence database.
Non-Redundant Sequences Database
The non-redundant sequences database is an extensive database of protein
sequences containing all non-redundant 69,159,658 sequences from the GenBank,
PDB, SwissProt, Protein Information Resource and Protein Research Foundation
databases. The PNPLA3 protein sequence underwent a protein-protein BLAST
against this database using default parameters. The primary sequences of these
homologues were aligned using COBALT322 and the alignment was visualized using
JALVIEW449.
PROTEIN STRUCTURE PREDICTION
There are many methods for predicting protein structure with the most common being
homology modelling, threading and ab initio protein structure prediction:
(i) Homology modelling, which is also known as comparative modelling, is a
template-based method that utilises existing protein structures. Using this
method the sequence of a protein is compared with the sequences of
proteins in a database such as the PDB with an empirically determined
structure. Identification of high sequence homology allows the residues of
the protein of interest to be spatially overlaid on to the protein structure that
has significant sequence homology generating a homology model.
(ii) Protein threading, which is also known as fold recognition, is another
template based method. In comparison to homology modelling this
technique is less reliant on high sequence homology instead requiring
conserved sequence motifs often found in conserved domains and folds.
Typically threading is an iterative approach where the sequence of interest
is threaded on to many hundreds of different template structures identified
from a domain database search. The accuracy of these template
alignments is scored algorithmically typically via estimating the free energy
of the threaded structure where the best structures are used to construct a
final structural model.
159
(iii) Ab initio structure prediction is a template-free method aiming to mimic
protein folding that occurs naturally by computational simulation. Protein
folding is a complex biophysical process where an unfolded protein chain,
which theoretically may take an infinite number of conformations, folds into
a well-defined structure all within the millisecond time scale.
Thermodynamic processes drive protein folding. Primarily, intramolecular
interactions and the torsional limits of a proteins backbone drive the
formation of secondary and tertiary structural elements, which
consequentially results in an overall folded structure. Hence, a folded
structure is thermodynamically stable relative to the unfolded protein chain
and thus a folded protein structure have a low free energy. There are two
primary methods to simulate protein folding process: molecular dynamics
(MD) simulations and Monte-Carlo (MC) energy minimisation simulations249.
The MD simulation approach involves computing the dynamic movements
of all the atoms in a protein and the surrounding solvent over a biologically
relevant timescale. The MC energy minimisation approach involves testing
multiple conformations of a protein structure and iteratively selecting those
structures with the lowest free energy.
Each structural modelling method has advantages and limitations. Homology
modelling may predict the structure of a protein with high accuracy, although this is
reliant on the existence of protein structures with high sequence homology (>30%
sequence identity). This limits this approach to a minority of proteins or only to certain
domains of protein. Protein threading overcomes this issue, partially, requiring only
remote sequence homology through the identification of conserved structural folds.
Never the less, threading is template dependent and can only be used when a related
empirically determined structure exists. The ab initio approach overcomes this
limitation through simulations of protein folding from sequence information alone (i.e.
template independence). However, this approach is limited by computational
complexity; for perspective, the millisecond time-scales required for MD simulations of
protein folding would take greater than a year to perform on a standard desktop
computer485.
ITASSER
The different structural modelling methods can be used in isolation or can be they can
be combined forming a composite approach as is applied by the software ITASSER331.
The approach of ITASSER involves a pipeline of these different processes split into
three stages (Figure 5-10).
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(i) Threading where using the meta-threading program LOMETS467 structural
templates or super-secondary structure motifs are identified from the PDB
database. LOMETS uses several different threading algorithms performing
thousands of threading alignments; the top ten template fragments are
selected for the following stage.
(ii) Structural assembly where using the top structural fragments generated by
threading undergo structural assembly into a full-length structure. Any
regions of the structure that are not covered by threading undergo ab initio
folding based on MC simulations. The full-length structural model
undergoes a second round of MC simulation refinement.
(iii) Atomic level structural refinement where the lowest free energy full-length
structural assemblies from the MC refinement stage undergo full atomic MD
simulations generating five top structural models for further analysis.
A full-length structural model prediction of PNPLA3 was generated using ITASSER
where its primary sequence as the entry parameter (Supplementary Sequence 1) and
other all parameters were set at the default.
Figure 5-10 A flowchart of the stages of the ITASSER structural modelling pipeline
Image from Yang et al, 2015472
Model Accuracy
The accuracy of the predicted by ITASSER structural models cannot be directly
determined without an experimentally validated structural model for comparison. Never
the less, the accuracy of the structure may be estimated using the confidence score
function (C-score). The C-score is calculated during the threading and structural
alignment stages of ITASSER structure prediction (Figure 5-10). Its calculation
involves the comparison of and its value ranges from -5 to 2 where the higher the score
the greater the estimated accuracy of the model.
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There are other, more commonly used, measures of protein structural similarity such
as the template modelling score (TM-score) and the root mean squared deviation
(RMSD). The RMSD is a measure of the average distance between aligned atoms in
two superimposed structures in angstroms (Å) where higher values indicates less
structural similarity between two structures. However, the RMSD metric is limited by its
sensitivity as to two structures can have significant structural overlap but contain small
regions of significant structural dissimilarity resulting in low RMSD values. The TM-
score is less influenced by small regions of dissimilarity479. As with the other metrics, a
higher value indicates greater structural alignment (a score >0.5 indicates a model of
correct topology and a score<0.17 means a random similarity).
The TM score and RMSD score cannot be directly calculated by ITASSER as such
metrics require the comparison with a validated protein structural model. However, for
comparability these metrics may be estimated from the C-score using experimentally
determined correlation coefficients derived from comparisons between the C-score and
RMSD and TM scores of comparisons between ITASSER predicted models and
empirically determined structural models479.
Comparison with Previous Modelling
A homology model prediction based on the patatin structure 1OXW has been used in
previous studies of PNPLA3170,470. This structure was downloaded from SwissProt19.
Comparison between this, and the ITASSER derived structural prediction was
performed using the software TM-align480. Structural model predictions were visualized
and analysed using the open source educational PyMol software383.
5.3.1 - RESULTS
PRIMARY SEQUENCE ANALYSIS
PNPLA3 has a predicted isoelectric point of 6.27 and thus at physiological pH it is likely
to have a net negative charge. The acid content of the protein is distributed amongst
all of the residue-types with leucine and serine being the most common (Figure 5-11).
It contains several cysteine residues and therefore may have a potential to form
disulphide bridges if exposed to non-reducing environments such as the lumen of the
rough endoplasmic reticulum, the intermembrane space in mitochondria. The proteins
grand average hydrophobicity235 is low (0.10) suggesting that that it is likely to be
relatively soluble in water. At a residue, level the hydrophobicity fluctuates along the
length of the protein chain and there are two short regions of the sequence that contain
predominantly hydrophilic residues (residues 247-297 and 410-451) (Figure 5-12).
Analysis of the primary sequence of PNPLA3 for regions of intrinsic disorder suggests
162
two regions of predicted intrinsic disorder (Figure 5-13) which correspond to the
regions with greater hydrophilicity (residues 265-298 and 401-481). Native structural
disorder is a feature of many proteins and is frequently found in in the linker region
joining two tightly folded domains of a protein where such regions often have low
sequence complexity.
Figure 5-11 The residue content of PNPLA3
Residues are grouped and coloured by their biochemical properties
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Figure 5-12 Plot of residue hydrophobicity along the sequence of PNPLA3
The average hydrophobicity is calculated on a sliding scale for every 20 residues where a value
below 0 suggests a region of hydrophobicity. Plot created using the method of Kyte and
Doolittle, 1982235
Figure 5-13 The predicted intrinsic disorder along the sequence of PNPLA3
The plot shows position in the sequence against probability of disorder. Regions above the
threshold confidence score (0.5) are classified as intrinsically disordered. Plot calculated using
DISOPRED448
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SEQUENCE ALIGNMENT
There are 1161 protein sequences from 281 different organisms in the with high
sequence homology to PNPLA3 in the non-redundant protein database (E-value < 1 x
10-30). The majority of these are likely to be orthologues or paralogues of PNPLA3
from other species. The sequences with the highest similarity to the human PNPLA3
occur in mammalian species from both placental and non-placental lineages. Of the
placental mammals, which consist the majority of mammalian species there are
homologous protein sequences in primates (21 species), carnivores (5 species),
hoofed animals (16 species) and rodents (13 species).
A subset of these mammalian protein sequences underwent multiple sequence
alignment with the human PNPLA3 sequence (Figure 5-14). Between the human and
mammalian orthologues there are two regions of almost complete sequence
conservations (residues 1-250 and 300–400). The regions with lower sequence
conservation correspond to those regions that are predicted to be intrinsically
disordered (Figure 5-13). The extreme C-terminal region of human PNPLA3 (residues
400-480) only occurs in the primate lineages in this comparison.
Figure 5-14 Multispecies alignment of mammalian PNPLA3 orthologues
Sequence alignments are coloured using blosum matrix colouring where residue positions of
conserved homology are a more intense shade of blue.
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STRUCTURE PREDICTION
Structure Prediction
The software ITASSER identified several structural models from the PDB sequence
database using a position-specific iterative BLAST (Table 5-1). The template
structures used for threading were 4AKF (VipD), 1OXW (Patatin), 3TU3, 4QMK and
4AKX (both ExoU).
Table 5-1 The top template structures used in PNPLA3 structural model building
Rank
PDB
Structure
Templates
Identity Normalised Z-score
1 4QMKA 17% 0.89
2 4AKFA 13% 1.92
3 4AKFA 13% 1.09
4 1OXWA 18% 5.87
5 4AKFA 17% 4.53
6 4QMKA 14% 1.61
7 4AKFA 17% 5.64
8 3TU3B 18% 1.72
9 4AKXB 14% 0.99
10 4AKFA 14% 1.34
The top ten threading templates used during ITASSER model building identified via the
LOMETS meta-server which generates thousands of template alignments using ten different
protein threading algorithms. One template of the highest Z-score is selected from each
threading algorithm used on the LOMETS server. Top-alignments are scored by the
Normalised Z-score where a score greater than 1 indicates a good alignment and vice versa
The level of sequence homology between human PNPLA3 and the template structures
identified by ITASSER was low (Figure 5-15). The core regions of sequence homology
between these sequences are those motifs, which characterise the patatin domain.
These include a glycine-rich, nucleotide binding, motif (Gly-X-Gly-X-X-Gly; residues 14,
16 and 19), a serine hydrolase catalytic dyad consisting of a catalytic serine motif (Gly-
X-Ser-X-Gly; residues 45, 47 and 49) and a catalytic aspartate motif (Asp-X-Gly/Ala;
residues 166 and 168). There are several other conserved regions in the protein
sequences including a patch of several small hydrophobic residues (residues 80-90)
and two hydroxyl group containing residues (residues 145-149). The residue at
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position 149 is a proline and it is conserved between all of the protein sequences. This
proline is notable as it occurs a single residue along from isoleucine 148, which is the
site of the Ile148Met substitution.
Figure 5-15 Top ITASSER threading template sequence alignments
Sequence alignment are coloured using blosum matrix colouring where residue positions of
conserved homology are a more intense shade of blue.
Accuracy of the Structure Prediction
Five full-length structural predictions of PNPLA3 were created using ITASSER. These
had C-scores ranging from -2.18 to -3.66. The most-accurate of these had a C-score
of -2.18, an estimated TM-score of 0.46 ± 0.15 and an estimated RMSD of 12.5 ± 4.3
Å. In the most accurate prediction, the level of estimated error differs along the
sequence of amino acids (Figure 5-13). Many of the regions have a low estimated
structural accuracy correspond to regions of predicted intrinsic disorder and low
sequence conservation in mammalian orthologues of PNPLA3.
The low C-score, high estimated RMSD and estimated TM-score values of this model
suggest that it is of low accuracy and it is therefore unsuitable for confidently inferring
the atomic level position of the Ile148Met residue in reference to the active site
residues. However, it does reveal a potential domain organisation of the entire protein
comprising an N-terminal patatin domain joined to an uncharacterized C-terminal
domain surrounded by intrinsically disordered linker regions.
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Figure 5-16 The estimated local accuracy of the PNPLA3 structural model
The predicted secondary structure of the model is shown along the X-axis by residue positions
Three-dimensional Structure
Visual analysis of the three-dimensional coordinates of the predicted structural mode of
PNPLA3 (Figure 5-16) demonstrates its putative domain organisation. The first N-
terminal domain corresponds to the predicted patatin-like domain of PNPLA3 and
contains the characteristic structural features of this domain such as the α/β serine 
hydrolase fold and the close proximity of the catalytic residues, Ser47 and Asp166
(Figure 5-18). The residue Ile148, which is the site of a natural variant associated with
alcohol-related cirrhosis, is sterically close to these active site-residues. The remainder
of the structure contains a separate domain-like structure composed of several α-
helices. Two α-helices from the first half of the predicted structures sequence
(residues 180-250) which correspond to a functionally characterized Brummer-box
motif56 extend into the putative C-terminal domain of the model. The putative linker
region (residues 250-320) has no secondary structure in this predicted structure.
Comparison with a Previous Predicted Structure
A predicted structure of PNPLA3 has been analysed previously 480. This predicted
structure is based on a homology model built around the plant patatin structure 1OXW.
There is significant structural alignment between this structure and the full-length
ITASSER model. When aligned both models are structurally similar between the first
170 residues of PNPLA3 with a RMSD of 2.99Å and TM score of 0.77 (Figure 5-17
(right image)). These two predicted models are therefore structurally homologous.
However, as they both use the same reference structure, albeit using different
techniques, they are non-independent.
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Figure 5-17 The top structural model of full length PNPLA3
The left image shows a cartoon representation with rainbow colouring from the C to N terminal
of PNPLA3 overlaid with a transparent model of the protein surface. The right image shows a
backbone of PNPLA3 (green) showing its alignment with the SwissProt structural model of
PNPLA3 (cyan)
Figure 5-18 The patatin domain of the top model
Active site residues are highlighted in the patatin-like domain of the structural model highlighting
the predicted close special proximity of the catalytic residues to the position of isoleucine 148.
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5.3.2 - SUMMARY
The computational analysis of the primary sequence of PNPLA3, using several
independent bioinformatics tools, indicates that the protein structure of PNPLA3 may
be composed of two domains joined by a disordered linker sequence. There are two
regions of high sequence conservation between mammalian orthologues. The regions
of low sequence conservation correlate with regions that are predicted to have high a
probability of high intrinsic disorder and high hydrophobicity. A predicted structure of
PNPLA3 highlights this putative domain organisation. The low estimated accuracy of
this model means that inferences on structure and function are limited. These domain
boundaries guided the design of recombinant plasmids for heterologous protein
expression trials.
5.4 - PROTEIN EXPRESSION VECTORS
5.4.1 - OVERVIEW
The computational analyses of the PNPLA3 protein sequence guided the design of
plasmids for the expression of PNPLA3 that were created and tested at the Oxford
Protein Production Facility (OPPF)440 (Figure 5-19). The OPPF is set up as a structural
proteomics facility to enable the development of plasmids for the heterologous
expression of protein for structural biology purposes. The protocols 31,36,37 employed
and developed at the OPPF, focus on high throughput cloning and protein expression
techniques with the aim of maximizing success through creating and testing a number
of plasmids in parallel.
Figure 5-19 Experimental stages to obtain a protein structure
At the second stage the primary aim is to develop a method for obtaining high yields of the
protein of interest, typically using recombinant DNA to express the gene of interest in a host
protein expression system
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5.4.2 - MATERIALS AND METHODS
TEMPLATE DNA
A template cDNA sequence of the human PNPLA3 gene was purchased
(SourceBioscience, Nottingham, UK) (Supplementary Sequence 2). This template
contains the rs738409[G] allele and hence codes for the 148Met variant of the enzyme.
POPIN SUITE VECTORS
The pOPIN vectors, which are used at the OPPF are derived from31 the commercial
pTriEx2 plasmid (Novagen, Nottingham, UK)31. There are several pOPIN vector types,
which largely differ in nucleotide sequence around their translated region. They all
share core features for recombinant protein expression such as the nucleotide
sequence encoding a polyhistidine tag and a 3C protease consensus cleavage and the
ability to express recombinant protein in multiple hosts (Figure 5-20).
Table 5-2 pOPIN suite vectors chosen for heterologous PNPLA3 expression
Backbone Fusion tag
Restriction
site for
linearisation
Forward primer
extension
Reverse primer
extension
pOPINE POI-3C-HIS NcoI, PmeI AGGAGATATACCATG GTGATGGTGATGTTT
pOPINE-3C-
eGFP
POI-3C- eGFP-
3C-HIS NcoI, PmeI AGGAGATATACCATG CAGAACTTCCAGTTT
pOPINE-3C-
HALO7 POI-3C- Halo7-HIS NcoI, PmeI AGGAGATATACCATG CAGAACTTCCAGTTT
pOPINM HIS-MBP-3C-POI KpnI, HindIII AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA
pOPINO SS-POI-HIS KpnI, PmeI CTACCGTAGCGCAAGCT GTGATGGTGATGTTT
pOPINS3C HIS-SUMO- 3C-POI KpnI, HindIII AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAGCTTTA
pOPINTRX HIS-TRX- 3C-POI KpnI, HindIII AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA
pOPINF HIS-3C-POI KpnI, HindIII AAGTTCTGTTTCAGGGCCCG ATGGTCTAGAAAGCTTTA
Abbreviations: POI – Protein of interest; HIS – Polyhistidine tag; MBP – Maltose binding protein;
eGFP – enhanced green fluorescent protein; TRX - thioredoxin reductase; SUMO - small
ubiquitin-like modifier; 3C - Rhinovirus 3C protease site; SS – signal sequence
Eight pOPIN vector types were selected for recombinant protein expression trials of
PNPLA3 (Table 5-2). The pOPINE and pOPINF vector types were the simplest vector
backbone selected, as these allow the expression of a protein with either an N- or C-
terminal polyhistidine tag. The others plasmids (pOPINE-3C-eGFP, pOPINE-3C-
HALO7, pOPINM, pOPINO, pOPINS3C and pPOPINTRX) were selected a priori for
their unique features. These features include nucleotide sequence which allows the
co-expression of an N or C-terminal fusion protein tag protein such as maltose binding
protein (MBP), green fluorescent protein (GFP), the small ubiquitin like modifier
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(SUMO) protein or thioredoxin reductase (TXR). The inclusion of fusion protein tags
may increase protein solubility, aid protein folding, and allow additional stages of
protein purification. The pOPINO vector differed from the other vectors as it produces
a fusion protein containing a signal sequence that secretes the protein into the
periplasmic space of E. coli. The periplasmic space is a reducing environment and
may aid the folding of proteins that contain native disulphide bonds.
Figure 5-20 The backbone of a pOPINE plasmid
Core features of pOPIN plasmids include: pUC origins of replication for high-copy replication in
E. coli; the ampicillin resistance gene (AmpR) for positive selection in ampicillin containing
media; T7 promoter, transcription terminator and a lac operator sequence for high-level
transcription in E. coli; a CMV enhancer, Chicken β-actin promoter and β-globin polyA signal 
sequences for transcription in HEK293T; recombination sites for integration into the baculovirus
genome for expression in insect cells; the p10 promoter/5′UTR for protein expression in insect 
cell lines; and, a poly Histidine tag adjoining a 3C protease cleavage site for affinity purification.
CONSTRUCT DESIGN
The design of PNPLA3 expression plasmids was guided by three parameters:
 The 96-well plate layout employed for high-throughput cloning at the OPPF
 The selection of pOPIN suite vector backbones available at the OPPF
 The selection of PNPLA3 inserts guided by computational analysis of domain
boundaries
The high-throughput cloning protocol employed at the OPPF utilises a 96-well plate on
which every cloning reaction is performed in duplicate. This limits the design to 48
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unique plasmids. A total of 8 pOPIN vector backbone types were selected for plasmid
design (Table 5-2) therefore allowing the trial of 6 different PNPLA3 inserts. The
selection of these PNPLA3 inserts were made corresponding to putative domains of
PNPLA3 identified by computational analysis (Figure 5-21). Hence, plasmids were
designed to express the full-length protein, the N-terminal patatin-like domain or the
putative C-terminal domain. These include the entire gene (from residues 2-481); two
insert fragment containing the patatin-like domain (from residues 2-175 and 2-250);
and, three insert fragments containing the predicted C-terminal domain (from residues
271-400, 300-400 and 300-481) (Figure 5-21).
Figure 5-21 PNPLA3 inserts selected for plasmid construction
The entire PNPLA3 protein and five regions of it were selected for recombinant protein
expression trials. The same PNPLA3 cDNA nucleotide sequence underwent PCR amplification
to amplify template nucleotide sequences for insertion into the backbone of pOPIN plasmids.
PLASMID CONSTRUCTION
The construction of plasmids was performed using high-throughput techniques (Figure
5-22). During the first stage different fragment of PNPLA3 were inserted into the
different pOPIN plasmid vectors creating constructs. In the second stage, the
constructs were tested for their efficacy in recombinant protein expression in E. coli.
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Figure 5-22 A schematic of the stages of high-throughput plasmid construction
High-throughput plasmid construction and validation was performed at the OPPF over a two
week period. During the first week, plasmids are constructed via the insertion of regions of the
into pOPIN plasmid. During the second week the plasmids undergo protein expression trials in
E.coli to explore whether they are suitable for recombinant protein expression.
The PNPLA3 template fragments were inserted into the pOPIN vector suite plasmids
using In-Fusion cloning36. This cloning method is DNA ligase-independent cloning
technology, which requires fewer stages than traditional cloning and is therefore suited
for high-throughput methods. The experimental process may be split into several
stages (Figure 5-23). This starts with PCR amplification of the template DNA (Table
5-3) using primers that have vector specific 15 base pair overhangs on the forward and
reverse primer sequences (Table 5-2). The success of PCR is determined via agarose
gel electrophoresis and comparison of the molecular weights of the PCR amplicons.
Table 5-3 The PCR amplification conditions used on the PNPLA3 insert
Number of Cycles Condition
1X 94°C 2 minutes
29X
98°C 10 seconds
60°C 30 seconds
68°C x 1min/kilo base-pair
length of template
1X 68°C 2 minutes
1X 4°C Hold
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Subsequently, each amplicons is incubated with a restriction endonuclease linearized
pOPIN plasmid backbone and the InFusion enzyme. The 96-well plate layout is
maintained and the several different pOPIN plasmid vectors are added to their pre-
determined positions on the plate (Figure 5-26). The InFusion enzyme has proof-
reading exonuclease activity and generates cohesive 15 base pair complementary
single stranded ends of both the amplicon and the linearized pOPIN vector. This
allows the cohesive strands of vector and template DNA anneal forming circular yet
nicked plasmids. These nicked plasmids were used to transform E. coli, which were
grown overnight on antibiotic selective LB-Agar covered with the galactose analogue X-
gal. During this period, transformants repair and replicate the nicked plasmid.
Transformants containing the inserted plasmid were selected by blue-white screening
and were grown overnight in antibiotic selective media. Finally, the construct plasmid
DNA is purified from E. coli by performing an alkaline lysis based miniprep. The
experimental methods used are given in greater detail in the published OPPF
protocol37.
Figure 5-23 Stages of InFusion cloning
The stages of InFusion cloning: 1 – A template vector is linearised with a restriction enzyme
generating overhanging DNA sequences; 2 – PCR amplification of template DNA generating in-
frame insert DNA for protein/fragment with vector complementary overhanging DNA sequence;
3 – Incubation of linearized vector with InFusion enzyme generating a circular plasmid
constructs; 4 – Spin column purification of plasmid constructs from InFusion assay mix; 5 –
Transformation of competent E. coli with constructs; 6 – Blue/white colony screening of E. coli
for positive transformation in antibiotic selective agar
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Table 5-4 PNPLA3 expression constructs created at the Oxford Protein Production
Facility
Position PNPLA3
Backbone Fusion Tag
Expected
molecular
weight (kDa)1
st
replicate
2nd
replicate
First
residue
Last
residue
A1 A7 2 481 pOPINE C-His 52.8
B1 B7 2 175 pOPINE C-His 19.14
C1 C7 2 250 pOPINE C-His 27.39
D1 D7 300 481 pOPINE C-His 20.01
E1 E7 300 400 pOPINE C-His 11.11
F1 F7 271 400 pOPINE C-His 14.3
G1 G7 2 481 pOPINE-3C-eGFP POI-3C-eGFP-KHIS6 81.8
H1 H7 2 175 pOPINE-3C-eGFP POI-3C-eGFP-KHIS6 48.14
A2 A8 2 250 pOPINE-3C-eGFP POI-3C-eGFP-KHIS6 56.39
B2 B8 300 481 pOPINE-3C-eGFP POI-3C-eGFP-KHIS6 49.02
C2 C8 300 400 pOPINE-3C-eGFP POI-3C-eGFP-KHIS6 40.11
D2 D8 271 400 pOPINE-3C-eGFP POI-3C-eGFP-KHIS6 43.3
E2 E8 2 481 pOPINE-3C-HALO7 POI-3C-HALO7-KHIS6 87.8
F2 F8 2 175 pOPINE-3C-HALO7 POI-3C-HALO7-KHIS6 54.14
G2 G8 2 250 pOPINE-3C-HALO7 POI-3C-HALO7-KHIS6 62.39
H2 H8 300 481 pOPINE-3C-HALO7 POI-3C-HALO7-KHIS6 55.02
A3 A9 300 400 pOPINE-3C-HALO7 POI-3C-HALO7-KHIS6 46.11
B3 B9 271 400 pOPINE-3C-HALO7 POI-3C-HALO7-KHIS6 49.3
C3 C9 1 481 pOPINF N-His 52.91
D3 D9 1 175 pOPINF N-His 19.25
E3 E9 1 250 pOPINF N-His 27.5
F3 F9 300 481 pOPINF N-His 20.02
G3 G9 300 400 pOPINF N-His 11.11
H3 H9 271 400 pOPINF N-His 14.3
A4 A10 1 481 pOPINM HIS6-MBP-3C-POI 97.91
B4 B10 1 175 pOPINM HIS6-MBP-3C-POI 64.25
C4 C10 1 250 pOPINM HIS6-MBP-3C-POI 72.5
D4 D10 300 481 pOPINM HIS6-MBP-3C-POI 65.02
E4 E10 300 400 pOPINM HIS6-MBP-3C-POI 56.11
F4 F10 271 400 pOPINM HIS6-MBP-3C-POI 59.3
G4 G10 2 481 pOPINO SS[OmpA]-POI-KHIS6 52.8
H4 H10 2 175 pOPINO SS[OmpA]-POI-KHIS6 19.14
A5 A11 2 250 pOPINO SS[OmpA]-POI-KHIS6 27.39
B5 B11 300 481 pOPINO SS[OmpA]-POI-KHIS6 20.02
C5 C11 300 400 pOPINO SS[OmpA]-POI-KHIS6 11.11
D5 D11 271 400 pOPINO SS[OmpA]-POI-KHIS6 14.3
E5* E11* 1 481 pOPINM HIS6-MBP-3C-POI 97.91
F5 F11 1 175 pOPINS3C N-His SUMO-3C-POI 19.25
G5 G11 1 250 pOPINS3C N-His SUMO-3C-POI 27.5
H5 H11 300 481 pOPINS3C N-His SUMO-3C-POI 20.02
A6 A12 300 400 pOPINS3C N-His SUMO-3C-POI 11.11
B6 B12 271 400 pOPINS3C N-His SUMO-3C-POI 14.3
C6 C12 1 481 pPOPINTRX HIS6-TRX-3C-POI 52.91
D6 D12 1 175 pPOPINTRX HIS6-TRX-3C-POI 19.25
E6 E12 1 250 pPOPINTRX HIS6-TRX-3C-POI 27.5
F6 F12 300 481 pPOPINTRX HIS6-TRX-3C-POI 20.02
G6 G12 300 400 pPOPINTRX HIS6-TRX-3C-POI 11.11
H6 H12 271 400 pPOPINTRX HIS6-TRX-3C-POI 14.3
*Sample E5 contained a pOPINM vector backbone rather than pOPINS3C due to an error
during the primer design stage.
Abbreviations: C – carboxyl terminus; GFP – green fluorescence protein; HIS – histidine; MBP –
maltose binding protein; POI – protein of interest; SUMO - Small Ubiquitin-like Modifier; TRX -
thioredoxin
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E. COLI EXPRESSION TRIALS
High throughput protein expression trials in E. coli were performed at the OPPF37
(Figure 5-24). Four different expression conditions were tested for every construct
using two different E. coli strains and two different induction conditions. The two E. coli
strains, Lemo21(DE3) and Rosetta(DE3) were transformed with the pOPIN-PNPLA3
constructs via heat-shock. Both of these E. coli strains have been optimised for
recombinant protein expression. The Lemo21(DE3) strain contains an additional
plasmid which allows for the tightly controlled induction of recombinant protein
induction382. The Rosetta(DE3) strain contains an additional pRARE plasmid that
expresses human tRNA genes, which reduces codon usage bias when inducing
proteins that are non-native to E. coli311. The transformed E. coli were streaked on to
the individual wells of antibiotic containing LB-agar 6-well plates, containing X-gal and
incubated overnight.
Positive transformants were selected from the overnight plates via blue/white
screening. The transformants were grown overnight in antibiotic containing LB in 96-
well deep-well blocks. These cultures were used to inoculate 24-well deep well plates
containing either terrific broth or auto-induction-media for overnight auto-induction or
IPTG induction respectively. The growth of E. coli was monitored via visual inspection
of LB transparency and when at a sufficient cell density IPTG was added to each well
of the cultures grown in terrific broth. Both auto-induction and IPTG induction cultures
of both Lemo21 and Rosetta were grown overnight at a reduced temperature (20°C).
On the final day, the E. coli were harvested from these cultures via centrifugation. Cell
pellets were lysed by freeze-thaw and resuspension in lysis buffer (supplemented with
1mg/mL Lysozyme and either 3 units/mL of Benzonase). Any recombinant
polyhistidine tagged proteins were purified from the cell lysate using a magnetic nickel
bead system on a 96-well plate. Protein expression was determined by separating
proteins using sodium dodecyl sulphate (SDS)- poly acrylamide gel electrophoresis
(PAGE) and visualizing them using Coomassie staining. Protein sizes were estimated
the according to a reference protein sample where the molecular weight of protein
bands in the reference was known in kilodaltons (kDa).
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Figure 5-24 Stages of E. coli protein expression trials
The stages of protein expression trials employed at the OPPF included: 1 – Transformation of
the E. coli recombinant protein expression strains, Lemo21 and Rosetta; 2 – Blue/white
screening of colonies for positive transformants; 3 – Overnight induction of recombinant protein
expression via the addition of IPTG or by auto-induction; 4 – Affinity purification of induced E.
coli cell lysates; 5 – SDS-PAGE screen of high yield recombinant protein expression.
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EUKARYOTIC EXPRESSION TRIALS
The pOPIN vectors may also be used for protein expression in Eukaryotic cell lines,
primarily the Sf9 insect cell line and the HEK293T human cell line. However, the
experimental methods required for these host systems are of greater technical
complexity than for E.coli. All high-throughput protein expression trials in the
Eukaryotic expression systems were performed by OPPF staff members using
published protocols307.
HEK293T
The HEK293T cell line (Life Technologies) is a derivation of human-embryonic kidney
cell line (HEK) that have been optimized for recombinant protein expression. Their
properties include neomycin resistance, higher transfection efficiency, vector
production and increased transduction efficiency. This cell line was transfected with
the purified plasmid constructs. Both soluble and insoluble fractions of cell-lysates
were analysed for recombinant protein expression via Western blotting using an anti-
histidine tag antibody.
Sf9
Sf9 cells are a clonal isolate from the insect S. frugiperda. In contrast to the other cell
types used for recombinant protein expression, these cells do not directly uptake the
plasmid vector. Instead, the recombinant genetic material is inserted into the Sf9
genome using the Baculovirus Expression system. The recombinant material is first
incorporated into a recombinant viral vector known as a bacmid. These high-molecular
weight nucleotide sequences contain the genome of the baculovirus as well as other
nucleotide sequences, which allow the insertion of template DNA. The Bac-to-Bac™
system (Invitrogen) was used for PNPLA3 construct insertion using the E. coli strain
DH10BAC, which have been genetically modified to contain a modified bacmid which
allows for the site-specific transposition of the pOPIN plasmid DNA into its nucleotide
sequence. This occurs due to two the presence of the p10 baculovirus promoter and
the flanking lef2 (ORF 603) and ORF1629 baculovirus recombination sites (Figure
5-20). The purified bacmids are used to infect sf9 cells resulting in the incorporation of
the bacmid genome as well as the construct nucleotide sequence into the genomes of
Sf9 cells. This infection requires several rounds of optimisation for high-yield protein
expression306. The soluble fractions of cell-lysates were analysed for recombinant
protein expression via Western blotting using an anti-histidine tag antibody.
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5.4.3 - RESULTS
PLASMID CONSTRUCTION
The majority of PNPLA3 template amplification PCR assays were successful, although
a minority failed (Figure 5-25). As these assays were performed in duplicate, there
were suitable inserts for all constructs except for the sample in position G5
(pOPINS3C-PNPLA3-1-250). These PCR amplified inserts, underwent InFusion
cloning with linearised pOPIN vector suite plasmid backbones. All of the plasmid
constructs, except for the sample in position D1 (pOPINE-PNPLA3-300-481), passed
through the stages of InFusion cloning, transformation and plasmid purification. The
remaining plasmid constructs were purified from having an average concentration of
433 ng/µL. From each duplicate well, a single plasmid construct was selected for
protein expression trials. The same 48-well plate layout was maintained, although well
positions G5 and D1 were empty and were henceforth used as positions for positive or
negative controls (Figure 5-26).
Figure 5-25 A comparison of correct PNPLA3 insert size for In-Fusion cloning
Different fragments of PNPLA3 underwent PCR amplification with primers containing pOPIN
backbone specific overhangs creating template DNA sequences suitable for insertion using
InFusion cloning. The success of PCR was confirmed on an agarose gel (in duplicate) of the
template DNA amplicons created using PCR amplification. Successful PCR amplification was
judged based on the presence of a single, well-defined band, which correlated with the
expected size of the template.
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Figure 5-26 Plate layout of pOPIN-PNPLA3 constructs
The plate layout of the 48 plasmid constructs that were suitable for further heterologous protein
expression trials in E.coli, Sf9 and HEK293T cells.
E. COLI EXPRESSION TRIALS
Overview
Two different strains of E.coli (Lemo21 and Rosetta) underwent expression trials under
two different protein induction conditions (IPTG induction and auto induction). In all
experiments, a positive controls plasmid (pOPINE-eGFP) was included in an empty
position (G5) on the plate. The positive control sample demonstrated high expression
of recombinant GFP under all conditions. In contrast, only a minority of the PNPLA3
pOPIN construct demonstrate visually discernible protein expression. The only
PNPLA3 construct that had consistent protein expression under all experimental
conditions (B5) produced bands that were at twice the expected molecular weight of
the recombinant protein. Several constructs (B3, B1, E5, B2, C2, H2, B4 and C4)
consistently expressed in the Rosetta strain under both the IPTG and auto-induction
conditions. Several constructs (A4, B3, B6, A6 and E5) also consistently expressed in
the Lemo21 strain under both IPTG induction and auto-induction conditions. However,
none of the bands produced by these constructs was of the expected molecular weight.
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Rosetta Auto-induction
The affinity purified lysates from the Rosetta strain following auto-induction reveals 6
distinct protein bands when analysed by SDS-PAGE (Figure 5-27). Aside from the
positive control (G5) none of the protein bands correspond with the estimated
molecular weight of the recombinant fusion protein. Two of the samples (B1 and B5)
show a distinct uniform band at approximately twice the size of the expected fusion
protein. Another position (E5) shows multiple bands between 35-50 kDa suggesting
partial cleavage of the recombinant protein. There are several faint bands on certain
lanes, which may correspond to the recombinant fusion protein without the protein of
interest attached. For example, the bands at around 40 kDa on lanes B4, C4 and D4
may correspond to the MBP fusion tag.
Figure 5-27 SDS-PAGE gels of affinity purified, auto-induced Rosetta lysates
The two images show Coomassie stained gels for the affinity purified samples from each
construct. Red arrows highlight bands with evident expression of significant quantities of
protein. The table below these images, gives the estimated molecular weight of these bands in
comparison to the expected molecular weight of the expressed protein.
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Rosetta IPTG Induction
The affinity purified lysates from the Rosetta strain following IPTG induction of
recombinant protein expression reveals 10 distinct protein bands when analysed by
SDS-PAGE (Figure 5-28). Aside from the positive control (G5) none of the bands are
at the expected molecular weight of the recombinant fusion proteins. Two positions
(B1 and B5) show clear bands at approximately double the expected molecular weight
of the expected fusion protein. Other positions (B2, C4 and E5) demonstrate multiple
distinct bands suggesting partial cleavage of the expressed protein. Two of the distinct
bands (C2 and F5) have similar molecular weights as the expected fusion protein tags
GFP and SUMO.
Figure 5-28 SDS-PAGE gels of affinity purified, IPTG-induced Rosetta lysates
The two images show Coomassie stained gels for the affinity purified samples from each
construct. Red arrows highlight bands with evident expression of significant quantities of
protein. The table below these images, gives the estimated molecular weight of these bands in
comparison to the expected molecular weight of the expressed protein.
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Lemo21 Auto-induction
The affinity purified lysates from the Lemo21 strain following auto-induction of
recombinant protein expression reveal 5 distinct recombinant protein bands when
analysed by SDS-PAGE (Figure 5-29). Aside from the positive control (G5), none of
the bands are at the expected molecular weight of the recombinant fusion proteins.
Lane B5 shows a clear band at approximately double the expected molecular weight of
the expected fusion protein. Lane B6 shows a clear band which is 10 kDa larger than
the expected fusion protein. Position A4 shows a predominant band at ~70 kDa and
multiple bands at around 36-45 kDa suggesting partial cleavage of the recombinant
protein. The distinct band in lane A6 has the same molecular weights as the expected
fusion protein tag SUMO.
Figure 5-29 SDS-PAGE gels of affinity purified, auto-induced Lemo21 lysates
The two images show Coomassie stained gels for the affinity purified samples from each
construct. Red arrows highlight bands with evident expression of significant quantities of
protein. The table below these images, gives the estimated molecular weight of these bands in
comparison to the expected molecular weight of the expressed protein.
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Lemo21 IPTG Induction
The affinity purified lysates from the Lemo21 strain following IPTG induction of
recombinant protein expression reveal 6 distinct recombinant protein bands (Figure
5-30). The intense bands correspond to the well positions: Aside from the positive
control (G5) none of the bands are at the expected molecular weight of the
recombinant fusion proteins. Lane B3 shows a clear band at, which is 10 kDa smaller
than the expected fusion protein. Lane B5 shows a clear band at approximately double
the expected molecular weight of the expected fusion protein. Lane B6 shows a clear
band which is 10 kDa larger than the expected fusion protein. Position A4 shows a
predominant band at ~70 kDa and multiple bands at around 36-45 kDa. The lane E5
also shows multiple bands between 35-45 kDa; both suggesting partial cleavage of the
recombinant protein. The distinct band in lane A6 has the same molecular weights as
the expected fusion protein tag SUMO.
Figure 5-30 SDS-PAGE gels of affinity purified, IPTG-induced Lemo21 lysates
The two images show Coomassie stained gels for the affinity purified samples from each
construct. Red arrows highlight bands with evident expression of significant quantities of
protein. The table below these images, gives the estimated molecular weight of these bands in
comparison to the expected molecular weight of the expressed protein.
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EUKARYOTIC EXPRESSION
HEK293T
The expression of protein in HEK293T cells was determined using Western blotting
(Figure 5-31). Due to the higher sensitivity of this technique over Coomassie staining,
it provides little information regarding levels of protein expression. Twenty of the
constructs expressed recombinant protein in HEK293T cells. Nearly all of the
constructs with a pOPINE-3C-HALO7 and pOPINE-3C-GFP backbones expressed a
recombinant protein at the expected molecular weight. There was a trend for the
expression constructs to contain a fusion protein tag.
Figure 5-31 PNPLA3 expression trials in HEK293T cells
Images show the results of a Western-blot on the crude lysate purified from HEK293T cells. The
black bands on these images represent protein samples containing a polyhistidine tag motif and
thus represent heterologous protein. Standardized molecular weight markers on the extreme
left-hand and right-hand lanes.
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SF9
The expression screen in Sf9 cells largely mirrored the results of the screen in
HEK293T cells (Figure 5-32). The majority of samples with discernible protein
expression contained a fusion partner tag. There was evident proteolytic degradation
in the Sf9 cells and in some instances, only the fusion protein tag was detected.
Figure 5-32 PNPLA3 expression trials in Sf9 cells
Images show the results of a Western-blot on the crude lysate purified from Sf9 cells. The black
bands on these images represent protein samples containing a polyhistidine tag motif and thus
represent heterologous protein. Standardized molecular weight markers on the extreme left-
hand and right-hand lanes.SUMMARY
A total of 46 plasmids were purified at a sufficient yield, for PNPLA3 expression trials.
The protein expression trials of these construct demonstrates some variability and
inconsistency between eukaryotic (HEK293T and Sf9) and prokaryotic (E.coli)
expression systems. In E. coli, several constructs demonstrated significant protein
expression, however, none of these protein samples were of the expected molecular
weight. In the Eukaryotic cell lines, a number of constructs also demonstrated protein
expression although these were mostly at the expected molecular weight. In the
HEK293T cells, most of the recombinant proteins were of their expected molecular
weight. In the Sf9 cells, results were largely similar albeit with evident proteolytic
degradation in several cases. It seems apparent that a number of plasmids have the
potential to express in PNPLA3 in E.coli, HEK293T and Sf9 cells.
The follow up of these constructs for protein crystallography purposes was guided by
practical as well as experimental factors. First, the UCL crystallography laboratory is
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optimised for heterologous protein expression and purification in E. coli. This
laboratory setup is common as E.coli are tractable to genetic manipulation and rapidly
attain a sufficiently large biomass required for obtaining milligram amounts of protein.
This is one of the reasons why over 90% of the protein structures in the protein
databank are purified using an E.coli expression system306. Therefore, plasmid
constructs were selected for follow up if they demonstrated protein expression in E.coli.
Second, this research is aimed at characterizing the effect of the Ile148Met amino-acid
substitution. For this reason, characterizing the patatin domain in which this
substitution resides is of a greater priority than the C-terminal region of PNPLA3.
In the constructs with discernible protein expression in E.coli, only three contained the
patatin domain (A4, E5, B1). Two of these wells contain identical constructs (A4 and
E5). The protein expressed by the E5 construct demonstrates distinct protein
expression yet significant proteolysis. The protein expressed by the A4 construct is of
a larger molecular weight (closer to the expected weight of PNPLA3) and appears to be
less degraded, however, there is also less protein expression. Based on these findings
and empirical decision making the plasmid in well A4 plasmid (Figure 5-33) was
selected for further characterization. This plasmid was selected as: (i) it demonstrates
heterologous protein expression in E.coli; (ii) it appears to express of the full length
PNPLA3 protein containing the patatin domain; and, (iii) the expressed protein
demonstrates less evident proteolytic degradation than similar constructs.
Figure 5-33 A plasmid map of the A4 plasmid construct
In this construct the gene sequence for the entire PNPLA3 protein is inserted into a pOPINM
vector backbone. The open reading frame should express an N-terminal polyhistidine tag motif
followed by a maltose binding protein fusion partner, a short linker region and then PNPLA3.
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5.5 - PROTEIN PURIFICATION
5.5.1 - OVERVIEW
The purification of proteins for crystallography purposes often requires an optimised
protocol. Determining the optimal conditions for such protocols is largely empirical.
The focus of this section is the verification and optimisation of a protein purification
protocol for a selected plasmid construct. This effort results in the verification of
recombinant PNPLA3 purification from an E.coli expression system with testing of the
proteins suitability for crystallography screening (Figure 5-34).
Figure 5-34 Experimental stages to obtain a protein structure
At the third stage, the primary aim is to purify the protein at a sufficient yield, in a suitable form
for further stages crystallography
5.5.2 - MATERIALS AND METHODS
PLASMID AMPLIFICATION & PURIFICATION
E. coli were transformed (MAX Efficiency® DH5α™, 18258-012, Invitrogen) using the 
manufacturer stated protocol using routine growth media (Table 5-5). The plasmid
DNA was purified from overnight cultures using an Axygen Mini Prep kit (CORNING
AXYGEN APMNP50, 14-223-009, Fisher Scientific) using the manufacturers protocol.
Plasmid Sequencing
Sanger sequencing was performed externally (SourceBioscience, Nottingham, UK) on
selected plasmid constructs378. Sequencing primers were designed for
complementarity to nucleotide sequence regions near the overlap between the plasmid
backbone and the PNPLA3 insert (Table 5-6). Sequencing results were visualized and
underwent alignment the predicted plasmid sequence using the software
SNAPGene159.
189
Table 5-5 Media used for propagating E. coli
Solution Recipe/Contents
1000X Ampicillin 100 mg/mL
LB (autoclaved) 10 mg/mL NacL,10 mg/mLTryptone, 5 mg/mL yeast extract
LB Agar (autoclaved) LB + 35 mg/mL Agar
All buffers made in double-deionized H2O except where otherwise explicitly stated
Abbreviations: LB – Luria Bertani
Table 5-6 Plasmid sequencing primers
Primer Name Sequence (5’3’)
T7 Forward TAATACGACTCACTATAGGG
Rabbit Beta Actin Reverse TTTTGGCAGAGGGAAAAAGA
Rs2076212 GAAGGTGACCAAGTTCATGCTCCAGCTCATCTCCGGCAAAATAG
Rs2076213 GAAGGTCGGAGTCAACGGATTGTTCCTCCGACAGGGTCTCG
RECOMBINANT PROTEIN EXPRESSION IN E. COLI
Transformation and Induction
E. coli (Lemo21(DE3), C2528H, New England BioLabs®) were transformed using the
manufacturer stated guidelines and grown in an overnight culture in 5 mL of LB with
antibiotics (0.5X Ampicillin and 1X Chloramphenicol). A 500 µL aliquot of this overnight
culture was mixed with 500 µL of glycerol, flash frozen, and kept for long-term storage
in a -80oC freezer. Another aliquot of the overnight culture was used to inoculate 6
litres of Terrific Broth (TB) media containing antibiotics (0.5X Ampicillin, 1X
Chloramphenicol) and grown for several hours (37oC, 150 RPM) until reaching an
optical density at 600 nm. At this cell density, recombinant protein expression was
induced via the addition of IPTG and the induction regulator L-rhamnose. Induction
was performed overnight 12-16 hours (21oC, with agitation at 150 RPM).
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Table 5-7 E. coli growth and induction media
Solution Constituents
TB (Autoclaved) Tryptone 12 mg/mL, 24 mg/mL Yeast extract, 0.4%glycerol, 17 mM KH2PO4, 72 mM K2HPO4
1000X Chloramphenicol 34 mg/mL chloramphenicol in 100% ethanol
IPTG solution 0.8 M IPTG
L-rhamnose 0.8 M L-rhamnose
All buffers made in double-deionized H2O except where otherwise explicitly stated
.Abbreviations: TB –Terrific Broth, IPTG - Isopropyl β-D-1-thiogalactopyranoside; mM – 
millimolar
Harvesting & Lysis
E. coli cells were separated from overnight growth media via ultra-centrifugation (40C,
3000 RPM, 30 minutes, Beckman Coulter rotor JA-25 550). The cell pellets obtained
following centrifugation were weighed and either directly lysed or stored in a -20oC
freezer. At the time of use, additional protease inhibitor tablets (cOmplete, Mini, EDTA-
free; 11836153001; Roche Life Science) and lysozyme (100 ng/µL, Sigma, L7651)
and, DNase1 (40 µg/mL) were added to all lysis buffers and were mixed with E. coli cell
pellets (~2.5 mL of lysis buffer per gram of cell pellet). The lysis mixture underwent
sonication (9 s pulse, 10 minutes, 10 kHz) on ice followed by separation in soluble and
insoluble fractions by ultracentrifugation (Beckman coulter, rotor JA 17), (40C, 30,000g,
45 minutes). The soluble fraction underwent syringe filtration (0.45 µm pore size), and
were stored on ice before further purification while insoluble fractions were stored at -
20oC.
NICKEL AFFINITY PURIFICATION
Nickel affinity purification relies on the formation of specific coordinate covalent bonds
between charged nickel (Ni2+) ions and the polyhistidine tag motif commonly
engineered on to recombinant proteins. In this work, HisTrap FF Crude columns of
both 1 mL (product code: 17-5319-01) and 5 mL (product code: 17-5255-01) column
volumes were used for affinity purification137. The process of affinity purification using
HisTrap is controlled either manually using a syringe or, with finer control, using a fast-
protein liquid chromatography machine. This allows the precise control of flow rate and
the use of elution gradients using different media as input. Elution of proteins bound to
columns was effected with the addition of a high imidazole elution buffer. Protein
concentrations in the eluted fractions were estimated by measuring the ultraviolet
absorbance at 280 nm using a nanodrop spectrophotometer.
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GEL ELECTROPHORESIS
SDS-PAGE
SDS-PAGE allows the estimation of protein molecular weight, protein concentration
and protein purity. SDS-PAGE gels were cast manually a maximum of 1 week before
use. Samples were prepared for SDS-PAGE by mixing with 2X Laemelli buffer (1:1)
followed by heat denaturation (95oC for 5 minutes). Gels were loaded into a cassette
and then into a tank and loaded with Tris-Glycine running buffer. No greater than 10
µL of the samples were loaded into each lane of any gel and these were run at
constant amps (25 mA, 1-2 hours). All gels were run with either Broad Range
(Promega, V8491) or Rainbow™ (GE Healthcare Biosciences RPN755E) protein
molecular weight markers.
Coomassie Staining
Protein band visualization was effected via immersion of SDS-PAGE gels in
Coomassie stain (with agitation at room-temperature, 1-2 hours) followed by immersion
in de-stain solution.
Table 5-8 The constituents of polyacrylamide gels, electrophoresis running buffers and
gel staining media
Solution/Media/Buffer Constituents
Separating gel 12% Acrylamide; 150 mM Tris-HCl (pH 8.8); 0.4% w/v SDS
Stacking gel 4% Acrylamide; 50 mM Tris-HCl (pH 6.8); 0.4% w/v SDS
Tris-Glycine running buffer 25 mM Tris-HCl pH 8.3; 192 mM glycine; 0.1% w/v SDS
SDS-PAGE loading buffer
(Laemelli Buffer)
100mM Tris (pH 6.8); 4% w/v SDS; 0.2% w/v Bromophenol
blue; 20% v/v Glycerol
Coomassie gel de-stain 40% Methanol; 10% Acetic Acid
Coomassie gel stain 0.125% w/v Coomassie blue; 50% v/v Methanol; 0% v/vAcetic acid
All buffers made in double-deionized H2O.
Abbreviations: SDS – Sodium dodecyl sulphate; Tris - Tris(hydroxymethyl)aminomethane; w/v –
weight per volume ratio; v/v –volume per volume ratio
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MASS SPECTROMETRY
Protein mass spectrometry (MS) allows the precise determination of the different
molecules present in a sample. Protein bands were cut from Coomassie stained SDS-
PAGE gels and underwent preparation for MS, involving: the removal of Coomassie
stain; reduction and alkylation to enhance sample coverage via the removal of
disulphide bonds; and, tryptic digestion of the protein into peptide fragments. MS
analysis of peptide fragments present in samples was performed on a Velos Orbitrap
Mass spectrometer. From the MS spectra data, the proteins present in each sample
were determined using Proteome Discoverer 1.3 via searches of the UniProt human
and E. coli database with the Mascot search engine. Carbamidomethylation was set
as a fixed modification with methionine oxidation as variable. The preparation of
samples for MS were performed using a standard protocol392.
SIZE EXCLUSION CHROMATOGRAPHY
Size-exclusion chromatography (SEC) separates molecules based on size. It is often
the final stage during protein purification through which the protein of interest is
separated from co-purified contaminants and its level of homogeneity determined. A
SEC column contains beads of either agarose or polyacrylamide; based on the column
design these beads have different molecular pore size and thus alter the passage of
molecules through the column effecting separation (Figure 5-35). All SEC on PNPLA3
protein samples were performed on a Varian Prostar high performance liquid
chromatography machine (HPLC) with monitoring the elution with an ultra-violet/visible
light detector (Model 345) and data were analysed using Varian Star 5.5 software. A
Superdex 200 10/300 GL column (Figure 5-35) with a volume of 24 mL was used in all
experiments; this column has an optimum separation range of for proteins with a
molecular weight ranging from 10-600 kDa. Before use, the column was primed with a
SEC running buffer via passing the media through the column for several column
volumes. Before use, all SEC buffers were degassed. To perform SEC, aliquots (50-
100 µL) of concentrated protein sample were injected into the HPLC machine at a flow
rate of 0.5 mL/min. Sample passage through the column was monitored via an elution
chromatogram (Figure 5-35).
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Figure 5-35 Principle of size-exclusion chromatography
This sequence an example of a sample flowing through a SEC column and the profile measured
on a UV detector based on elution where: A – a sample is injected into a column and a flow of
solvent is applied; B – Samples are separated by size when run through the column; C – larger
solutes pass more quickly through the column and are eluted first as measured by a peak on
the chromatogram; D – Smaller solutes pass more slowly through the column and are eluted
later as measured by a peak on the chromatogram.
Image from Striegel et al., 2009416
5.5.3 - RESULTS
PLASMID SEQUENCING
The sequence off the A4 plasmid was confirmed using insert specific primers (Table
5-6) and Sanger sequencing demonstrating that both MBP and PNPLA3 nucleotide
sequences were present in the A4 construct. This plasmid is expected to express a
fusion protein containing a N-terminal polyhistidine tag motif followed by a maltose
binding protein tag, a short linker region and the entire PNPLA3 protein. The sequence
of this fusion protein is expected to contain 869 amino acids and have a molecular
weight of 95.4 kDa.
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PROTEIN PURIFICATION
Two protein purifications experiments were performed independently at different time-
points:
1. The first purification experiment was a scale-up of the purification protocol
performed at the OPPF
2. The second purification experiment was optimised for the purification of a high-
yield protein suitable for crystallization experiments.
Between both of these experiments, the transformation procedure, strain of E. coli used
and over-night induction protocol used were identical, and were as given in the earlier
materials and methods. The primary difference between these purifications was the
choice of buffers (e.g. presence of reducing agents in buffers), the equipment used
during the purification (e.g. fast protein liquid chromatography) and characterization of
protein samples following purification (e.g. mass spectrometry).
First Protein Purification
In total, the 6 litres of overnight culture produced an E. coli cell pellet weighing 19.0
grams. The E. coli cell lysate was passed through a 1 mL FF HisTrap manually with a
syringe followed by the wash and elution buffer (Table 5-9). All flow-through and
washes were collected in 1 mL fractions and protein concentration determined. The
pooled sample was concentrated using 4 mL centrifugal concentrators (Vivaspin®,
Massachusetts, USA) until a protein concentration of >20 mg/mL in a volume of 500
µL. Analysis of the affinity purified eluent by SDS-PAGE and Coomassie straining
revealed three major bands corresponding to molecular weight of around ~40 kDa, ~45
kDa and ~66 kDa (lane 10: Figure 5-38).
Table 5-9 Buffers used in the first purification
Buffer Constituents
Wash Buffer 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, 20 mMImidazole, 0.05% Tween-20
Elution Buffer 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, 250 mMImidazole, 0.05% Tween-20
Lysis Buffer 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, 10 mMImidazole, 1% Tween-20
SEC buffer 20 mM Tris-HCl (pH 7.5), 300 mM NaCl, 5%Glycerol, 0.02% Sodium Azide
All buffers made in double-deionized H2O.
Abbreviations: SEC – Size exclusion buffer
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This protein sample underwent size exclusion chromatography (Figure 5-37) where it
eluted as two major peaks. The first sample to elute, corresponding to the first peak on
the chromatogram (Figure 5-37: fractions 20-25), eluted in the void volume of the
column. This void volume is essentially the volume of the liquid in a SEC column which
does not enter the permeable matrix of the beads (i.e. the mobile phase) showing that
the protein sample is of a greater molecular mass than the maximum pore size of the
SEC column (>600 kDa). The second sample to elute, corresponding to the second
peak on the chromatogram (Figure 5-37: fractions 30-35) corresponds to a protein
sample that has entered the permeable matrix of the beads (i.e. the stationary phase).
The peak fractions from each major peak were combined, spin concentrated and
visualized by SDS-PAGE (Figure 5-38). The fractions which eluted during the first
peak on the SEC chromatogram (fractions: 22, 23, 24) correspond predominantly to the
~66 kDa band protein sample; there are numerous other less intense protein bands of
varying size. Although the protein band on and SDS-PAGE gel runs at a mass of
~66kDa, it runs at a mass greater than It is likely that these proteins are forming a
soluble compound in solution with a mass greater than 600 kDa. The fractions which
eluted during the second peak on the chromatogram (fractions: 30, 31) correspond to
two bands with a mass of ~40 kDa and ~45 kDa respectively (lanes 6 and 7: Figure
5-38); these samples are relatively pure with little co-purification of other protein.
Figure 5-37 Size exclusion purification elution profile from the first purification
This chromatogram shows the UV absorption percentage (y-axis) versus the elution of the
sample into numbered fractions (x-axis). This demonstrates the elution of two peaks, the first
between fractions 21-23 and the second between fractions 29-32.
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Figure 5-38 The protein bands present in the peak elution fractions
The protein samples present in the peak fractions eluted during size exclusion chromatography
were visualized using SDS-PAGE. Lanes: (1) Marker; (2) Fraction 22; (3) Fraction 23; (4)
Fraction 24; (5) Fraction 28; (6) Fraction 30; (7) Fraction 31; (8) Fraction 38; (10) Affinity purified
sample
The four bands selected for MS analysis included the three most distinct bands and a
more faint band corresponding to the expected molecular weight of the PNPLA3-MBP
fusion protein (Figure 5-39). These were of predicted molecular weights 40 kDa (band
1: Figure 5-39), ~45 kDa (band 2: Figure 5-39), ~66 kDa (band 3: Figure 5-39) and
~100 KDa (band 4: Figure 5-39). MS analysis confirmed that bands 1 and 2 contain
the recombinant MBP fusion tag alone (Supplementary Table 7) whereas bands 3 and
4 contain both MBP and PNPLA3 (Supplementary Table 7). It is evident that the
majority of the PNPLA3-MBP fusion protein does not run at its expected molecular
weight on an SDS-PAGE gel.
Figure 5-39 The protein bands selected for mass-spectrometry analysis
This SDS-PAGE gel image is highlighted with the four bands that were cut from the gel and
underwent MS analysis. The proteins present in these bands were: band 1 = maltose binding
protein; band 2 = maltose binding protein; band 3 = maltose binding protein and PNPLA3; band
4 = maltose binding protein and PNPLA3
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Second Protein Purification
In total, the 6 litres of overnight culture produced an E. coli cell pellet weighing 28.97
grams. The soluble fraction of the E. coli cell pellet lysate was passed through a 5 mL
HisTrap affinity column using a fast protein liquid chromatography machine (Ӓkta, 
Sweden) (flow rate: 5 mL/min, fraction size: 2.5 mL), followed by 3 passages of wash
buffer followed by the gradient addition of the elution buffer over 100 mL (Table 5-10).
This lysis buffer differed from that used in the first purification as it contained a higher
salt concentration and the reducing agent DTT.
Table 5-10 Buffers used in the second purification
Buffer Constituents
Wash Buffer 50 mM Tris-HCl (pH 7.5), 500mM NaCl, 30 mMImidazole, 5% Glycerol
Elution Buffer 50 mM Tris-HCl (pH 7.5), 500mM NaCl, 500 mMImidazole, 5% Glycerol
Lysis Buffer 50 mM Tris (pH 7.5), 500 mM NaCl, 30 mMImidazole, 0.2% Tween-20, 2 mM DTT, 5% glycerol
SEC buffer 20 mM Tris-HCl (pH 7.5), 200 mM NaCl, 2mM DTT,0.02% Sodium Azide
All buffers made in double-deionized H2O
Abbreviations: SEC – Size exclusion chromatography
The protein sample eluted as two indistinct peaks across the imidazole gradient (Figure
5-41). SDS-PAGE visualization of the protein bands present in these peak fractions
(Figure 5-41) demonstrates that the imidazole gradient effected the separation of the
higher molecular weight protein samples, which correspond to the known band size of
the PNPLA3-MBP fusion protein from the lower molecular weight cleaved MBP tag
bands. The peak fractions of the higher molecular weight PNPLA3-MBP samples were
pooled (Figure 5-41: fractions 16 to 21) and concentrated, producing approximately 25
mg of protein.
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Figure 5-40 Fast liquid protein chromatography elution profile from an affinity column
Fast liquid protein chromatography was used to elute the bound protein samples from the nickel
affinity column during the second purification. The UV absorbance was measured (left-hand y-
axis, normalised to the maximum value) and plotted relative to the imidazole concentration
(right-hand y-axis) for each fraction that was eluted (x-axis). *The elution profile curve was
derived from kernel mean smoothing line fit to the UV absorbance values recorded for each
fraction
Figure 5-41 Visualization of protein samples eluted from affinity column
Aliquots of the cell lysate and different fractions from the fast liquid protein chromatography
elution of the sample form the second purification. The elution gradient effects the separation of
the cleaved MBP tag from the full-length protein sample. Lanes: (1) Marker; (2) Lysate; (3)
Flow-through; (4) Fraction 10; (5) Fraction 12; (6) Fraction 16; (7) Fraction 19; (8) Fraction 21
The concentrated sample was visualized at different concentrations to determine the
sample purity. At lower concentrations (Figure 5-42: lane 1) the sample appears
relatively pure with little co-purification of other proteins. However, when concentrated
(Figure 5-42: lane 6), other protein bands become visible. The sample was also tested
under semi-native PAGE conditions (i.e. without the presence of reducing agents or
detergent in loading buffer) (Figure 5-42: lane 9). Under this condition, the protein
sample fails to enter the separating polyacrylamide gel suggesting that the recombinant
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protein is forming a high molecular weight compound. When passed through a size
exclusion column, nearly all of the protein present elutes in the void volume of the
column (Figure 5-43), consistent with the protein forming a high molecular weight
compound in solution.
Figure 5-42 Visualization of sample at several dilutions and denaturation conditions
The concentrated protein sample purified from affinity purification was visualized at different
concentrations and under different denaturation conditions. The predominant bands correlate
with those bands from the previous purification, which were verified by mass spectrometry.
With increasing sample concentration (lane 2 to lane 6) it is evident that there are multiple
protein bands. When tested using different combinations of detergent and reducing agents
(lane 7 to lane 9) the sample run under semi-native conditions (lane 9) fails to enter the gel.
Lanes: (1) Marker; (2) 1:40 dilution of sample ; (3) 1:20 dilution of sample; (4) 1:10 dilution of
sample; (5) 1:5 dilution of sample; (6) 1:2 dilution of sample; (7) 1:10 dilution of sample +
Laemelli; (8) 1:10 dilution of sample + Laemelli + 8M Urea; (9) 1:10 dilution of sample + Loading
buffer (No BME or SDS)
Figure 5-43 Size exclusion chromatogram elution profile from the second purification
This schematic representation of an elution profile of the concentrated protein sample from the
second purification experiment. The UV absorbance was measured (left-hand y-axis,
normalised to the maximum value) and plotted for each fraction that was eluted (x-axis). *The
elution profile curve was derived from kernel mean smoothing line fit to the UV absorbance
values recorded at each fraction
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5.5.4 - SUMMARY
A protocol was developed and verified for the heterologous purification of PNPLA3
from an E. coli expression system. Despite purifying milligrams of the protein, the
protein is not eluting in a homogeneous form, instead forming a high molecular weight
compound. Before crystallography trials, this sample will require greater
characterization and the optimisation of a protocol resulting in a stable and correctly
folded protein.
5.6 - DISCUSSION
In silico analysis of the sequence conservation, intrinsic disorder and three dimensional
structure of PNPLA3 suggest the presence of two domains. The first amino-terminus
domain of PNPLA3 comprises the already characterized459 patatin domain, while the
second putative carboxyl-terminal domain of PNPLA3 shares little to no sequence
homology with any other known domains. Between these two domains, there is a
peptide sequence with low sequence conservation and high predicted intrinsic disorder
and hydrophobicity. This may be a domain linker region, although it shares similarities
with lipid droplet binding regions of a protein332 (e.g. predicted intrinsic disorder and
hydrophobicity) and thus may play other roles in protein function. Lipid droplet binding
is a known activity of PNPLA3, which may involve residues in this region of the
protein300.
Others have investigated structural models of PNPLA3170,198,233,470. The predicted
models of previous analyses share consistent features with model from the current
analysis, in particular, the close spatial positioning of the catalytic dyad residues to the
position of isoleucine 148. This similarity likely results, in part, from both models
relying on the same structural information for model determination from the PDB,
namely the structure of horse leaf nettle patatin (pat17). A unique feature of the
structural model generated in this work, is that it comprises the entire protein rather
than the patatin domain alone. Despite this, current predicted structural models of
PNPLA3 are of low accuracy and therefore experimental structural determination is
required to validate these models of PNPLA3.
Over forty plasmid constructs were created for the purpose of the heterologous
expression of PNPLA3 for crystallographic purposes. Of the constructs that
demonstrated significant protein expression, most generally contained a fusion protein
tag (e.g. MBP, GFP, SUMO or HALO). Fusion partner tags generally enhance the
solubility of proteins and therefore this finding may be consistent with insolubility of
PNPLA3 as it is a known lipid droplet binding protein56. Others have expressed and
purified heterologous PNPLA3170,187,233,334, with the purification protocols sharing in
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many instances, features identified in the current purification such as
insolublity144,157334, proteolytic degradation233 and the formation of higher than expected
molecular weight compounds334. It seems likely that PNPLA3 may be a challenging
protein to purify in a suitable form for crystallographic studies.
The purity and homogeneity of a protein sample are key parameters for the successful
crystallisation and the subsequent determination of a proteins structure using X-ray
crystallography140. Hence, the high molecular weight form of PNPLA3 purified in this
work was unsuitable for further crystallographic analysis. There are several
mechanism which could explain the formation of this high molecular weight compound.
The recombinant protein may be forming a soluble aggregate as MBP fusion proteins
are known to solubilise unfolded tag allowing aggregate formation476. PNPLA3 is also
a lipid droplet binding protein56 and thus the purified protein may interact with, and co-
purify with lipids forming a high molecular weight compound. Alternately, this may be
the native state of PNPLA3 as it has been observed to from oligomers
physiologically460. If ongoing studies determine that PNPLA3, or domains/regions of it,
are unsuitable for traditional protein crystallography due to its biochemical and
biophysical properties then there are a range of other techniques that could be used to
structurally characterise it. Circular dichroism could be used to determine the level of
folding of protein and its secondary structure features61. Solution state NMR also has
the potential to determine the structure of regions of the protein such as lipid droplet
binding motifs39 that are intractable to crystallisation.
In summary, a computational analysis of PNPLA3 guided design of plasmid constructs,
which lead to the development of a high-yield protocol for the purification of PNPLA3.
This analysis highlights several features of the PNPLA3 protein including a putative
carboxyl terminal domain. Despite producing milligram quantities of protein, the
sample was not homogeneous and hampered further crystallographic experiments.
Work is ongoing to characterise this protein sample and those from the other PNPLA3
expression constructs for utility in protein crystallisation assays, functional assays and
structure determination.
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CHAPTER 6 GENERAL DISCUSSION
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Liver disease is the third most common form of preventable death in the UK and in
contrast to most other nations in Europe, its mortality rates are increasing. Liver
disease is the only major cause of death in which such significant increases have
occurred (Figure 6-1). The majority of liver disease deaths in the UK are attributable to
alcohol-related liver disease. In 2012 in England and Wales, alcohol-related liver
disease accounted for 63% (4,425) of alcohol-related deaths in whom the majority
(31%) of deaths were among those aged 50-59 years315 (Figure 6-2). Morbidity and
mortality resulting from alcohol-related liver disease is a huge public health problem in
the UK, which is only likely to worsen in the near future458.
Figure 6-1 Standardized UK mortality rate data *Data were normalised to
100% in 1970. Image from Williams et al., 2014458
Figure 6-2 Alcohol-related causes of death by age-group in England and Wales in 2012
Data from Office for National Statistics, 2014315
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Only 10-20% of alcohol misusers develop the advanced stage alcohol-related liver
disease, namely cirrhosis241. It unknown why there is this difference in inter-individual
risk but it is clear that much of it is driven by complex interactions between the host and
the environment411. Factors relating to alcohol consumption play a large role in risk28
as do co-occurring causes of liver injury298, excess body-mass304, nutritional factors373,
gender24 and ethnicity102. It also seems that deprivation index impacts liver disease
mortality29, in part explaining the differences in mortality across the UK (Figure 6-3).
Figure 6-3 Directly standardized years of life lost due to chronic liver disease including
cirrhosis per population by primary care trust
There were significant increase in premature death from chronic liver disease between 1993
and 2010 in England and there is a 9-fold variation in deaths between primary care trusts.
Image modified from the NHS Atlas of variation in healthcare50
For a long-time it has been known that heritable, or genetic factors contribute to
alcohol-related cirrhosis risk185. However, the majority of genetic studies of alcohol-
related cirrhosis are candidate gene studies, which cover a tiny fraction of known
genetic variation411. Such studies are limited, at best, for characterizing the
contribution of genetic variation to a complex disease phenotype when there are
around 88 million genetic variants and around 24,000 genes in the human genome1.
There is now considerable evidence that PNPLA3 and in particular carriage of the
rs738409[G] allele confers significant risk towards the development of alcohol-related
cirrhosis 55,377,388,413,428,430. It has also been shown to be a significant risk factor for the
development of hepatocellular carcinoma in patients with established alcohol-related
cirrhosis122,164,309,430,432. It also seems that the rs738409[G] allele influences several
aspects of alcohol-related liver disease progression and outcome. Thus carriage of the
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rs738409[G] allele is associated with an earlier development of cirrhosis46; a reduction
in transplantation free survival133 and a poorer outcome following the development of
hepatocellular carcinoma443.
6.1 - REVIEW OF FINDINGS
This thesis has covered several areas of study, which although thematic are disparate.
Thus, a summary of the findings is provided to set the scene for a broader discussion.
6.1.1 - GWAS
This work contributes to the first GWAS44 of alcohol-related cirrhosis through which
variants in the genes PNPLA3, TM6SF2 and MBOAT7 were associated at genome-
wide significance levels. The UCL cohort comprised a significant proportion of the
alcohol-related cirrhosis cases (42.4%) and the phenotypically well-characterized no-
significant liver injury controls (24.2%). A major finding from this study was the primacy
of the genetic association between rs738409 in PNPLA3 and alcohol-related cirrhosis
risk. This variant has the largest effect on risk, when measured using odds ratios, of
any of the variants in validated loci. This analysis also demonstrates the similarity
between the genetic risk factors for alcohol-related cirrhosis and the NAFLD phenotype
as both PNPLA3370 and TM6SF2229 are already known NAFLD risk loci.
6.1.2 - EXTENDED GWAS
An extended GWAS was performed via the inclusion of an additional number of severe
alcoholic hepatitis cases recruited from the STOPAH trial. The harmonisation process,
merging and re-analysis of this data revealed several novel variants nearing genome-
wide significance levels while variants in PNPLA3, TM6SF2 and MBOAT7 also
remained significantly associated. The validity of imputed genotype was confirmed via
direct genotyping in the UCL and STOPAH cohorts, however, despite showing the
same directionality in all instances none of these variants replicated. One of the loci
identified via this analysis was between the genes LIPG and ACAA2, is also a validated
cholesterol level quantitative trait locus11,52,410,416, a feature that it shares with the
variant rs58542926 in TM6SF2.
6.1.3 - PNPLA3 AND ALCOHOL-RELATED CIRRHOSIS RISK
The variant rs738409 was directly genotyped in the entire UCL cohort allowing
comparisons between alcohol dependent cases, population controls and patients with
and without alcohol-related cirrhosis. These comparisons demonstrate the primacy of
the genetic association between rs738409 and alcohol-related cirrhosis and its
independence from alcohol-dependence risk. In patients with alcohol-related cirrhosis
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carriage of the rs738409[G] allele associated with several aspects of disease
progression including time to presentation, time to death or liver transplant and the
development of HCC. In patients with no-significant liver injury, carriage of the
rs738409[G] allele was paradoxically associated with increased lifespan. A population
attributable risk estimate for carriage of rs738409 on alcohol-related cirrhosis
demonstrates that it is likely a substantial contributor to the overall incidence of
cirrhosis in individuals of British and Irish ancestry who misuse alcohol.
6.1.4 - PNPLA3: STRUCTURAL AND FUNCTIONAL STUDIES
The PNPLA3 protein was investigated primarily for the purposes of structural
characterization. Through in silico analysis of the protein sequence two domains were
predicted, one of which is of unknown structural fold. This structural analysis guided
the design of over forty different recombinant plasmids, which created for the purposes
of high-yield protein expression in E.coli. High levels of protein expression were
detected for several plasmid constructs, however, there was significant heterogeneity
between the expected and experimentally determined molecular weight. One of these
plasmid, which should express the entire PNPLA3 protein bound to an MBP tag, was
selected for detailed characterization. This plasmid construct underwent DNA
sequencing and the expressed protein mass spectrometry validating efficacious
PNPLA3 expression from recombinant gene expression in E.coli. Milligram amounts of
the PNPLA3 protein were purified, yet despite this, the protein did not purify in a
homogeneous form suitable for further structural characterization.
6.2 - WHERE ARE WE GOING
6.2.1 - DETERMINING AT RISK GROUPS
The major causes of liver-disease related deaths in the UK are alcohol, obesity and
viral hepatitis. The UK now has the ability to eliminate the morbidity and mortality
attributable to viral hepatitis, namely hepatitis B and hepatitis C458. However, due to
the current alcohol misuse and obesity epidemics the prevalence of both alcohol-
related and NAFLD related cirrhosis are expected to increase in the near future. Thus,
beyond prevention strategies to reduce excess alcohol consumption, there is a need
for other strategies to minimize morbidity and mortality attributable to alcohol-related
liver disease.
The director of the National Health Service has recently published a strategy in which
extensive plans are entailed for the use of genomic technologies in personalised
medicine in the near future220. The genotyping of validated risk variants has a potential
to contribute to this plan, either through use of genotype information in ‘at risk’ tests for
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the prediction of disease and targeted prevention and early identification of a disease
or for guiding an evidence based targeted intervention strategy. A paradigm for this
already exists in the clinical management of hepatitis C viral infection. The variant
rs8099917 in IL28B is associated with sustained virological response to hepatitis C
virus, type 1 infection136. Although this information is not entirely predictive, and hence
should not guide treatment entirely, the European Association for the Study of the Liver
recommends that the genotyping of rs8099917 in IL28B ‘in selected cases with
genotype 1 [HCV], it may assist the physician and patient in management decisions ’118.
There are two points in the natural history of alcohol-related liver disease in which
rs738409 genotype could prove a useful biomarker: (i) the detection of liver disease
before the development of cirrhosis; and, (ii) prognosis relating to complications of liver
failure or the development of HCC following presentation with cirrhosis. As the
progression of alcohol-related liver disease is associated with increasing treatment
costs and decreasing potential for intervention, clearly the detection of liver damage
before the development of cirrhosis is preferable (Figure 6-4).
Figure 6-4 The potential for, and cost of, intervention during the course of liver disease
As liver disease progresses the opportunities for intervention diminish, whereas the relative
costs of interventions that can be applied increase. Image modified from the NHS Atlas of
variation in healthcare50
Liver function tests are often used in a primary care setting, although they are
inefficient for the detection of early stage alcohol-related liver disease: up to 90% of
people with early alcohol-related fibrosis and 75% of people with severe fibrosis have
normal liver function test results166,391,458. In alcohol misusing patients, intervention is a
cost effective means to reduce drinking and halt progression of alcohol-related liver
disease and up to 50% of patients will stop drinking when informed by a specialist that
they have cirrhosis444. For this reason there is a growing recognition for the role for the
low cost non-invasive detection of the early stages of alcohol-related liver disease. In
the UK, two models have been tested for this purpose: the Southampton Traffic Light
(STL) model390,391 in which the levels of serum biomarkers (hyaluronic acid, amino
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terminal type III procollagen peptide and platelet count) are used to stratify and inform
patients of their likelihood of developing cirrhosis followed by one year follow up for
drinking cessation; and, the Nottingham study166, in which a serum AST:ALT ratio was
used to stratify at risk groups (AST:ALT ratio ≥ 0.8) to undergo transient 
elastography330 and, if significant liver stiffness was detected referral to a specialist
hepatology clinic. These studies demonstrate that screening and intervention can
reduce alcohol misuse in at risk groups and increase detection rates of alcohol-related
liver disease. However, there are limitations, in particular the STL model and the
ALT/AST ratio have moderate sensitivities for the detection of significant fibrosis, and
could therefore waste screening resources due to false positives. For these purposes,
rs738409 genotype information could be used to improve the performance of these
detection algorithms, or develop new algorithms with the inclusion of other variables
such as self-reported current alcohol intake, age, gender24 or deprivation index29.
Cirrhosis is a primary risk factor for the development of HCC, which has an
approximate annual incidence of 2-4% in patients with established cirrhosis272,458. The
screening for HCC typically involves abdominal ultrasound scanning and measuring the
serum biomarker α-fetoprotein.  This surveillance increases the chance of curative 
therapy and survival and in the UK NICE308 will recommend screening at 6 monthly
intervals, for every patient with cirrhosis. However, this screening has modest
sensitivity and thus false negative results will occur397, which would be particularly
detrimental to patients with rapidly growing tumours. As there is considerable evidence
that rs738409[GG] homozygotes are more likely to develop HCC161,432, a case could be
made for either more frequent screening of rs738409[GG] homozygotes or more costly,
yet more accurate401, screening of homozygotes with magnetic resonance imaging.
Beyond rs738409 genotype per se there are many other genetic variants, which
contribute to alcohol-related liver disease risk. For example, variants in TM6SF2 and
MBOAT7 are associated with cirrhosis risk44 and the variant rs1800562 in HFE is
associated with HCC risk in alcohol-related cirrhosis200. Due to the moderate effect
size of most genetic variants, they are unlikely to have significant predictive value by
themselves. For this reason, it would be of greater value for their effects to be
incorporated into multivariate models, potentially with the inclusion of validated gene-
gene or gene-environment interaction effects. There is also growing enthusiasm for
polygenic risk score analysis104, in which the contribution of genetic variants that do not
meet traditional thresholds are incorporated into a polygenic model, which can be used
to predict risk. There is a clear opportunity for further evaluation of genetic data to
either stratify at-risk groups for targeted intervention or the monitoring of prognosis in
alcohol-related liver disease.
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6.2.2 - UNDERSTANDING DISEASE MECHANISMS
A feature of the GWAS of alcohol-related cirrhosis44 presented in this work is the
similarity in genetic risk factors with those identified in NAFLD such as rs738409 in
PNPLA3370 and rs58542926 in TM6SF2229,261. Conversely, the variant rs641738 in the
MBOAT7/TMC4 locus44, which is a novel alcohol-related cirrhosis risk locus, has
recently been associated with steatosis grade, necroinflammation and fibrosis stage in
NAFLD273. Based on the functions annotated to these genes, it seems likely that lipid
metabolic pathways are important in both disease modalities. From a clinical
perspective, it has long been recognised that both conditions share histopathological
similarities4, with clinical differentiation based on excessive alcohol consumption,
although the quantifiable extent to which genetic risk factors between these conditions
is unknown. Polygenic risk score analysis could be used estimate the overlap in
shared genetic risk factors using a bivariate linear mixed model as has been
successfully applied between GWAS of psychiatric illness71. This type of analysis
could also be used to compare shared genetic risk with phenotypes such as alcohol
dependence139 or other liver-related phenotypes53.
Due to their similarity, the paradigms that have emerged from genome-wide studies of
NAFLD are also likely relevant in alcohol-related liver disease. From this perspective,
the identification of the TM6SF2 variant rs5854296 (Glu167Lys) provides an example
through which a locus containing multiple non-independent genetic associations has
been validated, refined and characterized. Originally, genetic associations at a broad
region of linkage disequilibrium (chromosome 19p13.11) were ascribed to variants in
genes such as NCAN149,405 and PPP1R3B174. It was only following an exome-wide
association study of liver fat content229 and the functional characterization of genes in
this region269 that strong evidence was found implicating rs5854296 and TM6SF2 as
the most likely causal variant in this region. Subsequently, it has been demonstrated
that this variant is strongly associated with fibrosis stage and moderately associated
with HCC risk261 and intriguingly, it has been demonstrated that this variant has
opposite roles in cardiovascular disease and NAFLD risk101,337 (Figure 6-5). However,
it remains unknown whether all phenotypes associated with this chromosomal region
are attributable to the TM6SF2 rs5854296 variant or whether there are multiple
independent genetic effects209. Unanswered questions regarding the association at
TM6SF2 may apply to other alcohol-related cirrhosis risk loci: are multiple functional
variants contributing to risk in a single locus? Do the alleles, which protect against liver
disease, increase risk for other disease phenotypes? Does the variant influence
clinically relevant variables such as progression and the development of HCC?
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Figure 6-5 The opposing effects of the rs58542926 in TM6SF2
TM6SF2 is functionally involved in the transport of VLDL from the liver. The alternate alleles of
the variant rs58542926 have opposing effects on TM6SF2 function. Abbreviations: chol -
cholesterol; LDL - low-density lipoprotein cholesterol; IHTG - intrahepatic triglyceride; NASH -
nonalcoholic steatohepatitis; TG - triglyceride; VLDL - very low-density lipoprotein. Image from
Kahali et al., 2015209
With new cohorts undergoing GWAS, the identification of novel alcohol-related
cirrhosis risk loci is almost inevitable. The progression from genetic association to
understanding disease pathogenesis will require functional characterization of risk
loci131. Following the example of other disease phenotypes, the functional studies that
succeed GWAS will largely be empirical, and dependent on the context in which a
variant occurs (e.g. protein coding region, intergenic, promoter region etc.). In silico
techniques (e.g. fine mapping, expression quantitative trait loci, transcription factor
binding site, epigenetic modifications etc.) and molecular biological techniques (e.g.
tissue gene expression profiling, enzymatic assays, gene knockouts etc.) will probably
be used to explore and validate functional hypotheses. The ease and utility of
CRISPR/Cas9 genome editing70,270 system has clear potential for characterizing the
functional effects of genetic variants in model organisms and cell lines and will likely an
increasingly important role in functional studies of variants implicated in alcohol-related
cirrhosis risk.
6.2.3 - DEVELOPING NEW TREATMENTS
A number of pharmaceutical/nutritional therapies have been tested for efficacy in
treating aspects of alcohol related liver disease264. These therapies include antibiotics,
probiotics, antioxidants, anti-inflammatory compounds, stem cell progenitors and,
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biliary acids. Despite the promise of these new treatments, there is an urgent need to
develop new pathophysiology oriented therapies134. The genes and systems
implicated via GWAS are a potential therapeutic target due to their robust association
with the disease phenotype.
PNPLA3 is an obvious candidate for therapeutic intervention based on the functional
evidence implicating it in lipid metabolism and robust genetic evidence implicating it
with both NAFLD and alcohol-related cirrhosis risk. Accordingly, there are two patents
pending regarding PNPLA3-related therapies: one for the genotyping of variants for
predicting liver fat levels181 and another for small molecule inhibitors and weight loss in
obesity155. From a pharmaceutical perspective, it has been long known that certain
organophosphorus compounds are potent inhibitors of serine hydrolase superfamily
members203 such as PNPLA3. These compounds inhibit patatin domain enzymatic
activity via the formation of a covalent bond with the serine residue of the Ser-Asp
catalytic dyad455. However, as the 148Met variant most likely results in a loss of
enzymatic activity in the patatin domain400 enzymatic inhibition per se is unlikely to alter
pathogenic effects. Other therapeutic strategies could therefore aim to reduce its
accumulation on lipid droplets or simply abrogate its gene expression. For example,
liposome mediated RNA silencing of PNPLA3 expression could hold potential78.
The function of PNPLA3 remains enigmatic, particularly the mechanisms through which
the Ile148Met substitution effects fibrogenesis and the development of cirrhosis. Thus
greater structural and functional characterization is still required to guide the
development of therapeutics. Approaches to reduce the timespan and costs of drug
development329 such as structure based drug design and drug repurposing14 could all
hold potential for the development of PNPLA3-related therapies.
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APPENDICES
DNA EXTRACTION
Three different techniques were used to obtain the genomic DNA samples that
comprised the entire UCL cohort.
Phenol-Chloroform
The majority of genomic DNA samples were extracted from lymphocytes extracted
from whole blood using a phenol-chloroform based protocol. The first day, of this
protocol involves separating lymphocytes from the other constituents of blood by.
Separation is performed using rounds of rounds of centrifugation and washing with red-
blood cell lysis buffer. The separated lymphocytes are then lysed using a lysis buffer
with the addition of proteinase K and left overnight in a water bath at 50oC. The
second day of this protocol involves removing non-DNA impurities, such as proteins,
from the solution using phenol and chloroform:IAA phase separation. In this
purification process proteins and other compounds dissolve into the organic layer (the
phenol and chloroform) while the DNA remains in the solution of the aqueous layer.
The aqueous layer can be separated from the organic layer and from this; the DNA is
precipitated with concentrated sodium acetate and absolute ethanol. The precipitated
DNA is washed in 70% ethanol to remove excess salts followed by rehydration in TE
buffer.
Day One
1. Thaw blood in a 37oC water bath for 30-45 min.
2. Once the blood is thawed store on ice.
3. Transfer blood from Vacutainer tubes into falcon tubes.
4. Add 5-10 mL lx Lysis Buffer, shake and then top up to 50 mL.
5. Spin solution at 3,000 rpm for 15 min and 4ºC.
6. Pour off supernatant and re-suspend in 5-10 mL 1x Lysis Buffer to a final volume of
50 mL.
7. Spin solution at 3,000 rpm for 15 min and 4ºC.
8. Pour off supernatant and re-suspend in 5 mL Proteinase K Buffer, vortex, then top
to 10 mL.
9. Add 500 µL 10 % SDS.
10. Add 50 µL of 20 mg/mL Proteinase K solution
11. Mix then incubate in a shaking 55oC water bath overnight.
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Day Two
12. Weigh out 1g of PVPP into a fresh falcon tube and add 5ml TE.
13. Add 5 mL TE-equilibrated Phenol and 5 mL Chloroform:IAA (24:1).
14. Shake to emulsify.
15. Transfer lysate to falcon tube with PVPP.
16. Shake to emulsify.
17. Centrifuge at 3,000 rpm for 5-10 Min at room temperature.
18. Transfer the upper aqueous phase into new falcon tubes. Take care to avoid
degraded proteins at the interface.
19. Back extract if necessary by adding TE Buffer and centrifuging again.
20. Add 1 to 1.5 mL 3M (0.1 X volume) sodium acetate then immediately add 100%
Ethanol to a final volume of 35-40 mL.
21. Mix gently by inverting the tube once or twice.
22. Remove the White DNA using a fresh inoculation loop.
23. Briefly rinse the DNA in a 1.5 mL tube containing 70 % ethanol.
24. Allow the DNA to dry for five min.
25. Transfer the DNA to a 1.5 mL tube containing 500 µL TE (use 250 µL TE if the yield
of DNA is low).
26. Leave at room temperature for 3-5 days to dissolve.
Supplementary Table 1 Standard media for phenol/chloroform based genomic DNA
extraction
Media Constituents
Tris-EDTA (TE) Buffer 10 mM Tris. 1 mM EDTA
Low Tris-EDTA buffer 10 mM Tris. 0.1 mM EDTA
10X Lysis buffer 100 mM NaCl, 100 mM EDTA,
Proteinase K buffer 50mM Tris.HCl (pH8.0), 50mM EDTA, 100mMNaCl
Proteinase K Proteinase K enzyme (20 mg/mL)
1:24 Isoamylalcohol:chloroform solution 40 mL Isoamylalcohol: 960 mL chloroform
DNA precipitation solution Absolute ethanol (Sigma-Aldrich, UK)
DNA precipitation solution 3 M Sodium Acetate
Phenol Phenol (equilibrated with 10 mM Tris HCl, 1 mMEDTA ph 8.0)
Poly(vinylpolypyrrolidone) (PVPP) Cross-linked form of PVPP
DNA cleaning solution 70% Ethanol
*All of the reagents used to create these media were purchased from Sigma-Aldrich
All buffers made in double-deionized H2O except where otherwise explicitly stated
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PureGene
The PureGene method was used to extract genomic DNA from whole blood samples.
This method has been adapted from a protocol provided from a commercial Gentra
Puregene kit. As with the other protocol, lymphocytes are separated from other
constituents of the blood through stages of washing with red-blood cell lysis buffer and
centrifugation. The lymphocytes are lysed using a lysis buffer containing proteinase K,
releasing both the DNA and other cellular components into solution. These cell debris
are removed from the solution through precipitation using a protein precipitation
solution. The remaining eluent containing the DNA is mixed with DNA precipitation
solution. The precipitated DNA is separated from the solution through centrifugation
and is then washed in 70% Ethanol before rehydration in TE buffer.
1. Thaw blood in a 37oC water bath for 30 min.
2. Pour defrosted blood and 30 mL 1X RBC Lysis solution into a labelled 50 mL
Falcon Tube.
3. Incubate samples for 5 minutes at RT. Invert several times during incubation.
4. Centrifuge for 5 minutes at 3000 RPM and 4oC.
5. Pour off supernatant into leaving the cell pellet.
6. Re-perform the earlier steps twice until the supernatant is visibly clear of
haemoglobin.
7. Add 15 μL of Proteinase K solution to the cell pellet and any remaining RBC 
lysis solution. Vortex until homogeneous.
8. Add 10 mL of Cell lysis solution to each sample and vortex this for 10 seconds.
9. Leave in water bath at 55oC for a minimum of 30 minutes. The sample should
turn a straw yellow colour.
10. Place sample in ice for 5 minutes. When cool add 3.33 mL of Protein
Precipitation solution and vortex this. Leave the tube on ice, and vortex it
intermittently until the mixture inside it turns translucent/opaque.
11. Spin solution at 3,000 rpm for 10 minutes at 4ºC.
12. Carefully transfer supernatant, avoiding the precipitated protein pellet into
another falcon tube containing 10 mL isopropanol.
13. Invert tube several times until the DNA strands precipitate.
14. Spin solution at 3,000 rpm for 5 minutes to pellet the DNA.
15. Pour off the supernatant keeping the DNA pellet. To this add 10 mL of 70%
Ethanol, vortex and leave on shaker for 10 minutes.
16. Spin the DNA ethanol solution at 3,000 rpm for 5 min to pellet DNA.
17. Carefully pour off supernatant. Dry the DNA pellet for until all residual ethanol
has evaporated.
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18. Re-suspend DNA pellet in 500 μL of TE buffer (use 250 µL TE if the yield of 
DNA is low).
19. Incubate the samples in a water bath at 55oC for 1 hour.
20. Leave the DNA in a shaker at 37oC overnight.
21. Transfer samples into tubes.
Supplementary Table 2 Standard media for purgene based genomic DNA extraction
Media Constituents
Red blood cell (RBC) Lysis
Buffer 100mM NaCl, 10mM EDTA, 1.5M NH4Cl.
Cell Lysis Solution 10 mM Tris-HCl pH 8.0, 25 mM EDTA, 0.5% SDS
Protein Precipitation solution 5M Ammonium Acetate
DNA precipitation solution Absolute isopropanol
DNA cleaning solution 70% Ethanol
*All of the reagents used to create these media were purchased from Sigma-Aldrich
All buffers made in double-deionized H2O except where otherwise explicitly stated
From saliva
At sample recruitment sites without trained phlebotomists or where blood was difficult
to obtain saliva DNA collection kits (Oragene® DNA (OG-500)) were used. The
extraction protocol from these kits involves requires reagents and protocol provided by
the manufacturer. This protocol involves the inactivation of nucleases through heat
treatment overnight. The following day proteins and other turbid compounds are
precipitated through salting out. DNA is precipitated through addition of ethanol and
collected through centrifugation. DNA pellets were rehydrated in TE buffer.
DNA Quantification
DNA quantification was performed using a Qubit® 2.0 Fluorometer. Using the double
stranded DNA broad range assay (ThermoFisher scientific, Q32850), quantification
was performed following manufacturer stated guidelines. All DNA concentrations were
determined from the average of four readings taken from two independent replicate
samples.
DNA Storage
DNA samples were stored in several different formats for the purposes of routine
genotyping and long-term storage (Supplementary Figure 1). Quantified DNA samples
were normalised to a stock concentration with TE buffer and normalised to a maximum
concentration of 50 ng/μL, 100 ng/μL, 200 ng/μL or 500 ng/μL.  These long-term stock 
DNA samples were stored at -80oC. From the stock DNA normalised working stock
DNA solutions were created at a concentration of 25 ng/µL for storage at 4oC. These
samples were stored on 96-tube plates with sample ID mapped to a unique position on
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each plate. Deep well plates were created maintaining the same 96-well layout as
stored on a centrally backed up database. DNA samples were diluted to a
concentration of 3.33 ng/μL in low TE-Buffer.  These deep well plates were stored at -
20oC. Using an epMotion 5070 Automated Pipetting system (Eppendorf, Stevenage,
UK) 3.33 ng of genomic DNA from four 96-deep well plates were pipetted and
dehydrated on to LightCycler® 480 Multiwell 384 plates (Roche, UK).
Supplementary Figure 1 A schematic of DNA plate creation
Stock DNA is transferred and normalised for routine use at 25 ng/µL. This DNA is then
transferred to a deep-well plate at a working concentration from which it is automatically
pipetted on to 384 well-plates.
KASPAR GENOTYPING
All genotyping experiments performed in the UCL Molecular Psychiatry lab were
performed using KASPAR genotyping (K-Bioscience, Hoddenson, UK).
The sequences of genotyping primers were determined using the software
Primerpicker lite (version 0.27) and manually checked for efficacy using the in silico
PCR tool on the UCSC genome browser 216. For each variant that was genotyped, two
allele specific forward primers and two unique reverse primers were purchased
(SigmaAldrich, UK) at a reverse-phase cartridge purity level. For each set of primers,
several PCR conditions (Supplementary Table 5) were tested for the optimal
fluorescent detection of genotypes. This optimisation tested several different
concentrations of magnesium chloride or the dimethyl sulfoxide in the assay mix
(Supplementary Table 3). The two reverse primers were also tested for their efficacy
with the most efficacious primer selected for genotyping.
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Supplementary Table 3 Primer assay mix constituents
Primer Volume (µL)
Forward Allele Specific primer 1 6
Forward Allele Specific primer 1 6
Reverse Primer 15
Water 73
Total 100
Supplementary Table 4 KASPAR genotyping optimisation conditions
10 reactions
A B C D E F
1.8mM
MgCl2
2.2mM
MgCl2
2.5mM
MgCl2
2.8mM
MgCl2
5%
DMSO
10%
DMSO
DNA 10 10 10 10 10 10
2X RXN mix (+KTAQ) 20 20 20 20 20 20
Assay mix 1.1 1.1 1.1 1.1 1.1 1.1
5 mM MgCl2 0 3.2 5.6 8 0.0 0.0
Water 8.9 5.7 3.3 0.9 6.9 4.9
Total 40 40 40 40 40.0 40.0
DMSO 0 0 0 0 2.0 4.0
Abbreviations: RXN – reaction; KTAQ - ; DMSO – dimethyl sulfoxide
The PCR cycling conditions used in all assays are standard involving a hot-start
activation and subsequent touch-down denaturation and annealing/extension stages
(Supplementary Table 5). The KASPAR PCR reaction was performed either directly
inside the LightCycler480 or in separate PCR machines machines (Eppendorf®
Mastercycler® Pro Thermal Cyclers). The fluorescence detection stage was performed
on the LightCycler480 (Roche, UK). The process of fluorescence detection is effected
by the unique KASP chemistry (Supplementary Figure 2) from which genotype cluster
plots can be created and hence genotypes determined.
For the routine genotyping of the thousands of samples present in the UCL cohort, the
assay mix condition determined during optimisation was scaled up for the necessary
number of samples and automatically plated on to LightCycler® 480 Multiwell 384
plates (Roche, UK).
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Supplementary Table 5 LightCycler480™ KASPAR cycling conditions
KASP Cycling Conditions
Hot start activation 94oC for 15 minutes
10 cycles of;
94oC for 20 seconds
65oC to 57oC for 60 seconds
(decreasing by 0.8oC cycle)
26 cycles of: 94
oC for 20 seconds
57oC for 60 seconds
Reading 1 1st Reading at 37oC
3 cycles of: 94
oC for 20 seconds
57oC for 60 seconds
Reading 2 2nd Reading at 37oC
3 cycles of: 94
oC for 20 seconds
57oC for 60 seconds
Reading 3 3rd Reading at 37oC
Supplementary Figure 2 The molecular biological mechanism of fluorescent genotype
detection by KASPAR genotyping
This technique couples allele specific PCR with the fluorescent dyes VIC and FAM and can be
used to genotype SNPs as well as short insertion/deletion variants using a standard proprietary
reaction mix and allele specific primers. The proprietary reaction mix contains two universal
primers which are chemically bound to a fluorescent molecule which absorb light at unique
wavelengths. The allele specific primers are custom designed for each genetic variant under
investigation - these are designed to contain an allele specific base at their 3’ end and a 5’ tail
sequence which is complementary to the nucleotide sequence present on the universal primers.
During a PCR reaction, the each allele specific primers will only amplify the template DNA which
contains the specific allele to which they bind. The two fluorescently labelled universal primers
present in the reaction mix will anneal to the amplified templates and from the fluorescence
ratios genotypes can be determined. Using a real-time PCR machine the absorbance ratio
between the wavelengths at which VIC and FAM absorb the genotype of a DNA sample may be
determined.
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Supplementary Table 6 Top hit variants associated with alcohol-related cirrhosis in the
German discovery cohort
Chromosome Variant Hg19Position
Significance
P Odds Ratio
Lower
CI (95%)
Upper CI
(95%)
22 rs738408 44324730 5.26X10-23 2.40 2.02 2.85
22 rs738409 44324727 5.26X10-23 2.40 2.02 2.85
22 rs3747207 44324855 5.61X10-23 2.40 2.02 2.85
22 rs2294915 44340904 5.03X10-22 2.36 1.99 2.80
22 rs201016637 44325479 3.68X10-18 2.28 1.90 2.74
22 rs1977081 44330128 1.15X10-17 2.36 1.96 2.84
22 rs4823173 44328730 1.31X10-17 2.38 1.98 2.87
22 rs2294433 44329275 1.34X10-17 2.38 1.98 2.87
22 rs12484801 44325565 1.38X10-17 2.38 1.97 2.86
22 rs12483959 44325996 1.38X10-17 2.38 1.97 2.86
22 rs12484809 44325631 1.39X10-17 2.38 1.97 2.86
22 rs12485100 44325516 1.39X10-17 2.38 1.97 2.86
22 rs16991158 44327179 1.44X10-17 2.38 1.97 2.86
22 rs36055245 44327192 1.44X10-17 2.38 1.97 2.87
22 rs11090617 44326700 1.46X10-17 2.38 1.97 2.86
22 rs9625962 44326272 1.46X10-17 2.38 1.97 2.86
22 rs2076211 44329078 1.50X10-17 2.37 1.97 2.86
22 rs12484700 44327273 1.52X10-17 2.38 1.97 2.86
22 rs2294922 44379565 2.04X10-17 2.10 1.77 2.50
22 rs1977080 44330031 2.10X10-17 2.37 1.97 2.85
22 rs1997693 44331513 2.20X10-17 2.35 1.95 2.83
22 rs2896019 44333694 2.43X10-17 2.37 1.97 2.85
22 rs12484466 44330213 2.81X10-17 2.34 1.95 2.82
22 rs2072906 44333172 2.93X10-17 2.36 1.96 2.84
22 rs2281135 44332570 2.95X10-17 2.36 1.96 2.84
22 rs36038527 44332888 2.97X10-17 2.36 1.96 2.84
22 rs2896020 44333968 3.00X10-17 2.36 1.96 2.84
22 rs2401512 44333945 3.02X10-17 2.36 1.96 2.84
22 rs4823176 44334476 3.16X10-17 2.36 1.96 2.84
22 rs4823177 44334486 3.17X10-17 2.36 1.96 2.84
22 rs1883348 44331815 3.22X10-17 2.35 1.95 2.82
22 rs13056638 44331778 3.29X10-17 2.35 1.95 2.82
22 rs1883349 44331943 3.33X10-17 2.35 1.95 2.82
22 rs2281138 44332477 3.37X10-17 2.35 1.95 2.83
22 rs2281137 44332493 3.37X10-17 2.35 1.95 2.83
22 rs2076207 44333370 3.38X10-17 2.35 1.96 2.83
22 rs2072907 44332653 3.38X10-17 2.35 1.95 2.83
22 rs2072905 44333479 3.39X10-17 2.36 1.96 2.83
22 rs16991175 44335331 3.41X10-17 2.36 1.96 2.83
22 rs35621602 44335406 3.44X10-17 2.36 1.96 2.83
22 rs34352134 44335416 3.44X10-17 2.36 1.96 2.83
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22 rs34376930 44335453 3.45X10-17 2.36 1.96 2.83
22 rs2073081 44335744 3.55X10-17 2.36 1.96 2.83
22 rs4823178 44334529 3.58X10-17 2.35 1.96 2.83
22 rs34879941 44332878 3.63X10-17 2.35 1.95 2.83
22 rs1010023 44336098 3.67X10-17 2.36 1.96 2.83
22 rs1010022 44336310 3.85X10-17 2.35 1.96 2.83
22 rs13056555 44339526 3.93X10-17 2.35 1.95 2.83
22 rs2281293 44334842 4.01X10-17 2.35 1.95 2.83
22 rs926633 44337533 4.22X10-17 2.35 1.96 2.83
22 rs36069781 44340086 5.14X10-17 2.34 1.95 2.82
22 rs8142145 44336496 5.38X10-17 2.34 1.95 2.82
22 rs73176497 44336957 5.69X10-17 2.31 1.92 2.77
22 rs2294916 44340922 5.93X10-17 2.34 1.95 2.82
22 rs4823179 44341193 6.22X10-17 2.34 1.95 2.82
22 rs4823180 44341298 6.32X10-17 2.34 1.95 2.82
22 rs13055900 44341666 6.56X10-17 2.34 1.95 2.81
22 rs13055874 44341672 6.57X10-17 2.34 1.95 2.81
22 rs4823181 44341606 6.60X10-17 2.34 1.95 2.81
22 rs2008451 44342969 7.50X10-17 2.34 1.94 2.81
22 rs1810508 44343151 7.61X10-17 2.34 1.94 2.81
22 rs13054885 44345771 1.22X10-16 2.32 1.93 2.79
22 rs12484795 44343626 2.90X10-16 2.21 1.85 2.65
22 rs2092501 44347251 1.03X10-14 2.21 1.84 2.67
22 rs34912062 44348446 1.04X10-14 2.21 1.84 2.67
22 rs56373884 44356468 1.70X10-14 2.20 1.83 2.66
22 rs1474745 44349236 1.78X10-14 2.20 1.83 2.66
22 rs2294921 44361842 3.02X10-14 2.19 1.82 2.64
22 rs3761472 44368122 3.92X10-14 2.19 1.82 2.63
22 rs4823108 44381340 4.96X10-13 2.11 1.74 2.57
22 rs12167845 44380767 5.02X10-13 2.12 1.74 2.57
22 rs71313378 44380170 5.24X10-13 2.12 1.74 2.57
22 rs9626079 44380009 5.30X10-13 2.12 1.74 2.57
22 rs2294923 44379740 5.52X10-13 2.12 1.74 2.57
22 rs2235777 44378809 5.58X10-13 2.12 1.74 2.57
22 rs2235776 44377999 5.77X10-13 2.12 1.74 2.57
22 rs4823183 44378672 5.90X10-13 2.12 1.74 2.57
22 rs4823109 44381482 6.79X10-13 2.09 1.72 2.54
22 rs61473277 44371406 7.88X10-13 2.12 1.75 2.58
22 rs2281298 44391234 7.77X10-11 1.94 1.61 2.34
22 rs2143571 44391686 9.17X10-11 1.94 1.61 2.33
22 rs2073079 44385594 1.06X10-10 1.94 1.61 2.33
22 rs3827385 44388817 1.14X10-10 1.94 1.61 2.33
22 rs2073080 44394402 1.20X10-10 1.94 1.61 2.33
22 rs2401514 44394019 1.27X10-10 1.94 1.61 2.33
22 rs2294927 44382684 1.82X10-10 1.65 1.41 1.95
22 rs2235778 44389514 1.88X10-10 1.65 1.40 1.94
22 rs10656207 44387932 1.93X10-10 1.65 1.40 1.94
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22 rs1986095 44387108 1.94X10-10 1.65 1.40 1.94
22 rs3788604 44388417 1.94X10-10 1.65 1.40 1.94
22 rs6006602 44383400 1.99X10-10 1.65 1.40 1.94
22 rs6006468 44383432 1.99X10-10 1.65 1.40 1.94
22 rs6006469 44383617 2.18X10-10 1.65 1.40 1.94
22 rs6006473 44393075 2.59X10-10 1.65 1.40 1.93
22 rs2281292 44395389 2.91X10-10 1.64 1.40 1.93
22 rs1007863 44395451 2.96X10-10 1.64 1.40 1.93
22 rs12165526 44361713 5.68X10-9 1.75 1.38 2.22
22 rs1883350 44328043 7.05X10-9 1.62 1.37 1.91
22 rs67450864 44376335 1.12X10-8 1.56 1.33 1.84
22 rs4823182 44377442 1.24X10-8 1.56 1.33 1.84
22 rs66812091 44335670 2.18X10-8 1.62 1.38 1.91
22 rs2294917 44341986 8.15X10-8 0.59 0.49 0.71
20 rs11696461 40899315 2.24X10-7 3.40 1.82 6.33
22 rs738407 44323955 4.25X10-7 1.51 1.28 1.77
22 rs2294926 44382533 8.00X10-7 1.49 1.26 1.76
22 rs2179642 44391588 1.01X10-6 1.50 1.27 1.77
22 rs2281297 44390568 1.22X10-6 1.49 1.26 1.76
22 rs6006474 44393241 1.32X10-6 1.50 1.27 1.77
22 rs11912828 44348116 2.36X10-6 0.61 0.50 0.76
22 rs2294919 44342325 2.81X10-6 0.62 0.50 0.76
22 rs6006599 44382004 2.92X10-6 1.51 1.27 1.78
14 rs74893904 28476657 3.19X10-6 1.79 1.36 2.36
18 rs57083541 77755460 3.29X10-6 2.46 1.50 4.04
14 rs67608825 28476537 3.30X10-6 1.79 1.36 2.35
22 rs139052 44327012 3.68X10-6 1.59 1.29 1.95
8 rs117106349 77431741 4.07X10-6 2.38 1.53 3.72
16 rs300019 86661105 4.09X10-6 2.10 1.51 2.93
22 rs13055235 44400149 4.14X10-6 2.18 1.56 3.06
22 rs56219234 44357894 4.34X10-6 1.50 1.27 1.77
4 rs17886348 123533820 5.01X10-6 1.98 1.51 2.60
22 rs738491 44354111 5.48X10-6 1.49 1.26 1.76
4 rs17879298 123533834 5.80X10-6 2.00 1.52 2.63
4 rs62324196 123530977 5.80X10-6 2.00 1.52 2.63
4 rs62324197 123532202 5.83X10-6 2.00 1.52 2.63
16 rs56237022 86659426 5.87X10-6 2.06 1.48 2.86
11 rs143612609 1701967 5.88X10-6 1.47 1.22 1.77
4 rs45589038 123532319 5.89X10-6 2.00 1.52 2.63
5 rs13182940 76306771 6.09X10-6 1.34 1.14 1.58
11 rs11039418 1702170 6.10X10-6 1.47 1.22 1.77
4 rs45532838 123535124 6.13X10-6 1.99 1.51 2.62
5 rs41096 76310835 6.22X10-6 1.34 1.14 1.58
4 rs62324208 123557430 6.44X10-6 1.99 1.50 2.62
4 rs62324207 123557331 6.44X10-6 1.99 1.51 2.62
4 rs7667072 123556921 6.59X10-6 1.99 1.51 2.62
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5 rs6898403 76303398 6.81X10-6 1.34 1.14 1.58
4 rs2893008 123552814 6.85X10-6 2.00 1.52 2.63
4 rs6833795 123553388 7.13X10-6 1.99 1.51 2.62
4 rs149787056 123552022 7.30X10-6 1.99 1.51 2.62
5 rs7728968 76306006 7.42X10-6 1.34 1.13 1.58
5 rs7723775 76305856 7.43X10-6 1.34 1.13 1.58
4 rs142775319 123550665 7.62X10-6 1.99 1.51 2.61
4 rs62324201 123545119 7.63X10-6 1.98 1.51 2.61
4 rs62324206 123548328 7.64X10-6 1.99 1.51 2.61
4 rs62324205 123548192 7.64X10-6 1.99 1.51 2.61
4 rs4326027 123547272 7.65X10-6 1.99 1.51 2.61
4 rs78780360 123547001 7.65X10-6 1.99 1.51 2.61
4 rs17880969 123541473 7.65X10-6 1.99 1.51 2.61
4 rs62324203 123546463 7.65X10-6 1.99 1.51 2.61
4 rs45441794 123544324 7.65X10-6 1.99 1.51 2.61
4 rs62324202 123545147 7.65X10-6 1.99 1.51 2.61
11 rs58237691 1702238 7.69X10-6 1.45 1.21 1.75
4 rs78541112 123526068 7.75X10-6 1.98 1.51 2.61
4 rs62324194 123524666 7.76X10-6 1.98 1.51 2.61
4 rs62324193 123524632 7.76X10-6 1.98 1.51 2.61
4 rs62324191 123523832 7.77X10-6 1.98 1.51 2.61
4 rs62324192 123524257 7.80X10-6 1.98 1.51 2.61
5 rs32900 76310114 7.92X10-6 1.33 1.13 1.57
4 rs62324170 123521851 8.03X10-6 1.98 1.51 2.60
4 rs74985076 123520646 8.09X10-6 1.98 1.50 2.60
16 rs12051337 86663934 8.11X10-6 2.10 1.51 2.93
4 rs62324169 123519601 8.16X10-6 1.98 1.50 2.60
22 rs59436064 44362688 8.20X10-6 1.46 1.23 1.73
4 rs6842843 123512132 8.28X10-6 1.97 1.50 2.60
4 rs74388271 123508611 8.63X10-6 1.97 1.50 2.59
4 rs62324166 123504864 8.71X10-6 1.97 1.50 2.59
4 rs62324167 123507715 8.82X10-6 1.96 1.49 2.58
2 rs3731944 45616849 9.19X10-6 0.47 0.35 0.63
11 rs11211884 106597231 9.87X10-6 1.38 1.17 1.62
Abbreviations: CI – confidence interval, Hg19 – human genome 19
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Supplementary Sequence 1 The primary amino acid sequence sequence of PNPLA3
Accession: NP_079501
001-MYDAERGWSLSFAGCGFLGFYHVGATRCLSEHAPHLLRDARMLFGASAGA
051-LHCVGVLSGIPLEQTLQVLSDLVRKARSRNIGIFHPSFNLSKFLRQGLCK
101-CLPANVHQLISGKIGISLTRVSDGENVLVSDFRSKDEVVDALVCSCFIPF
151-YSGLIPPSFRGVRYVDGGVSDNVPFIDAKTTITVSPFYGEYDICPKVKST
201-NFLHVDITKLSLRLCTGNLYLLSRAFVPPDLKVLGEICLRGYLDAFRFLE
251-EKGICNRPQPGLKSSSEGMDPEVAMPSWANMSLDSSPESAALAVRLEGDE
301-LLDHLRLSILPWDESILDTLSPRLATALSEEMKDKGGYMSKICNLLPIRI
351-MSYVMLPCTLPVESAIAIVQRLVTWLPDMPDDVLWLQWVTSQVFTRVLMC
401-LLPASRSQMPVSSQQASPCTPEQDWPCWTPCSPKGCPAETKAEATPRSIL
451-RSSLNFFLGNKVPAGAEGLSTFPSFSLEKSL___________________
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Supplementary Sequence 2 The nucleotide sequence of the PNPLA3 cDNA
CGCTTGCGGGCGCCGGGCGGAGCTGCTGCGGATCAGGACCCGAGCCGATTCCCGATCCCGACCC
AGATCCTAACCCGCGCCCCCGCCCCGCCGCCGCCGCCATGTACGACGCAGAGCGCGGCTGGAGC
TTGTCCTTCGCGGGCTGCGGCTTCCTGGGCTTCTACCACGTCGGGGCGACCCGCTGCCTGAGCG
AGCACGCCCCGCACCTCCTCCGCGACGCGCGCATGTTGTTCGGCGCTTCGGCCGGGGCGTTGCA
CTGCGTCGGCGTCCTCTCCGGTATCCCGCTGGAGCAGACTCTGCAGGTCCTCTCAGATCTTGTG
CGGAAGGCCAGGAGTCGGAACATTGGCATCTTCCATCCATCCTTCAACTTAAGCAAGTTCCTCC
GACAGGGTCTCGGCAAATGCCTCCCGGCCAATGTCCACCAGCTCATCTCCGGCAAAATAGGCAT
CTCTCTTACCAGAGTGTCTGATGGGGAAAACGTTCTGGTGTCTGACTTTCGGTCCAAAGACGAA
GTCGTGGATGCCTTGGTATGTTCCTGCTTCATGCCTTTCTACAGTGGCCTTATCCCTCCTTCCT
TCAGAGGCGTGCGATATGTGGATGGAGGAGTGAGTGACAACGTACCCTTCATTGATGCCAAAAC
AACCATCACCGTGTCCCCCTTCTATGGGGAGTACGACATCTGCCCTAAAGTCAAGTCCACGAAC
TTTCTTCATGTGGACATCACCAAGCTCAGTCTACGCCTCTGCACAGGGAACCTCTACCTTCTCT
CGAGAGCTTTTGTCCCCCCGGATCTCAAGGTGCTGGGAGAGATATGCCTTCGAGGATATTTGGA
TGCATTCAGGTTCTTGGAAGAGAAGGGCATCTGCAACAGGCCCCAGCCAGGCCTGAAGTCATCC
TCAGAAGGGATGGATCCTGAGGTCGCCATGCCCAGCTGGGCAAACATGAGTCTGGATTCTTCCC
CGGAGTCGGCTGCCTTGGCTGTGAGGCTGGAGGGAGATGAGCTGCTAGACCACCTGCGTCTCAG
CATCCTGCCCTGGGATGAGAGCATCCTGGACACCCTCTCGCCCAGGCTCGCTACAGCACTGAGT
GAAGAAATGAAAGACAAAGGTGGATACATGAGCAAGATTTGCAACTTGCTACCCATTAGGATAA
TGTCTTATGTAATGCTGCCCTGTACCCTGCCTGTGGAATCTGCCATTGCGATTGTCCAGAGACT
GGTGACATGGCTTCCAGATATGCCCGACGATGTCCTGTGGTTGCAGTGGGTGACCTCACAGGTG
TTCACTCGAGTGCTGATGTGTCTGCTCCCCGCCTCCAGGTCCCAAATGCCAGTGAGCAGCCAAC
AGGCCTCCCCATGCACACCTGAGCAGGACTGGCCCTGCTGGACTCCCTGCTCCCCCGAGGGCTG
TCCAGCAGAGACCAAAGCAGAGGCCACCCCGCGGTCCATCCTCAGGTCCAGCCTGAACTTCTTC
TTGGGCAATAAAGTACCTGCTGGTGCTGAGGGGCTCTCCACCTTTCCCAGTTTTTCACTAGAGA
AGAGTCTGTGAGTCACTTGAGGAGGCGAGTCTAGCAGATTCTTTCAGAGGTGCTAAAGTTTCCC
ATCTTTGTGCAGCTACCTCCGCATTGCTGTGTAGTGACCCCTGCCTGTGACGTGGAGGATCCCA
GCCTCTGAGCTGAGTTGGTTTTATGAAAAGCTAGGAAGCAACCTTTCGCCTGTGCAGCGGTCCA
GCACTTAACTCTAATACATCAGCATGCGTTAATTCAGCTGGTTGGGAAATGACACCAGGAAGCC
CAGTGCAGAGGGTCCCTTACTGACTGTTTCGTGGCCCTATTAATGGTCAGACTGTTCCAGCATG
AGGTTCTTAGAATGACAGGTGTTTGGATGGGTGGGGGCCTTGTGATGGGGGGTAGGCTGGCCCA
TGTGTGATCTTGTGGGGTGGAGGGAAGAGAATAGCATGATCCCACTTCCCCATGCTGTGGGAAG
GGGTGCAGTTCGTCCCCAAGAACGACACTGCCTGTCAGGTGGTCTGCAAAGATGATAACCTTGA
CTACTAAAAACGTCTCCATGGCGGGGGTAACAAGATGATAATCTACTTAATTTTAGAACACCTT
TTTCACCTAACTAAAATAATGTTTAAAGAGTTTTGTATAAAAATGTAAGGAAGCGTTGTTACCT
GTTGAATTTTGTATTATGTGAATCAGTGAGATGTTAGTAGAATAAGCCTTAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
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Supplementary Table 7 MASCOT sequence alignment results for the SDS-PAGE gel
bands that underwent mass spectrometry
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>MBP:1 MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVG
51 KKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSG
101 LLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPN
151 PPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENG
201 KYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAM
251 TINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKE
301 LAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENA
351 QKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITK
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>MBP:1 MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVG
51 KKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSG
101 LLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPN
151 PPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENG
201 KYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAM
251 TINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKE
301 LAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENA
351 QKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITK
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>MBP:1 MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVG
51 KKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSG
101 LLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPN
151 PPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENG
201 KYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAM
251 TINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKE
301 LAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENA
351 QKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITK
>PNPLA3:1 MYDAERGWSLSFAGCGFLGFYHVGATRCLSEHAPHLLRDARMLFGASAGA
51 LHCVGVLSGIPLEQTLQVLSDLVRKARSRNIGIFHPSFNLSKFLRQGLCK
101 CLPANVHQLISGKIGISLTRVSDGENVLVSDFRSKDEVVDALVCSCFIPF
151 YSGLIPPSFRGVRYVDGGVSDNVPFIDAKTTITVSPFYGEYDICPKVKST
201 NFLHVDITKLSLRLCTGNLYLLSRAFVPPDLKVLGEICLRGYLDAFRFLE
251 EKGICNRPQPGLKSSSEGMDPEVAMPSWANMSLDSSPESAALAVRLEGDE
301 LLDHLRLSILPWDESILDTLSPRLATALSEEMKDKGGYMSKICNLLPIRI
351 MSYVMLPCTLPVESAIAIVQRLVTWLPDMPDDVLWLQWVTSQVFTRVLMC
401 LLPASRSQMPVSSQQASPCTPEQDWPCWTPCSPKGCPAETKAEATPRSIL
451 RSSLNFFLGNKVPAGAEGLSTFPSFSLEKSL
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>MBP:1 MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVG
51 KKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSG
101 LLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPN
151 PPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENG
201 KYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAM
251 TINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKE
301 LAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENA
351 QKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITK
>PNPLA3:1 MYDAERGWSLSFAGCGFLGFYHVGATRCLSEHAPHLLRDARMLFGASAGA
51 LHCVGVLSGIPLEQTLQVLSDLVRKARSRNIGIFHPSFNLSKFLRQGLCK
101 CLPANVHQLISGKIGISLTRVSDGENVLVSDFRSKDEVVDALVCSCFIPF
151 YSGLIPPSFRGVRYVDGGVSDNVPFIDAKTTITVSPFYGEYDICPKVKST
201 NFLHVDITKLSLRLCTGNLYLLSRAFVPPDLKVLGEICLRGYLDAFRFLE
251 EKGICNRPQPGLKSSSEGMDPEVAMPSWANMSLDSSPESAALAVRLEGDE
301 LLDHLRLSILPWDESILDTLSPRLATALSEEMKDKGGYMSKICNLLPIRI
351 MSYVMLPCTLPVESAIAIVQRLVTWLPDMPDDVLWLQWVTSQVFTRVLMC
401 LLPASRSQMPVSSQQASPCTPEQDWPCWTPCSPKGCPAETKAEATPRSIL
451 RSSLNFFLGNKVPAGAEGLSTFPSFSLEKSL
